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Abstract
Asthma is a respiratory disease that causes chronic airway inflammation. Affecting more than 300
million individuals worldwide, it is a growing public health hazard. Inhalation therapy is the preferred
strategy for medication delivery. This therapy is executed through specific delivery devices, whereas
the pressurized Metered-Dose Inhaler (pMDI) is one of the most preferred. However, the pMDI
efficiency is highly dependent on a correctly executed inhalation procedure. For children under 5
years old (or elderly individuals), it is advisable to use the pMDI coupled with an add-on device (i.e.
spacer). Within the spacers, the Valved Holding Chamber (VHC) is the mostly used, due to its good
capacity to reduce the pMDI spray coarse fraction and the oral-pharyngeal deposition (≈80%).
Additionally, the VHC’s one-way valve allows the patient to maintain his tidal breathing during
treatment. The VHC typically delivers a Fine Particle Mass (FPM) that is≈20% of the labelled dose.
Several design characteristics dictate the VHC performance, such as, the dimensions and the ma-
terials. The study herein focus on the assessment of eight commercial VHCs, through experimental
and numerical methods. An experimental setup was developed, allowing the evaluation of the
devices at constant flow rate (30 L/min and 60 L/min) and at variable flow (sine breath pattern).
The waveform was obtained through a breathing simulator specially developed for this purpose,
based in a cam-follower mechanism. The salbutamol sulphate (i.e. Ventolin) was collected using
a cascade impactor (i.e. MSLI), and assessed by UV-Vis spectrophotometry analysis. Several
metrics, regarding VHC performance, were calculated. Results have shown that the VHC capacity
reduce the oral-pharyngeal deposition (64% - 94%), which is deeply related with the VHC valve
design. It was observed that the VHC reduces the plume coarse fraction (≈70%), keeping the FPM
bioequivalent to the pMDI solo. A correlation between the fine particle fraction and the volume of
air passing through the VHC was proposed. Patient relevant metrics were suggested to classify the
ix
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VHC devices upon quantitative and qualitative characteristics. A Computational Fluid Dynamics
(CFD) model was developed where the air flow (i.e. 60 L/min)) was calculated along with the
pMDI spray modelling as a discrete phase. The spray particle-wall interaction was modelled using
different approaches and compared against literature and experimental data. This study, shed
some light upon the spray evaporation process inside the VHC, showing that the efficiency of
evaporation process is related with the VHC volume. A new VHC design, based in CFD dimen-
sional optimisation of the VHC body is proposed, which shows an improvement of the FPM delivered.
Palavras chave: Asthma Treatment; Valved Holding Chamber (VHC); pressurized Metered-Dose
Inhaler (pMDI); Performance; Computational Fluid Dynamics (CFD); Design.
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Resumo
A asma é uma doença respiratória que causa a inflamação crónica das vias aéreas. Mundialmente,
afeta mais de 300 milhões de indivíduos e é um problema crescente de saúde publica. A terapia
de inalação é a estratégia preferida para administrar a medicação de controlo ou de alívio. Esta
terapia é executada através de dispositivos específicos, entre os quais o Inalador Pressurizado com
Válvula Doseadora (IPVD) é o mais usual. Contudo, a eficiência do IPVD é dependente de uma
técnica de inalação correta. Para crianças com menos de 5 anos (ou idosos), é recomendável o
uso do IPVD acoplado a um espaçador. Entre os espaçadores, a Câmara Expansora (CE) é a mais
utilizada, devido à sua boa capacidade de redução das partículas grandes do aerossol do IPVD, e
da redução da deposição orofaringeal (≈80%). Adicionalmente, a válvula de sentido único da CE,
permite que o paciente mantenha a sua respiração normal durante o tratamento. A CE emite,
tipicamente, uma massa de partículas finas (MPF) que é ≈20% da dose calibrada do IPVD. Este
estudo foca-se na avaliação de oito CEs, através de uma metodologia experimental e numérica.
Uma instalação experimental foi projetada para a avaliação dos dispositivos a fluxo constante (30
L/min e 60 L/min) e variável (um padrão respiratório sinusoidal). A onda foi obtida através de
um simulador respiratório especialmente desenvolvido para este propósito, o qual foi baseado
num mecanismo cam-seguidor. O sulfato de salbutamol (Ventilan HFA) foi recolhido utilizando um
impactor em cascata em vários estágios (Aparelho C da Farmacopeia Portuguesa), e quantificado
por espetrofotometria UV-Visivel. Foram calculadas várias métricas sobre o desempenho das CEs.
Os resultados demonstram a capacidade da CE para reduzir a deposição orofaringeal (64% - 94%),
a qual está intrinsecamente relacionada com o design da válvula do dispositivo. Foi observado
que a CE reduz a fração de partículas grandes na pluma (≈70%), mantendo a MPF bioequivalente
à emitida pelo IPVD. Foi proposta uma correlação entre a fração de partículas finas e o volume de
xi
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ar que atravessa a CE. Foram também sugeridas métricas com relevância para o paciente, que
classificam as CEs de forma quantitativa e qualitativa. Foi desenvolvido um modelo de Dinâmica
Computacional de Fluidos (DCF), onde o fluxo de ar (a 60 L/min) foi calculado juntamente com o
aerossol do IPVD, tendo sido este modelado como uma fase discreta. A interação entre partícula
e parede foi modelada utilizando diferentes aproximações matemáticas, sendo posteriormente
comparadas com a literatura e dados experimentais. Este estudo contribui com um melhor
conhecimento do processo de evaporação das gotas do aerossol dentro da CE, onde se verificou
que este processo está relacionado com o volume da CE. Foi proposto em novo design para CE,
baseado numa otimização das dimensões do corpo da CE, que demonstra melhoria da MPF
emitida.
Palavras chave: Tratamento da Asma; Câmara Expansora (CE); Inalador Pressurizado com
Válvula Doseadora (IPVD); Desempenho; Dinâmica Computacional de Fluidos (DCF); Design.
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1 Introduction
1.1 Motivation
Regarding the strong prevalence of the asthma and other obstructive diseases in the world, the
techniques and the devices used in the treatment of these pathologies have been under constant
development. Being the inhalation therapy one of the most effective and widespread procedures
of treatment in the world, inhalation devices are the object of a great deal of development.
The pressurized Metered-Dose Inhalers (pMDI/MDI) together with the Nebulizers and the Dry
Powder Inhalers (DPI) are the three main categories of devices used in the treatment of asthma
by inhalation. In the specific case of children, for whom the asthma incidence is stronger and
the respiratory coordination to use the pMDI is required, the incorporation of an add-on spacer to
the pMDI represents an effective solution. Spacer devices, mainly the Valved Holding Chamber
(VHC), coupled to the pMDI correspond to the cheapest and most efficient way to treat the
asthma in children (3 to 8 years old) [Can08]. Thus, it is of utmost importance to study the
main characteristics of these add-on devices in order to improve its efficiency, suggest further
optimisation criteria in terms of geometry features and, at last, propose a new and enhanced
design for a VHC device.
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1.1.1 Relevance of Research Developments in Inhalation Therapy
The inhalation therapy is cornerstone to the asthma treatment [VCD+08]. Asthma is an inflamma-
tory chronic disease characterised by airway obstruction disorders, in which pMDIs are favoured
devices for treatment delivery [Glo14]. This disease already affects over 300 million people world-
wide and causes the death of 220 thousand per year. In Portugal, the prevalence of the disease is
estimated between 3 to 5% (see Figure 1.1), showing a clear tendency to increase all over the world
[MFHB04]. One of the most critical issues in this field of knowledge concerns the effectiveness
Proportion of population (%)
≥ 10.1
7.6 - 10.0
5.1 - 7.5
2.5 - 5.0
0.0 - 2.5
No standarized data avaliable
Figure 1.1: Graphical representation of the asthma prevalence in the world
of drug delivery in the patients’ lungs during the treatments [Mar07, Abr07]. The drugs used in
the asthma treatment have anti-inflammatory and bronchodilator properties, with the objective of
reducing the inflammation of the pulmonary tissue (i.e. diameter reduction of the bronchus), thus
increasing the pulmonary capacity [Mar07, Dol04].
The nebulizer benefits from a simpler usage procedure but it needs to be attached to a power
source, which affects patient mobility. Nebulizers also present a greater waste of drug and require
longer treatments sessions. Thus, this inhalation device is reported with a lower efficiency than
the other devices [CRR04]. The DPI is one of the most efficient devices but it also has a few
important disadvantages. Aside from their high cost, DPIs require a minimum inspiratory flow rate
by the patient in order to work with optimum efficiency. Concerning the pMDI, they are the most
commonly used for aerosol delivery of bronchodilators in ambulatory patients [DF01, Smy03],
and they have been the backbone of inhalation therapy for asthma for, approximately, 60 years
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[VCD+08, New06]. Drug dose effectiveness in inhaled delivery is difficult to measure due to
the fact that only a small fraction of the pMDI nominal dose reaches the lower respiratory tract.
The pMDI is a small, cost-effective and very portable device, containing between 100 and 400
doses. This device comprises a disposable canister with a pressurized mixture of propellants,
surfactants, preservatives, flavouring agents and active drugs. This mixture is released from the
canister through a metering valve. The best feature of a pMDI device is that is always ready to be
used, making it a magnificent example of an engineering solution [Dun97]. Its major drawbacks
are the high spray velocities which creates the so called “cold-freon” sensation on the back of the
throat and the necessity of inspiratory coordination with the actuation. This causes the younger
and/or older patients to not being able to use the pMDI device properly [New06, DF01, Tas98].
With the objective to solve some of the pMDI limitations, spacers were created, back in 1956
[PM61]. These devices can be characterised in three categories: simple tube, Valved Holding
Chamber and reverse flow. The most common type is the VHC, in which the drug is fired into
the device, reducing the spray high velocity impact in the throat and the need for inspiratory
coordination. One of the main advantages of these add-on devices lies on the fact that the patient
can keep quiet breathing during treatment. The one-way valve makes the normal respiratory
cycle possible by foreclosing the expiration flux back inside the device. VHCs produce a fine,
slower-moving, more breathable aerosol with less impaction of drug in the oropharyngeal zone
than simple tubular spacers, or even the pMDI alone [DF01]. Although mechanically robust
and clinically effective, when properly designed and pre-conditioned, the VHCs can show great
performance. However, it is of utmost importance to study numerically and experimentally several
causes of inconsistent medication delivery. These include: electrostatic charge; incorrect operation
of inhalation and exhalation valves; geometry configuration, total volume, weight, etc. In addition,
behavioural factors, such as: the patient not following the instructions for use and maintenance,
and imperfect breathing technique. Those factors amplify overall variability. Features, such as, the
valve movement indicators that provide patient feedback are helpful in order to minimise these
factors [MN07]. Table 1.1 lists the potential factors that may result in inconsistent medication
delivery from VHCs.
There are several VHC models in the market but there is a great opportunity to improve its effi-
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ciency or propose a new design. Some authors present different materials and geometries but
the waste of drug versus price is not settled [New04]. A comprehensive market analysis of the
commercial models available is presented in chapter 2. Due to the variety of materials used in
their construction, the range of sizes and type of inhalation valves, a deep and meticulous study
can provide significant insights into the relationship between those features and efficiency of the
VHC devices. Minimising the loss of fine particles by deposition in the VHC is essential to an
effective drug delivery to the lungs [ASAT08]. This fraction of particles has a major importance in
effectiveness of the treatment because in the smaller airways of the respiratory tract, only particles
below 5 µm in diameter can reach the alveolus and enter the blood stream (except those that are
exhaled, diameter below 1µm) [BOS01].
Table 1.1: Potential factors that may result in inconsistent medication delivery from VHCs
Device related Patient related
Electrostatic charge – associated with both
aerosol from the inhaler and inner surfaces
of the VHC device
Choice of appropriate VHC and patient interface
(mouthpiece or facemask) – infant, child, adult
Inhalation valve function – most important with
devices intended for use by infants whose in-
spiratory flow may not open a valve that has
stuck closed
Disease modality and severity – may affect abil-
ity to use a particular patient interface
VHC volume in relation to patient breathing
pattern – more important for infants and small
children
Handling and correct maintenance of the de-
vices - may conduce to inappropriate storage
procedures
Universal adapter seal integrity – essential, es-
pecially for infants and small children
Improper respiratory maneuver, such as, the
patient not hold breath after inhalation
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1.1.2 Where is the Research Opportunity?
The research opportunity is related with the possibility of optimising the geometric features of the
VHC devices, improving their efficiency without increasing their purchase cost. Therefore, this
research opportunity arising from the following research question: Is it possible to develop a VHC
with better efficiency? Underlying this main research question, others may be formulated in the
quest of VHC optimisation (Figure 1.2).
What?
How?
Is it possible to
develop a VHC
with better
efficiency?
Figure 1.2: Schematic of the most important research points resulting from the research question
The first sub-question requires the understanding of what VHC’s characteristics should be improved
in order to achieve a better efficiency. To answer this question, the first step of the procedure is to
study the devices available in the market. This requires a selection of different devices with distinct
geometrical profiles, materials and types of valves to be studied under different conditions.
The second sub-question is to understand how those VHC features can be studied and assessed.
Although VHC devices have been proven to enhance the amount of medication that will reach
patient lungs, some medication is lost through deposition occurring on the VHC walls. Since one
of the aims of this thesis is to investigate the main aspects that influence the drug deposition
within several VHC models, the methodology and proper procedures has to be defined to quantify
the most important metrics in their evaluation. The drug deposition and relevant metrics can be
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quantified experimentally and modelled numerically.
Thus, this work provides the opportunity to use Computational Fluid Dynamics (CFD) tools, as well
as, the construction of an experimental apparatus to provide significant validation of the numerical
model. CFD methodology provides a cost-effective mean of simulating real flows by using modelling
equations (mathematical physical problem formulation) and numerical methods (discretisation
methods, solvers, numerical parameters, and grid generation). These approaches allow the
engineers to predict the behaviour of systems and understand the relationship between the most
important variables and propose optimised solutions without complex experimental setups or
construction of prototypes. Yet, experimental methods have played an important role in validating
and exploring the limits of the various numerical predictions, since reliable information about
physical phenomena is usually given by measurements. In some circumstances, an experimental
investigation involving full-scale equipment can be used to predict how the equipment would
perform under given conditions.
This thesis also aims to study the effects of different inhalation flow rates (including a breath profile)
on the amount of medication that reaches a patient’s lungs, using both pMDI solo and coupled
with VHC devices. These considerations are very important in order to determine if deposition
occurs due to inertial impaction. For a patient suffering from acute asthma, it is important that a
sufficient amount of medication reaches the lungs and, therefore, this research intends to optimize
the devices and, consequently, improve the life quality of those patients.
1.2 Objectives
The project is focused in the study of the transient airflow, due to the human respiratory cycle, in
VHC devices. The study of the drug behaviour inside the device is fundamental to the evaluation
of the VHC efficiency. To achieve this main objective, specific objectives can be defined in the
project:
• Study the human respiratory cycle in the target population: asthmatic children under 6
years old and persons with reduced inspiratory flow capacity for use DPI devices. This cycle
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needs to be mechanically reproduced in the experimental apparatus as an input.
• Develop a computational model using CFD tools where a model for the particle motion
inside the VHC, is added. The input parameters to this model are based in the spray
characteristics, which will need to be well studied, based in the literature and experimental
measurements. The computational model will be developed in FLUENT software (from
ANSYS®).
• Construct and validate an experimental apparatus that replicates the human breathing
cycle, which will allow the comparison of particle collection for different VHC between the
experimental tests and the CFD results. This objective comprises the construction of a
fully functional breath simulator. The breath simulator will be based in the principle of
volume displacement. It will be composed by an in-house made cylinder connected to a
displacement mechanism.
• Assembly of the experimental setup for testing of VHC. To do so, the breath simulator will
be coupled to the setup, to create changes in the constant flow in a way that reproduces
the human waveform at the United States Pharmacopeia (USP) Induction Port (IP) and
therefore in the VHC device to be tested. A cascade impactor, the 5-stages Multi-Stage Liquid
Impinger (MSLI) (US Pharmacopeia ”Apparatus 4”, Portuguese and Eur. Pharmacopeia
”Apparatus C”) will be used, since it is the equipment available in the laboratory.
• Test and quantify, experimentally, the aerosol Fine Particle Mass (FPM) of the dose emitted
by different VHC devices under constant flow (30 L/min and 60L/min), as well as, under
an human breathing pattern.
• Perform the numerical simulations using the CFD model to obtain the prediction of the VHC
devices performance.
• Validate of the computational model by means of experimental measurements. As the
model accuracy increases, the CFD tools will be validated and compared with experimental
results and results from similar studies in the literature.
• Develop an improved design of a VHC device by using full factorial Design Of Experiments
(DOE) applied to the VHC body expansion corner. The assessment will be numerically
performed using FLUENT software (from ANSYS®).
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1.3 Research Methodology
The scientific knowledge is not fully predictable and there are no guidelines or an infallible procedure
to achieve it. The technical procedures and philosophies to be followed by the researcher are
selected according to specific criteria and conditions of the research study. After a detailed
description of the project idea, the research methodology can be described as an overall ”path”
[SLT09]. A simplified way to summarize is shown in Figure 1.3.
New Design
Motivation
Literature Review
Development of a Experimental
Setup for Assessment
Validation
Hypothesis and Plan
Development of
Computational Model
Optimisation
Figure 1.3: Representation of the research process to be used in this project
The methodology that should be followed in order to build up this project starts with a comprehensive
literature review, in order to understand all the issues related with the inhalation therapy devices,
as well as the state-of-the-art concerning to the numerical modelling techniques and experimental
apparatus for testing the device.
The experimentation stage will start with the design and construction of the experimental apparatus.
Experimental flow tests will be conducted in order to ensure the reproducibility of the experiments
and later the validation of the drug collection through an adequate technique. This will allow
calibrating the computational model parameters and later a sensitivity analysis. The validation
should be focused in understanding the model sensitivity to key variables used and the best
8
1.4. Structure of the Thesis
outcome of the device, for instance, the VHC drug delivery efficiency.
The computational modelling comprises the generation of a numerical model based on CFD tools.
The model generation includes the data for the definition of all parameters involved in the physical
phenomena simulation. To do so, it is required a comprehensive survey to create the database.
This step should include all the variables for the geometry, the dimensional boundary conditions
of the simulation. In order to obtain the necessary inputs for the pMDI spray, expert reports and
case studies should be assessed.
In the final stage, the optimisation of the geometry will be the main focus. The best geometric design
will be obtained through the usage of optimisation methods, searching for the best combination of
drug delivery with volume and size constraints. This step of the project will be an iterative process
where the results of the computational simulations and the experimental tests will be used to
validate the best predicted model and proceed with the new VHC design.
1.4 Structure of the Thesis
The present thesis is organized in nice chapters: (1) Introduction; (2) Background and Literature
review; (3) Development of the CFD Model; (4) Project of the Experimental Setup; (5) Experimental
Methodology; (6) Experimental Results; (7) Numerical Results; (8) Optimisation of the VHC
Geometry by using CFD Models; and finally, (9) Conclusions and future work. In the first chapter,
the general motivation for this research work is presented and the framework is provided. The
objectives, the research methodology and the main contributions of the present study are also
described.
The second chapter concerns the background knowledge in the field of the human respiratory
system mechanics, the inhalation therapy and the most used approaches in the treatment of the
asthma and other chronic inflammatory diseases with special focus on the add-on devices, the
VHC. A concise literature review on the most important experimental and numerical research
studies is also presented. The state-of-the-art is divided in in vitro studies, in vivo studies (both
experimental) and numerical studies.
In chapter three, the complete mathematical formulation to develop the computational model is
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presented. All the governing equations for fluid and particles flow solving, the definition of Euler-
Lagrangian discrete phase tracking model and heat and mass transfer are presented. The fourth
chapter reports the project of the experimental setups, describing all the components with special
focus on the breathing simulator. In the fifth chapter, the experimental methodology, including the
protocol and the procedures, as well as, the equipment used to perform the experimental tests
are explained.
The research results are divided in two chapters. Chapter six discloses the main experimental
results from the study. The results were divided in four main groups: results from the Full Dose (FD)
tests; the results from the Cascade Impactor (CI); the results from a multi-variable comparison; and
finally the results for the most relevant metrics for the patient. The numerical results are presented
in the seventh chapter. These results are presented considering the analysis of flow distribution
along the VHC devices, the drug deposition and the analysis of the particles evaporation during
the simulations. It is also presented, an important discussion regarding the validation of both
numerical and experimental results, which are then compared with literature data.
Based on the main conclusions from the numerical and experimental work, an optimized design
of a VHC device is proposed in chapter eight. The new design was obtained from a DOE study
performed using FLUENT. Finally, the main conclusions of the research and some suggestions for
further developments are pointed out in chapter nine.
1.5 Contributions of this Work
This thesis provides some contributions for the scientific research community, as well as, for the
medical community. The most relevant are given here:
• Report several medically relevant metrics through experimental assessment of the drug
(Ventolin) delivered when a pMDI is coupled to commercial VHCs. These metrics provide a
source of data on the clinically performance of the VHCs at constant flow rate (30 L/min
and 60 L/min) and under a breath pattern (tidal volume of 150 mL).
• Perform an exhaustive experimental analysis to compare different commercial VHC models
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tested under controlled conditions. The comparison of the experimental results will allow
observing that not all the VHCs in the market have the same performance at the distinct
flow rates. This study will also increase the understanding of the importance of the valve
design in the distinct VHC performance.
• Develop a numerical model to provide insights into the pMDI spray evaporation phenomena
that occurs inside the VHC devices. The realistic parameters used in the simulation will
bring the state-of-art, on CFD modelling of spacers, one step forward.
• Use the computational tool to evaluate and optimize the design of the devices for inhalation
therapy without expensive production costs of physical prototypes.
• Propose a new design for a VHC device. The new design will represent the most important
achievement of the project and its development represents the outcome from the exper-
imental and numerical conclusions. This new design must take into account the most
device- and patient-related factors that promote consistent medication delivery.
The fundamental problems in the design and assessment of VHC devices are related with the time
consumption of the processes and the cost of manufacturing prototypes. In most of the cases,
finding the geometrical parameters of the devices is based on insufficient and costly experimental
information. This means that improvements to the design are being achieved through high-cost
and time-consuming trial and error procedures. Regarding this, numerical modelling techniques
represent a great opportunity to identify the key parameters and, together with a well-founded
experimental basis, optimize the devices using a cost effective process.
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2 Background and Literature Review
2.1 Human Respiratory Mechanics
The respiratory system’s main function is gas exchange, providing oxygen (O2) to the body tissues
and eliminating carbon dioxide (CO2). The exchange of gases takes place at the alveoli, where O2
diffuses into the lung capillaries in exchange for carbon dioxide. Exhalation begins after the gas
exchange and the air containing CO2 begins the return journey through the bronchial airways and
back out to the external environment, through the nose and/or mouth. Secondary functions of the
respiratory system include filtering, warming, and humidifying the inhaled air. This includes the
vocal cords in the larynx for sound generation, the lungs for homeostasis, and the olfactory bulbs
(in the nose) for smell, as presented in Figure 2.1 [TIA13].
The respiratory system can be separated into regions based on function or anatomy. Anatomically,
the respiratory system can be divided into the upper and lower respiratory tracts. The upper tract
includes the organs located outside of the chest cavity area (e.g. nose, pharynx, larynx), whereas
the lower respiratory tract includes the organs located almost entirely within it (i.e. trachea, bronchi,
bronchiole, alveolar duct, alveoli and diaphragm).
Functionally, there is the conducting zone (nose to bronchioles), which consists of the respiratory
organs that form a path to conduct the inhaled air into the deep lung region.
The majority of the large inhaled particles are entrapped by this filtration mechanism, or impact
on the walls of the nasopharynx due to the turbulent flow. When breathing through the mouth, air
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filtration and heating does not occur, and the resistance to air flow is lower. These reasons, make
mouth breathing a more effective route for the administration of aerosol medication. The right
lung has 10% higher volume than the left one (due to the need to accommodate the heart), which
makes it more susceptible to infections. The different lengths and angles of the bronchi also have
an impact on the aerosol particles lung deposition. There are around 23 generations from the
trachea to the alveoli sacks, where the upper 16 generations are considered to be the conducting
zone and the lower seven correspond to the respiratory zone [TIA13].
Figure 2.1: Respiratory system divided by the upper and lower respiratory tract regions
The respiratory zone (from the alveolar duct to the alveoli) consists of tiny passageways, where
gas transport occurs by diffusion. The alveolar ducts are small polyhedral sacks (with a large
surface area), where the air can diffuse due to the fact that the walls are only one cell thick. It is
of vital importance that the alveoli contain residual air volume (even during exhalation) because,
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when collapsed, the alveoli require a large amount of pressure to re-inflate. To prevent this from
occurring, the alveolar walls are covered with a lipid substance (a surfactant), which will maintain
their stability to remain continuously open.
The thoracic cavity is constituted by the ribs, the diaphragm, the sternum and the intercostal
muscles. The diaphragm provides approximately 75% of the power required for perform a quiet
breathing, where the remaining 25% is provided by the ribcage movement.
2.1.1 Breath Profile
The breathing is a respiratory process composed by two phases: the inhalation – the movement of
the air into the lungs; the exhalation – the movement of the air to the outside. In this process, the
pleural fluid between the lungs and ribcage act simultaneously as a lubricant, allowing unrestricted
movement. During quite breathing (i.e. tidal breathing), the inhalation movement starts with the
contraction of the diaphragm. This creates negative pressure inside the thoracic cavity forcing the
lungs to expand, consequently, the air flows into them. Exhalation is a passive process whereby
the diaphragm and the intercostal muscles do not contract, so that the diaphragm rises and the
ribs move downwards. Thus, the volume of the lungs decreases, forcing air out [TIA13].
Other muscles, such as the sternocleidomastoid muscles, are more involved in inhalation and,
with increased force, the ratio of time for inhalation to time for exhalation decreases. The exercise
practice or hyperventilation may induce this increased force. As well as the major muscle groups,
muscles in the linings of the airway walls are also used in respiration. The expansion and the
contraction of the airways, due to these muscles, assist in increasing and decreasing lung volumes.
This affects the diffusive process of gas exchange. The inhalation flow rates fluctuate, due to
several of reasons: lungs volume/capacity, patient age, weight, physical activity and respiratory
health.
Inspiratory flow rates are important when administering therapeutics drugs as an aerosol, or for
inhalation therapy. The devices such as pMDIs, DPIs and nebulisers are affected by inspiratory
flow rates as they influence the locations of the lungs that the aerosol will reach, the amount that
will be taken in during one breath, and the turbulence that will be present in the flow.
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Spirometry is the most used methodology to evaluate the respiratory capacity. This technique
allows the diagnosis of respiratory diseases through the evaluation of certain indexes. Those are
compared with predicted values, based in age, gender, weight, and ethnicity [DS03].
Figure 2.2 depicts a healthy adult typical flow-volume curve, against one from a adult with asthma
and one with Chronic Obstructive Pulmonary Disease (COPD) [Mil05]. It can be seen that the
presence of asthma affects the adult capacity to exhale, reducing its flow rate. The COPD not only
reduces the exhalation flow rate but also reduces the volume of air exchanged.
Normal healthy adult Adult with asthma Adult with COPD
Exhalation
Inhalation
Figure 2.2: Flow-volume typical curves for adults: healthy, asthma and COPD [Mil05]
Human breathing waveform is usually characterised by two parameters: the number of Breaths Per
Minute (BPM) and the duty cycle (i.e. the ratio of the inhalation time to the tidal breath duration).
These two characteristics, together with the current volume of air during quiet breathing, can
define a typical waveform. The breath patterns are usually approximated to a sine or square
waveform, and those three parameters give it shape [DM04]. Nikander et al. (2001) performed
an experimental assessment of the nebulizer rate of delivery using a human breathing pattern, a
sine waveform and a square waveform. They concluded that the shape of the waveform had no
influence in the rate of delivery from the nebulizer [NDSW01].
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2.1.2 Pulmonary Capacity
The volume and the compliance capacity of lungs and chest wall, influence the behaviour of the
respiratory system. Normally, the lung volumes are measured with a spirometer, and its lung
capacity is then inferred from the measurements. The lung capacity and the air volumes displaced,
are of vital importance in determining health of this organ (see Figure 2.3).
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Figure 2.3: Representation of the vital lung capacities and volumes
There are five volumes and four capacities used to characterize the lung operation [TIA13]:
• Total Lung Capacity (TLC) is the total air volume supported by the lungs.
• Tidal Volume (VT ) is the amount of air that is inhaled and exhaled during normal quiet
breathing. 7–9 mL/kg of ideal body weight ≈8–10% of TLC.
• Inspiratory Reserve Volume (IRV) is the maximum air volume that can be inhaled above the
tidal volume.
• Expiratory Reserve Volume (ERV) is the maximum volume that can be exhaled below the
tidal volume.
• Residual Volume (RV) is the volume left in the lungs after maximum exhalation.
17
Chapter 2. Background and Literature Review
• Functional Residual Capacity (FRC) is the volume of air left in the lungs after a tidal
exhalation.
• Inspiratory Capacity (IC) is the maximum volume of air that can be inhaled.
• Vital Capacity (VC) is the air volume difference between a forced inhalation and a forced
exhalation.
Gas exchange through the respiratory system occurs either by convection or diffusion. The factor
that determines the type of exchange occurring between two gases, is given by the ratio of the
diffusive time to the convective time for transport. In the upper airways, the gas transport is mostly
done by convective transport, whereas at the lower generations of the respiratory system, diffusion
is the main process of gas transport. The gas exchange across the alveoli membrane is controlled
by diffusion mechanism, that occurs due to the large surface area.
2.1.3 Respiratory Diseases
Asthma, COPD and bronchitis are diseases that affect the conductive and gas exchange zones of
the human respiratory system. These diseases seriously affect the capacity for normal respiratory
function, due to the airway inflammation.
COPD is a disease that frequently occurs later in patients’ life and, predominantly, corresponds
to an effect from smoking habits. COPD increases the airway resistance due to various factors:
clogging of the airways due to the excess of mucous, loss of airways elasticity, or inflammation
of the airways. Treatment of COPD includes the delivery of bronchodilators to reduce airway
inflammation. As the disease is obstructive and restrictive, the total lung capacity is reduced
and, consequently additional treatment is required. Those treatments can include: pulmonary
rehabilitation, in order to learn how to use the reduced amount of available air; or supplemental
oxygen [TIA13].
Bronchitis is an infection disease, which results in inflamed bronchi, generally caused by a viral
source. Its treatment is similar to the ones associated with COPD. Bronchitis can be treated with
medication, such as, inhaled salbutamol sulphate in order to reduce the inflammation at the
bronchi [Spr14].
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Asthma is also a chronic disease involving the airways in the respiratory tract. Asthma symptoms
are coughing, chest tightness and dyspnoea (shortness of breath). These symptoms are due to
increased resistance to air flow. The asthma attacks are caused by airway hyper-reactivity, in
which the bronchi and bronchioles suffer a great constriction, causing increased resistance to air
flow. This hyper-reactivity is due to, for example, inhaling allergens or exercise (particularly in the
cold environments). The bronchial hyper-reactivity is usually associated to the increase in mucous
production. The treatment is usually done by inhalation therapy, where pMDIs are a preferred
device. A third of asthma patients show symptoms before the age of ten and, in most cases, it is
diagnosed before the age of 40 [MN07].
2.2 Inhalation Therapy
According to Crompton, inhalation therapy can be traced as far back as 4000 years ago in India,
and many ”hundreds of ingenious devices and hopeful medications” (according to Sanders) have
been discovered so far. Inhalation therapy is so important nowadays that is hard to imagine the
treatment of asthma without a proper inhalation therapy procedure, an inhalation device, and a
the necessary drug [Cro06, San07].
Briefly reviewing the antecedents of contemporary inhalation therapy and medicines used for the
management of asthma over the last 50 years, Crompton presents the 19th century hand-held
glass bulb nebuliser up to the introduction of the first pMDI, which came into common clinical
practice in 1956 [Cro06]. Sanders, detailing the inhalation therapies since ancient times, refers
several inhaler devices, such as: the C. Bennet’s inhaler (dated from 1654); the J. Mudge’s inhaler
(from 1778, and adapted from a pewter tankard); the first pressurised inhaler (presented in 1858,
in Paris, France, by Sales-Girons); the Improved Nelson inhaler (proposed in 1865 by S. Maw
& Sons, London) which is still being manufactured up to this day; and the Siegle’s steam spray
inhaler (a German invention from early 1860’s that marked the beginning of the nebuliser therapy)
[San07].
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2.2.1 Medication
Anti-inflammatory and bronchodilator drugs are used with the objective of reducing the inflammation
of the pulmonary tissue, which causes the diameter reduction of the bronchus [Dol04, Glo14]. In
the inhalation therapy, the drugs used are divided in several groups, being the two major ones
the Inhaled Corticosteroids and the bronchodilators agonists of long and short action [Dol04].
Within them, there are different active molecules, although each has its own major delivery system
associated, some of them are:
• Short-Acting β2 Agonists (SABA)
– Salbutamol (Ventolin)
– Levalbuterol (Xopenex)
• Long-Acting β2 Agonists (LABA)
– Salmeterol (Serevent Diskus)
– Formoterol (Foradil)
• Inhaled Corticosteroids (ICS)
– Budesonide (Plumicort)
– Beclomethasone dipropionate (QVAR)
– Fluticasone propionate (Flovent)
A study about medication prescribed for asthma treatment, to children, up to 15 years old, in
six countries (Belgium, Ireland, Italy, Portugal, Spain, England, North Ireland and Scotland), has
shown that the most prescribed drugs are the SABA and LABA, mainly in emergency situations
[JBGJ00].
Another study, made in Holland, shows that the major prescribed medication (82%) to treatment
of asthma in 165 children during the first 4 years of living, was the β2-agonists by inhalation
[ZSB+08].
In Trindad and Tobago, a study was carried out with asthmatic patients of all ages. The study
concluded that the majority of them use salbutamol drug (Ventolin) as the prescription of choice
[PCS01]. Most recently, the Inhaled Corticosteroids are used, in small doses, for daily control
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medication of asthma symptoms [Glo14, Tan15].
2.2.2 Inhalation Delivery Devices
In the inhalation therapy, the mostly used delivery devices are: the nebulizers; the DPI; and the
pMDI, which can be coupled with an add-on device [DD11, DF01, DM04, New04].
Nebulizer
Introduced in the 1800s, nebulisers were one of the first devices used for aerosol drug delivery.
These devices convert a liquid into aerosol droplets suitable for patient inhalation through a
mouthpiece or face mask. The use of nebulisers for the treatment of asthma is declining, but they
are still used if the prescribing physician suggests it, or if a patient requests it. Nebulisers are also
still used for drug administration for other illnesses.
Nebulizers use oxygen, compressed air or ultrasonic power to break up medical solutions and
suspensions into small aerosol droplets that can be directly inhaled from the mouthpiece of the
device. The use of ultrasonic waves is the most expensive, the smallest and the most portable
method available, requiring an ultrasonically vibrating crystal. Jet nebulisers use either electrical
or gas compressors to pass a stream of air or oxygen through the liquid medication. These devices
require a mouthpiece or face mask attached. Because of their shape and size, jet nebulisers are
less portable, which represents an inconvenience. Whether ultrasonic or jet, the nebulisers operate
continuously while medication is being administered, which takes approximately 10 to 15 minutes.
During the procedure, the patient breathes normally through the face mask or mouthpiece. As
inhalation only makes up one third of a breathing cycle, the majority of medication released is not
actually inhaled. This problem is only solved with a specially designed mouthpiece to control the
medication release. Yet, this also affects the nebulisers efficiency because part of the delivered
medication is entrapped in the plastic walls or in the facemasks. On the other hand, the aerosol
large particles that will impact in the device walls do not reach the patient mouth, whereas the
small repairable ones do.
The use of Nebuliser is decreasing mainly because the alternative therapies are more convenient,
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less expensive and more efficient in treating asthma. However, for illnesses such as arthritis, the
nebulisers can still be the preferred method because the patient’s conditions (e.g. weakness). At
hospitals, because of their design and the lack of requirement for a certain inspiratory flow rate,
nebulisers are regularly used when patients can only breathe passively [DD11, Hic03].
Nebulisers are also beneficial for situations where large doses are required, but it has been found
that using a large volume spacer with a puffer is also a plausible alternative.
Recently, new nebulizer models have been developed. These models improve the portability by
reducing the power consumption an allowing the use of small rechargeable batteries. Some models
have the ability to operate upon breath solicitation, reducing the waste of drug. Nevertheless, they
are very expensive devices [DD11].
Dry Powder Inhaler (DPI)
A DPI is a handheld device used for administering medication in the form of a dry powder. There
are several types of DPIs which use medication stored in different ways: in blister packs, in reservoir
devices or, in some cases, the medication can be stored within the device itself (which requires a
pre-metering part of the DPI design).
Medication is in powder form and inhalation is the propelling force used to actuate the device.
DPIs can be used to deliver medication such as, salbutamol sulphate, but they are more common
for use with preventative medication [FBGD00].
When using a DPI, the patient inhales deeply at a rate between 30 L/min and 90 L/min. Because
the device is self-actuated (i.e. actuated by the breath) there is no requirement for the patient
to synchronise their breathing with actuation, which can be problematic for some patients. This
device is also beneficial for patients with arthritic hands as it does not have an external trigger that
needs to be pressed. The devices are also portable and small which makes them a good choice in
treating of asthma.
Nevertheless, DPI devices are not suitable for all type of asthmatics. The high inspiratory flow rate
requirement can be problematic for younger patients and those suffering from COPD, or who have
another condition which causes difficulty in taking deep breaths. Without the deep breath, the DPI
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will not actuate. In order to have a correct actuation, a substantial pressure drop is required which
can only be achieved with a significantly deep breath. DPIs are not usually prescribed to patients
under six years old or in the case of elderly sick people. Typically, a DPI deliver between 10-40% of
the dose to the bronchi.
The limitations from using a DPI arise when patients exhale into the actuator, as the added humidity
can cause obstruction of the powdered medication, meaning that the efficiency decreases in the
medication delivery [New06].
pressurized Metered-Dose Inhaler (pMDI)
Regarding the pMDI, it has a low cost and it is widely trusted by the patients and physicians alike.
It delivers a dose of medication in the form of an high velocity spray, powered by a propellant
kept at high pressure inside the canister. It is very portable and simple to operate and it does not
dependent on the patient’s Peak of Inspiratory Flow (PIF).
However, its major drawbacks are: the high spray velocity, which creates the so called ”cold-Freon”
sensation on the back of the throat; and the necessity of inhalation-actuation coordination, which
makes impractical for younger and/or older patients to use the device properly. This problem
is mitigated the implementation of classes to teach the correct usage procedure, resulting in
increased efficiency [New06, DF01, Tas98].
2.3 pressurized Metered-Dose Inhaler (pMDI)
The pMDI, shown in Figure 2.4, is the mostly used aerosol delivery device in the world for the
treatment of asthma. In 2000, an estimated production of 800 million units have been reported
[Smy03, DF01]. It has been the backbone of inhalation therapy for asthma for approximately 50
years [New06]. The pMDI contains 100 - 400 doses packaged into a small and (very) portable
device, that can be easily concealed in a pocket. The best feature of a pMDI device is that, it is
always ready to be used, making it a magnificent example of an engineering solution.
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Figure 2.4: A pMDI, Ventolin HFA, and its dust cap
2.3.1 Characterisation
The pMDI device essentially incorporates a disposable canister, where the drug formulation is
stored, which can be replaced for a new one at any time, mounted in an actuator with a mouthpiece
zone and usually a dust cap is included [New06, New05]. The four basic components that can
be found in all pMDIs are: the formulation canister; the metering valve; the actuator; and the
container [Dun97]. On the following list are described the components of a pMDI device (see
Figure 2.5) [DF01, RG99]:
• Canister with O-Ring
• Formulation
– Active Pharmaceutical Ingredient (API)
– Propellant(s)
– Surfactant(s)
– Lubricant(s)
– Co-Solvent(s)
• Ferrule Gasket
• Complete Valve
– Mounting cup
– Valve core assembly
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• Diaphragm
• Stem
• Spring
• Seal
– Metering tank
– Retaining cup
• Adaptor with dust cap
Aerosol Can win O-Ring
Formulation:
Drug Substance
Propellant(s)
Surfactant(s)
Lubricant(s)
Co-Solvent(s)
Ferrule Gasket
Complete
Valve
Adaptor with
Dust Cap
Complete
Valve
Mounting Cup
Valve Core
Assembly
Metering Tank
Retaining Cup
Valve Core
Assembly
Diaphragm
Stem
Spring
Seal
Figure 2.5: The pMDI main components, adapted from [RG99]
The spray pattern and Mass Median Aerodynamic Mass (MMAD) are influenced by: the ambient
temperature; the design of the actuator nozzle and valve stem; and by the vapour pressure of the
propellant in the formulation [DF01].
The formulation is composed by the drug, the propellants gases and it often contains surfactant
and other excipients. In the formulation, the propellant is the component which creates vapour
pressure inside the canister, allowing the drug to exit the pMDI and to form a spray plume every
time the device is actuated. When the drug particles exit the pMDI, they are encapsulated in a
droplet made of propellant, which evaporates as it travels through air. Some of the formulation’s
characteristics, in one of the most common used medicine in asthma treatment (Ventolin), are
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listed in Table 2.1.
Table 2.1: Ventolin’s formulation showing two propellant types, HFA and CFC [New05]
Ventolin HFA Ventolin CFC
Active ingredient Salbutamol sulphate Salbutamol sulphate
Excipient None Oleic acid
Propellants HFA-134a CFC-11/12
Formulation type Suspension Suspension
The canisters for a pMDI are typically made of aluminium and they are designed to be light,
compact and strong to hold the high internal vapour pressure of 3 to 5 bar made by the propellant
in the formulation [New06, New05]. Its typical capacity ranges between 15 mL and 30 mL
[Dun97]. The metering valve of a pMDI is crimped into the container. There are several designs of
valves but they all work under the same principle: while the canister is in the inverted position,
by gravity action, the valve fills a cavity with the formulation through a channel, gathering the
desired measured dose; at the priming moment, this channel closes and another one opens
in the opposite side of the metering valve, allowing the formulation to rapidly expand into the
expansion chamber. The actuator pit and the valve stem constitute the expansion chamber
where the propellant begins to boil [Dun97, New05]. This process is often referred as the
primary atomisation, where a flash evaporation of the propellant takes place [Dun97, Fin01].
Afterwards, it exits the expansion chamber through the actuator nozzle and it rapidly expands
in the shape of a solid-cone plume [Dun97, New05]. In this way, the metering valve of a pMDI
is a critical component in the effectiveness of the delivery system. Thus, its main functions are
[Tas98, DF01, New06, Smy03, New05, Dun97]:
• Deliver (accurately and reproducibly) a measured volume (20-100 µL), containing between
20-5000 µg of the dispersed drug;
• Form a tight seal for the high pressure propellant in the canister.
The actuator is normally a single plastic piece produced by injection moulding that consists of a
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mouthpiece, body and nozzle [New06, Smy03, New05, Dun97, SHB+06]:
• The mouthpiece is the interface part to the patient mouth;
• The body provides support for the canister;
• The nozzle has a very important role in controlling the atomisation process, to guarantee
a spray plume formation. The nozzle diameter interferes directly with the particles size
distribution [Cla91, CYF+14b, SBB+06].
When the pMDI reached the market in 1956, it was composed of an elongated mouthpiece (around
8 cm); nowadays, it was reduced to a more compact size (from 2 to 3 cm) to improve the portability
[New05].
2.3.2 Add-on Devices (spacers)
Despite having a number of advantages, the pMDI is usually coupled to add-on devices in order to
improve the fraction of medication that deposits in the lungs. The first known pMDI, produced
in the 1950s, had an elongated mouth-piece to the actuator. This was, in fact, the first pMDI
spacer device, once the purpose of this design was to provide sufficient distance and time for
the propellant to evaporate. Years after, the development of a much larger device to be used by
children was reported. Subsequently, a range of add-on products has been described as devices
that help patients to get the adequate amount of medicine when a pMDI is used [New04].
These add-on devices are classified in three main categories: simple/tubular spacers; reverse flow
devices; and Valved Holding Chamber (VHC). Briefly, it can be summarized the three main roles of
the add-on devices: they allow an easier use of pMDIs by reducing the need to coordinate actuation
with inhalation; they increase the pulmonary targeting, by lowering the velocity of inhaled drug
particles; and they act as an alternative to nebulisers, for delivering large doses of bronchodilators
in patients with severe asthma [MN07].
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Tubular Spacer
Tubular spacers are the simplest add-on devices to couple with a pMDI. Its operating principle
is based in the addition of distance between the patient’s throat and the actuator nozzle. This
allows the propellant, in the spray’s plume, to increase its evaporation rate. It allows reducing
the droplets size and decreasing the plume velocity, resulting in lower oral-pharyngeal deposition
and improved lung delivery. Nevertheless, the patient needs to be able to breathe in as the pMDI
is actuated, because the device does not hold any of the medication. From a practical point of
view, this category of add-on devices is an extension to the inhaler mouthpiece, requiring the same
inhalation-actuation coordination.
The idea for the spacer was firstly developed by Maison and Porush (1956) [PM61], two decades
after the invention of pMDI. By that time the problems regarding the complexity of the pMDI
technique were well documented. Their design was simple, consisting of a tubular extension (7.6
cm) of the pMDI actuator mouthpiece. One year passed and a tubular spacer was developed as
an accessory for the pMDI [vS59].
A great research effort was made to better understand the spacer dimensions and reach an
optimum value. Kirk (1972) studied the elongation of the pMDI actuator mouthpiece from 3.7
cm to 8.0 cm, concluding that this increased the ability to deliver the dose [Kir72]. Móren (1978)
shown (through an in vivo study) that the optimum spacer length should be 10 cm, beyond this
value no further reduction of the impaction was noticed. Increasing the diameter of the tube was
proved beneficial for reducing the particle loss and improving the drug delivery [Mor78]. He also
suggested that pear-shaped devices could actually be the next best bet for spacer design [MW79].
Barry and O’Callaghan (1995) experimentally correlated the emitted FPM with the length (5 –
50 cm) and diameter (3 – 10 cm) of tubular spacer (and their volume), concluding that both the
length and diameter increase the output. A correlation was found between the volume and the
FPM, for which volumes above 1 L do not provide greater improvement [BO95].
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Reverse Flow Spacers
In the case of the reverse flow add-on devices, the medication plume is initially directed away
from the patient into a chamber (equipped with air vents). The air is inhaled through the device’s
mouthpiece, bringing drug particles along, which rested in the chamber. This type of spacer allows
the spray plume to evaporate in the stagnant air of the chamber, prior to being inhaled. This add-on
category has no one-way valve, allowing the patient to exhale into the device. The coordination
between the actuation and inhalation is nullified, but the tidal breathing is not advisable [New04].
Valved Holding Chamber (VHC)
The valved devices usually contain a inhalation one-way valve, close to the mouthpiece, which
represent their most differentiable characteristic. Holding chambers commonly provide the largest
distance between the actuator and the patient which is important for a rapid decrease of particles’
velocity. Studies demonstrate that there is a correlation between the spray plume velocity and the
particle’s impaction on the oral-pharyngeal area. The volume of the holding chamber allows the
delivery of high quantities of medication, mostly in severe cases of chronic respiratory diseases
[New05].
The VHC devices vary in volume, design, materials and features. Concerning the design there are:
pear-shaped spacers; straight spacers; and cone-shaped spacers. However, the device volume
should not exceed the breathing capacity of the patient, so the medication would not be wasted.
2.3.3 Delivery Procedure
The actuation, also called priming, discharges the spray plume (also known as puff), into the air.
The actuation of the pMDI needs to follow some procedure steps to result in an efficient delivery
to the patient’s lungs, or else almost all drug will be trapped in the throat [PCS01, Fol02]. The
procedure can be resumed to a few steps, which are advised for all patients using pMDI solo:
1. Remove the dust cap and hold the inhaler upright
2. Shake the inhaler
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3. Exhale fully
4. Place the pMDI actuator in the mouth
5. Breathe in deeply and slowly
6. Press on inhaler (coordinating actuation with inhalation)
7. Keep inhaling for 3 to 5 seconds
8. Hold breath for 10 seconds
9. Exhale slowly
10. One actuation per inhalation
11. Wait 1 minute before second actuation
By studying the technique of the pMDI used by the patients, it was found that the majority of the
patients have difficulty to execute all the steps correctly. The study included children (n= 26),
adolescent (n= 23), adult (n= 209) and elderly (n= 66) patients. Among them, the children
are those with more difficulty in coordinating the inhalation-actuation. The elderly have more
difficulties in just doing one actuation per procedure and waiting before going for the second
round. Adolescents and adults are the patients with better abilities to use the pMDI device correctly
[PCS01].
Without a proper technique, the use of pMDI can not be effective. In the case of corticosteroids, it
can even be harmful. This is the reason why several asthma treatment guidelines recommend
the use of add-on devices for children under 5 years old. The USA national asthma treatment
guidelines state the use of holding chambers for “…children less than 4 years of age will have less
difficulty with a pMDI plus VHC with a face mask…”. During a child dose (for children under 12
years old) of SABA drugs, it is again stated “4–8 puffs every 20 minutes for 3 doses, then every
1–4 hours inhalation manoeuvre as needed. Use VHC; add mask in children < 4 years” [Nat07].
According to the British guidelines for asthma treatment “children and adults with mild and
moderate exacerbations of asthma should be treated by pMDI + spacer with doses titrated
according to clinical response”. It also states that “In children aged 0-5 years, pMDI and spacer
are the preferred method of delivery of β2-agonists or inhaled steroids. A face mask is required
until the child can breathe reproducibly using the spacer mouthpiece”. And that “Children receiving
β2-agonists via pMDI + spacer are less likely to have tachycardia and hypoxia than when the same
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drug is given via a nebulizer”, “There is good evidence that pMDI + spacer is as effective as, if not
better than, nebulizers for treating mild to moderate asthma in children aged ≤ 2 years” [SB11].
The Global Initiative for Asthma (GINA) report provides global guidelines for asthma treatment
with the VHC: “In general, a metered-dose inhaler (MDI) with spacer is preferable to nebulized
therapy due to its greater convenience, more effective lung deposition, lower risk of side effects,
and lower cost… Use of a spacer also reduces oropharyngeal side effects… In severe acute asthma
exacerbations a nebulizer is often used, although an MDI with a spacer is equally effective” [Glo14].
It is also stated that the preferred device for asthma treatment in children (≤ 6 years old) is the
pMDI + spacer.
A major literature review on the asthma inhalation treatment, from surveys on medication to delivery
devices, was assembled by a group of renowned researchers in the field in 2001 [BRW+01]. In
this document, an extensive compilation of studies previously made about asthma is available,
and it is possible to find a summary of the previously recommendations on the guidelines related
to spacers.
2.4 Valved Holding Chamber (VHC)
The VHCs are coupling devices that attach to pMDI. As previously mentioned, its basic function
is to add distance between the spray and the patient’s throat, giving it time for the propellant to
evaporate. The VHCs remove the plume’s ballistic component (i.e. coarse particles); reduce the
potential for systemic absorption of drug deposited in oral-pharyngeal (≈80% reduction); and retain
the aerosol plume in the chamber allowing the patient to inhale it at his own time [New04]. More
importantly, VHC nullify the actuation-inhalation coordination, which gives the patient possibility to
inhale the dosage using tidal breathing. The one-way valve at the mouthpiece avoids the patient to
exhale inside the chamber.
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2.4.1 Characterisation
As shown in Figure 2.6, a VHC consists of four parts: adapter, body, valve and mouthpiece. These
may be made from different materials, as well as, the existence of flow indicators (i.e. whistle),
dust cap, or even exhalation valve.
pMDI
Adapter Inhalation
One-way Valve
Mouthpiece
Body
Figure 2.6: Schematic of the VHC components
Its most important characteristic is the one-way valve for inhalation, because this allows the tidal
breathing to happen without losing drug particles. Some devices have exhalation one-way valves,
which improve VHC’s performance. This device is usually accompanied by a facemask, that plays
an important role in improving the drug delivery to very young children [MvHvK+14, EFAvV+04].
Many VHCs are lined on the inside with an anti-static coating and their volume varies between 100
and 750 mL. The VHCs volume is related to the patient pulmonary physiology (age-related), the
tidal volume.
The materials used have a greater role in the efficiency and cost of VHC devices. Several studies
indicate that the electrostatic effect of the material walls affects the emitted dose from the device,
reducing the amount of drug that reaches the lungs [Bis95, KCC06, DGB03, WDH+96]. A metal
VHC device, Nebuchamber, was developed to avoid this problem, as well as other devices with
antistatic properties [Bis95, JWE+02, BO99b]. Other studies suggest that pre-treatment of VHCs
with a washing bath in a surfactant solution, before its use, resulted in a reduction of electrostatic
charge and increases drug delivery [WDH+96].
Electrostatic charge is a commonly-reported cause of unreliable drug delivery from VHCs. The
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electrostatic force can be much higher than the gravity for highly charged particles. Most aerosol
particles carry electric charge, which affects aerosol retaining within the VHC device, as well as,
the drug deposition at lungs. The electrostatic charge removal is required from the standpoint
of achieving consistent deposition of drug particles in the lower respiratory tract [RR13]. Also,
electrostatic charges increase as the result of: (1) the friction created by the contact and separation
of dissimilar materials; (2) the interaction between pMDI components and particles. VHCs made
from non-conducting polymers acquire surface electrostatic charge during manufacture, packaging
and even storage process. As a result, if precautions are not taken to mitigate this phenomenon,
the efficiency of the drug delivery can be affected. Pre-washing VHCs with solution containing a
small quantity of ionic detergent is an acceptable approach to reduce the negative effects of the
electrostatic charges since detergents are essentially surfactants with the capability to spread onto
a surface as a monolayer.
The VHC valves (inhalation and exhalation) must operate effectively over the entire pressure range
during the use of the VHC device. This requirement is a problem for children/infants because
they have some difficulties in reaching a pressure of 100 to 300 Pa, below which the valves
are stuck closed. The correct valve operation requires at least a 50 mL of tidal volume, an
inhalation/exhalation ratio of 40/60 and 30 breaths/min [MN07]. The ability to observe valve
movement in response to patient breathing is a significant benefit in confirming their correctly
operation.
There is a great diversity regarding the VHC devices volume which can also affect efficiency of drug
delivery. Smaller devices are advantageous for infants because of its compact size, portability,
easier handling and because they minimise the number of inhalations necessary to empty the
chamber.
2.4.2 Requirements
Although efficiency is the major reason why the study is justified, there are some requirements to
be taken into account in the study of VHC devices. They can be classified of user or physician
nature.
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User Requirements
Patient do require some aspects of the VHC device that are related to its usability and transportation.
Those should be kept in mind while developing a new VHC [Dol04].
• Portability
– Lightweight
– Reduced size
• Cost
– Simple production process (e.g. injection moulding)
– Cheap materials (e.g. polymers)
• Easy usage
– No complex mechanisms
– Ergonomic
• Easy cleaning
– If modular, needs to be of easy assembling
– Cleaning using normal domestic products
• Resistant
– Avoid losses of efficiency due to the continuous cleaning
– Endure drops from children usability
These desired characteristics are not always compatible with each other, and seldom are all present
in the various types of VHC available in the market.
Physician Requirements
The physician requirements are mostly focused in the efficiency of the device, where the maximi-
sation of the FPM (keeping the bioequivalence with the pMDI solo) is the main concern. Other
topics must be taken into account:
• Efficiency
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– Low electrostatic materials
– Reduction of the spray velocity
– Functional one-way valve for low inhalation flow rate
– Features that can perform inhalation flow control
– Reduced drug entrapment
• Materials
– Non harmful (health)
• Volume
– Must be adequate to the patient age
2.4.3 Market Analysis
There are several VHC models commercially available in the market. In Table 2.2, the main
characteristics of eight commercial VHC devices used in this work, are described. There are other
commercial devices, however their availability depends on the country. Many more VHC projects
are patented but they never reached the market. The VHC devices described in Table 2.2 are all
available in the United Kingdom, and the majority of them were obtained next to the producers
(excepting Vortex, Nebuchamber and Volumatic). The most sold VHC devices are the Volumatic,
Aerochamber Plus and Vortex. In Table 2.2 is also provided information regarding the devices
weight, volume, body length and price, among other characteristics.
In the majority of the VHCs, the adapter is made of a flexible material (e.g. silicon rubber), allowing
a good air sealing with most of the commercial pMDI actuators. On the other hand the Volumatic,
was developed to be used with the Ventolin pMDI and Nebuchamber was specifically developed to
be used with Plumicort pMDI.
Other observable characteristics of these devices were the existence of flow control whistle (present
only in Aerochamber and Optichamber), which would activate at a certain inhalation air flow rate.
This feature was further studied by Sanders and Bruin (2013), where they observed that the whistle
activation is highly dependent on the pMDI product used. This fact is related to the pressure drop
associated to each pMDI product. If the pressure in the pMDI actuator is high, than the air will
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preferable pass through the whistle, activating it for lower flow rates [SB13]. The development of
the whistle is based in the vibration (and sound waves) produced by air turbulence around a blunt
body, this geometry is dimensioned for a given flow rate. Its development is made by trial and
error, which is a very time consuming process.
Among the eight VHC devices selected, some common design characteristics were observed, such
as the valve. Thus, the devices were grouped by their valve design (see Table A.5).
• Leaflets - an open-centre design that is composed by several (e.g. four) leaflets, bending
from the centre to the sides, similar to the heart valves.
– Compact Space Chamber (CSC)
– Space Chamber (SC)
– A2A Spacer (A2A)
• Duck - an open-centre design that is similar to a duck beak, opening the centre by bending
of two surfaces.
– NebuChamber (NC)
– OptiChamber Diamond (OCD)
– Vortex (V)
• Annulus Flap - an non open-centre design that is composed by a annulus ring, where the
innermost edge zone bends.
– AeroChamber (AC)
• Coin - an non open-centre design that is a rigid body with a coin shape, that moves upon
flow solicitation to allow or restrict air passage.
– Volumatic (VOL)
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Chapter 2. Background and Literature Review
Some of the eight VHCs are equipped with an exhalation one-way valve (i.e. CSC, SC, AC, OCD and
NC). This is a great feature, that seals potential co-flows during inhalation and reduces excessive
pressure against the inhalation valve during exhalation phase (see section A.5). Volumatic and
A2A Spacer simply possess two air vents, for the exhalation flow to escape. However, the larger
the vent dimension, the higher is the co-flow entering during inhalation. This reduces the volume
of air inhaled from the VHC body (containing drug particles), and lowering the effectiveness of the
treatment.
Despite the Nebuchamber has been discontinued, the study will include this device due to the
fact that its body is entirely made of stainless steel. Given the fact that the material highly affects
the efficiency of the VHC device, the Nebuchamber will allow to infer if this device high weight is
counterbalanced by its efficiency, in comparison to more recent devices in the market.
2.5 Literature Review
This section presents a few literature studies involving VHC devices. Those studies are divided in
four sub sections: reviews, in vivo, in vitro and numerical.
2.5.1 Reviews
Wong et al. (2012) reports the increasing use of CFD-DEM approach in numerical studies for
predicting the drug deposition and delivery in inhalation devices. The increase in the use of this
approach can be seen for the number of recent studies concerning DPI devices. They point that
the use of numerical tools is not a replacement of experimental evaluation and should be used
with careful considerations on the numerical models used. CFD predictions should always be
accompanied with some experimental validation data [WFT+12].
Ruzycki and his team (2013) compile the use of CFD tools in the prediction of drug deposition for
inhaler design. He overviews the numerical software’s used in the simulation of nebulizers, DPIs,
pMDIs with and without spacers. The authors concluded that the use of CFD is becoming more
common in pharmaceutical applications, for improving medical devices or study drug deposition in
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the airways, stating that the most beneficial results are those provided with experimental validation
[RJF13].
Nikander et al. (2014) review the historic evolution of spacers and VHCs starting 1970s up to
today, focused in the spacer design, patented inventions, adherence and technique [NNDP14].
2.5.2 In Vivo Studies
Newman and his collaborators (1984) evaluated the aerosol delivery using a VHC device (750
mL) in nine patients, using an in vivo radiotracer technique. Results shown that the throat
deposition was greatly reduced and the lung deposition is similar to the pMDI solo when properly
used [NMLJ+84]. A delivery efficiency study was made by Olof Selroos and Maija Halme in a
Finnish hospital, with nine asthmatic adults medicated with a corticosteroid drug. The results
shown that patients that do not use a pMDI with the Volumatic VHC, tend to ingest excess of drug,
which bring adverse health effects to the human system, therefore the patients are advised to
rinse their mouth after treatment [SH91].
Other study explores how the usage of a metal versus a plastic VHC, can produce different results
in young asthmatic children. Bisgaard focused the study in a group of 164 children aged from 6
months to 7 years old. The results show that a plastic VHC might cause age dependence in the
delivery of drug in opposite to the metal one [Bis95].
Castro-Rodriguez and his team (2004) compared the efficacy of drug delivery using a pMDI+VHC
against the use of nebulizer, for asthmatic children under 5 years old, in an emergency department.
The pMDI+VHC has proven to be more effective than the nebulizer, by decreasing the hospitalisation
time [CRR04].
Khan and his team (2006) analysed the efficacy of fluticasone delivered by two VHC devices
(AeroChamber Plus - conventional and AeroChamber Max - antistatic) in twelve children (1 - 6
years old). The drug delivery was assessed through blood samples taken from the subjects 1
hour after the treatment. Results have shown that the antistatic VHC increased the drug delivered
[KTH+06].
Rodriguez-Martinez et al. (2012) assessed the pMDI, with or without a spacer (a tubular and a
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VHC). A two-sequence crossover clinical trial for the treatment in 31 stable asthmatic children
(6-18 years old) was used, by assessing their spirometry. Results showed that the use of both
spacers produced similar treatment results [RMSBCR12].
Ditcham et al. (2014) conducted a survey in asthmatic children (3-5 years old), using radiolabeled
albuterol, on the effect of using a VHC with or without a facemask. Lung delivery was higher 4.4%
when the facemask was used [DMZ+14].
Minh et al. (2014) studied the patient (children 1 – 4 years old) compliance, air flow and facemask
force. The research was conducted using a custom made OptiChamber Diamond, that was embed
with a Facemask Datalogger, for recording the air flow passing through the VHC and the force
made by the patient for keeping the facemask sealed against the face. Results show that older
children emptied the VHC faster with fewer breaths and showing better cooperation. The mean
force applied by the patients was ≈4 N [MvHvK+14].
2.5.3 In Vitro Studies
Wildhaber and his collaborators (1996) studied the effect of the plastic spacer (i.e. Volumatic) wall
electrostatic charge, on the salbutamol sulphate drug delivery. The assessment was executed at
constant flow rate of 60 L/min using a MSLI CI, and using different washing techniques for the
spacer (i.e. new, used, plastic rubbed, water rinsed, foil covered, cationic detergent coated and
anionic detergent coated). Results show an increased drug delivery for cationic detergent coating
technique, followed by foil covering and anionic detergent coating. The new spacer out of the box
delivered the least dose. The coating using ionic detergent removed the charge for at least 24h
[WDH+96].
Finlay et al. (1997) reported the evaluation of two VHC devices (i.e. Aerochamber and Space-
Chamber) salbutamol and beclomethasone delivery at 28.3 L/min, collected in a Andersen CI.
The Space-Chamber increased (i.e. 32%) the FPM of beclomethasone when compared to the
pMDI solo, no differences were found for the salbutamol delivery. Aerochamber delivered similar
FPM to the pMDI solo both for beclomethasone and salbutamol. Throat deposition was highly
reduced by the use of spacers (i.e. ≈ 98%) [FZM97].
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Mitchell and Nagel (1997) evaluated three VHCs (i.e. AeroChamber, Space Chamber and Vent-170),
on the delivery of salbutamol and beclomethasone dipropionate. A breath profile passed through
the VHC, and the emitted mass was collected in a filter. Results indicate that AeroChamber emitted
the highest dose for both formulations, at tidal volumes from 50 mL to 200 mL. The other devices
were not able to deliver any drug at 50 mL. The authors concluded that tests mimicking the patient
breath pattern are essential to identify differences (i.e. valve operation) that are not observable at
constant flow tests [MN97].
Finlay and Zuberbuhler (1998) determined the amount of salbutamol and beclomethasone deliv-
ered from pMDI attached to four spacers (i.e. AeroChamber, OptiChamber, Space Chamber and
E-Z Spacer), using a variable flow setup for simulating the inhalation profile of an infant, toddler
and older child. The results indicate that the emitted FPM dependent on the drug used, spacer
model and waveform [FZ98].
Barry and O’Callaghan (1999) evaluated three spacers (i.e. Aerochamber, Nebuhaler and
Nebuchamber) on the delivery of budesonide using a breathing simulator (generating sine waves
with different tidal volumes). The drug collect increased with the tidal volume (i.e. from 50 mL to
300 mL). This increase was higher (i.e. ≈ 56 µg) for the high volume (i.e. Nebuhaler – 750 mL)
and the metal spacers (i.e. Nebuchamber – 250 mL), while it was lowest (i.e. 26.7 µg) for the
smallest one (i.e. Aerochamber) [BO99b]
Foss and Keppel (1999) developed a variable flow setup for collecting the salbutamol sulphate
(i.e. Ventolin) emitted by four spacers (i.e. MediSpacer, Aerosol Cloud Enhancer, OptiHaler and
AeroChamber) when actuated at the start of the inhalation and at the start of the exhalation. This
study focused in the evaluation of the spacer devices performance when misused, concluding that
the four devices had less FPM delivered when badly actuated. Not only the timing affects the drug
delivery, but also the device design has great influence when the inhalation is delayed [FK99].
Barry and O’Callaghan (1999) assessed the drug emitted from three pMDI (i.e. Becotide, Sarevent
and Flixotide) through three spacers (i.e. Babyhaler, Volumatic and Aerochamber). The drug
assessment was executed using a 4-stage MSLI CI at 60 L/min with an actuation-inhalation delay
of 2 s. The results pointed that the each pMDI had a different output for each spacer, leading to
the conclusion that each spacer needs to be fully evaluated for each drug prescribed [BO99a].
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Chew and Chan (2000) studied the effect of four spacers (i.e. Fisonair, Breath-A-Techm Volumatic
and Nebuhaler) in the delivery of two pMDI formulations (i.e. Tilade and Intal), using a Marple-Miller
CI at 30 L/min. The results pointed that the high volume spacers (i.e. Fisonair > Nebuhaler
> Volumatic) increased the FPM output, while the smaller spacer (i.e. Breath-A-Tech) did the
opposite. They concluded that the proper choice of the spacer is important for the optimal delivery
of the pMDI dose [CC00].
Rahmatalla and his collaborators (2002) assessed the pMDI QVAR mouth-throat (i.e. idealized
Alberta model) deposition under three constant inhalation air flow rates (i.e. 28.3, 60 and 90
L/min) [RZLF02].
The study was conducted using a single filter or an 8-stage Andersen CI for the pMDI with and
without a VHC (i.e. Aerochamber). They observed that the VHC contributed to a reduction of the
throat deposition between 45% and 66% (higher for lower flow rate). The dose delivered increased
with the flow rate from 42% to 69%, whereas the VHC did not added much variation. Results
showed that the plume MMAD did not suffered significant changes with the use of a VHC.
Janssen et al. (2002) compared ametal (i.e. Nebuchamber) against a polymer VHC (i.e. Volumatic),
in terms of salbutamol (i.e. Ventolin) drug delivery using an Andersen CI at 28 L/min. It was
observed that the small volume (i.e. 250 mL) metal spacer was able to deliver a similar dose to
the high volume (i.e 750 mL) polymer VHC [JWE+02].
Nagel et al. (2002) evaluated the performance of AeroChamber Plus and Volumatic in the delivery
of fluticasone propionate and salmeterol xinafoate using an Andersen CI at 28.3 L/min. The use
of either VHC devices increased the FPF in ≈40% for both formulation in comparison to the pMDI
solo. Whereas the FPM emitted from the both VHC devices was slightly greater to the pMDI solo
[NWBM02].
Asmus and his team (2004) studied the fluticasone delivered through seven VHC (i.e. BreatheRite,
E-Z Spacer, EasiVent, AeroChamber, InspirEase, OptiChamber and Space Chamber) and six spacer
devices (OptiHaler, ACE, Gentle-Haler, MediSpacer, Elipse and a 6-inch tube). Their FPM was
determined using a CI. Results shown the Ellipse (104 µg) to be spacer with higest FPM. Between
the VHC devices the Space Chamber (58.3 µg) emitted the highest respirable fraction [ALCH04].
Using a constant flow extraction setup with a laser photometric measurement, Verbanck and
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colaborators (2004), assessed the Ventolin (i.e. salbutamol sulphate) emitted over time from a
high (i.e. Volumatic) and low (i.e. Aerochamber) volume VHC. Observing that the low volume VHC
would take less time to achieved total drug delivery than a high volume VHC. The emitted drug
filter collection showed an increased amount for the high volume device [VVSV04].
Rau et al. (2006) assessed the emitted albuterol from Vortex, AeroChamber Max, OptiChamber
Advantage, ProChamber, Breathrite, PocketChamber and ACE, with and without pre-treatment,
for 2 and 5 s delays between actuation-inhalation. The FPM assessment was conducted in an
Andersen CI at 28.3 L/min. The results shown that the AeroChamber Max emitted the highest
FPM (i.e. 23.8 µg). Also, it was concluded that the VHC devices made of electrically conductive
materials emit higher FPM (for both 2 s or 5 s delays), then those made of non-conducting materials
(even when pre-treated) [RCN+06].
Goncalves et al. (2013) compared the performance of three VHC (i.e. Able Spacer, AeroChamber
Plus and Vortex) in the delivery of beclomethasone dipropionate and formoterol, using a NGI at
30 L/min. All VHCs reduced the throat deposition in comparison with the pMDI solo. Vortex and
AeroChamber Plus presented advantages over the Able Spacer in terms of emitted FPM [GAN+13].
Sheth et al. (2014) evaluated the QVAR FPM delivered from a pMDI when combined with non-
conventional spacers (i.e. nebulized reservoir, rolled paper, toilet paper roll, paper towel roll,
bottle-holding chamber and bottle spacer) and a commercial one (i.e. AeroChamber). Perfor-
mance was assessed for two throat models (i.e. USP IP and AIT) using a Respirable Impactor and
Aerodynamic Particle Sizer. Any add-on device will reduce the throat deposition and increase the
respirable fraction, whereas the paper towel roll had the greatest effect. The actuation-inhalation
delay affects the performance, which is mainly mitigated by the use of the paper towel roll or the
bottle-holding chamber [SBKM14].
Xu and his collaborators (2014) studied the delivery efficiency of the VHC (i.e. OptiChamber
Diamond, AeroChamber Plus, Pocket Chamber and Volumatic) in combination with facemasks,
using three age-specific Soft Anatomical Model (SAM) faces. The setup allowed the testing of
simulated breathing patterns and assessment of the mask leakage and delivered dose. The lowest
leakage was found for the OptiChamber Diamond + LiteTouch facemask [XHvH+14].
Hatley and collaborators (2014) assessed the drug delivery of two pMDI (i.e. albuterol and be-
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clomethasone) with or without a VHC (i.e. OptiChamber Diamond - antistatic, AeroChamber Plus
- conventional and AC Z-Stat - antistatic) at 15 and 30 L/min, using an NGI. The two antistatic
VHCs were equivalent for both formulation, and their emitted FPM has higher (at 15 L/min) than
the conventional VHC [HvHSS14].
2.5.4 Numerical Studies
Kleinstreuer and his team (2007) numerically studied the delivery of pMDI (HFA and CFC) spray
droplets to the patient lungs using a human upper airway model with or without the use of a spacer.
Results showed that HFAspray is more efficiency than CFC, delivering a higher dose to the lungs.
The addition of the spacer to the pMDI provided an increase in the delivered dose by removing the
coarse fraction of the plume [KSZ07].
Oliveira and his collaborators (2012) modelled the airflow inside various VHC body and valve
designs, using an inhalation profile. Their aim was to study the air flow patterns and the formation
of recirculation zones as well as their size. Results showed that some designs were more proficient
than others, having fewer recirculation zones. They concluded by proposing a new design for VHC
[OTS+12].
Oliveira et al. (2014) simulated the drug delivered by four VHC devices (i.e. A2A Spacer, Ae-
rochamber Plus, Nebuchamber and Volumatic) at 30 L/min. The particles were considered inert,
three particle size distributions were injected and tracked in FLUENT using Euler-Lagrangean
approach. The results showed that coarser plumes tend to get more deposited inside the VHC
device, Volumatic has higher deposition than the other devices and that Nebuchamber has the
greatest throat deposition. Also it was observed that Aerochamber delivers the highest amount of
FPM [OTMT14a].
Oliveira and his team (2014) focused in the numerical modelling of the pMDI spray in still air, using
a realistic approach that accounted for the evaporation of the propellant. Results shown a rapid air
temperature drop of 3.3 degrees Celsius near the actuator nozzle and air velocity increase of 3.27
m/s [OFT+14].
Yazdani and his team (2014) numerically studied the air flow inside three spacers (i.e. type I, type
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II and type III) and their drug delivery, by modelling the injection of a pMDI (i.e. Proventil HFA)
spray in an air co-flow at 30 L/min. Using FLUENT they manage to track the a batch of solid inert
particles, using an Euler-Lagrangean approach, and predict the deposition fraction on those spacer
devices. They notice that certain types of spacer designs are more prone to particle deposition by
impaction than others. Not all spacer designs perform equally for all formulations [YNY+14].
Yousefi et al. (2015) modelled the drug deposition in idealized oral airway geometry, at 15, 30
and 60 L/min air flow rates, to optimize a VHC one-way valve design. Particles were modelled as
an inert discrete phase using Euler-Lagrangean approach. It was noticed that particle deposition
occurred mostly at the larynx, and this effect increases with the flow rate growth. The results
pointed some guidelines for developing an impaction plate, located downstream the one-way valve.
This would direct the particle + air jet towards specific zones where the oral deposition is lower
[YIT15].
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3 Development of the CFD Model
3.1 Mathematical Modelling
The Navier-Stokes equations are a specific application of the fluid conservation principle, which
are not possible to solve by conventional numerical means, as each of them implies several
considerations according to the specifics of the problem. The equations for the mass and
momentum conservation are given bellow, and are only applicable to a non-accelerating reference
frame and for viscous flows (i.e. presence of turbulence).
3.1.1 Mass Conservation
Mass conservation implies that the mass entering a control volume equals the mass flowing out,
creating a balance between input and the output flows for a certain volume. This concept is
mathematically expressed by Equation 3.1, which is valid for compressible and incompressible
flows [ANS13, VM95, FP03, Whi98].
∂ρ
∂t
+∇ · (ρ~v) = Sm (3.1)
where Sm is the source of mass added to the continuous phase (air in this case) by the dispersed
phase (particles/droplets) caused by vaporisation, for example. ρ stands for density, t for time
and ~v represents the velocity vector.
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Equation 3.2 presents the special case for 2-D axisymmetric geometries.
∂ρ
∂t
+
∂
∂x
(ρvx) +
∂
∂r
(ρvr) +
ρvr
r
= Sm (3.2)
where x and r are, respectively, the axial and radial coordinates and vx and vr their, respectively,
velocity components.
3.1.2 Momentum Conservation
Momentum conservation is given by Equation 3.3, where p represents the static pressure, ρ~g and
~F correspond respectively to the gravitational body force and the external body force (interaction
with the dispersed phase, for example). The τ identifies the stress tensor and is given by the
Equation 3.4.
∂
∂t
(ρ~v) +∇ · (ρ~v~v) = −∇p+∇ · (τ)+ ρ~g + ~F (3.3)
τ = µ
[(∇~v +∇~vT )− 2
3
∇ · ~vI
]
(3.4)
where the µ represents the molecular viscosity, I is the unit tensor, and the second term on the
right hand side of the equation (− (2/3)∇ · ~vI) accounts for the effect of volume dilation. For
2-D axisymmetric flows, equations get a bit more complex due to the need to separate axial from
radial momentum, and they are described by Equations 3.5 and 3.6.
∂
∂t
(ρvx) +
1
r
∂
∂x
(rρvxvx) +
1
r
∂
∂r
(rρvrvx) =− ∂p
∂x
(3.5)
+
1
r
∂
∂x
[
rµ
(
2
∂vx
∂x
− 2
3
(∇ · ~v)
)]
+
1
r
∂
∂r
[
rµ
(
∂vx
∂r
+
∂vr
∂x
)]
+ Fx
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∂
∂t
(ρvr) +
1
r
∂
∂x
(rρvxvr) +
1
r
∂
∂r
(rρvrvr) =− ∂p
∂r
(3.6)
+
1
r
∂
∂x
[
rµ
(
∂vr
∂x
+
∂vx
∂r
)]
+
1
r
∂
∂r
[
rµ
(
2
∂vr
∂r
− 2
3
(∇ · ~v)
)]
− 2µvr
r2
+
2
3
µ
r
(∇ · ~v) + Fx
where
∇ · ~v = ∂vx
∂x
+
∂vr
∂r
+
vr
r
(3.7)
3.1.3 Turbulence
RANS Formulation
In this work, the turbulence was modelled using a Reynolds-Averaged Navier-Stokes (RANS)
approach, using linear eddy viscosity models of three equations, more specifically the k−ω Shear
Stress Transport (SST) model. In Reynolds averaging the instant velocities are composed by mean
velocity (or time averaged) and fluctuating components (see Equation 3.8).
vi = v¯i + v
′
i (3.8)
where the v¯i is the mean and the v′i is the fluctuating velocity components (i=1,2,3 – for three
dimensions). Likewise this formulation, accounting for mean and fluctuating parts, is applicable
for pressure and other scalar quantities (e.g. energy or species concentration).
By substituting expressions using this form for the flow variables into the instantaneous continuity
and momentum equations (3.1 and 3.3) and taking a time average yields the ensemble-averaged
mass and momentum equations. When written in a Cartesian tensor form, the variables are
presented as in Equations 3.9 and 3.10.
∂ρ
∂t
+
∂
∂xi
(ρvi) = 0 (3.9)
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∂
∂t
(ρvi) +
∂
∂xj
(ρvivj) =− ∂p
∂xi
+
∂
∂xj
[
µ
(
∂vi
∂xj
+
∂vj
∂xi
− 2
3
δij
∂vl
∂xl
)]
(3.10)
+
∂
∂xj
(−ρv′iv′j)
Equations 3.9 and 3.10 are known as the RANS equations. These are similar to Equations 3.1 and
3.3 but with additional terms that represent the effects of turbulence. These turbulent Reynold
stresses (−ρv′iv′j ) need to be modelled using linear or non-linear eddy viscosity models.
Boussinesq Approach
Modelling the turbulence stresses in Equation 3.10 requires the application of an approach known
as the Boussinesq hypothesis, described in Equation 3.11. This hypothesis is used to relate the
Reynolds stresses to the mean velocity gradients, in an isotropic way by means of the turbulent
viscosity (µt).
−ρv′iv′j = µt
(
∂vi
∂xj
+
∂vj
∂xi
)
− 2
3
(
ρk + µt
∂vk
∂xk
)
δij (3.11)
This approach has a relative low computational cost since the turbulent viscosity is computed as a
function of two equations, k and ω. Since the turbulence is considered isotropic, this approach
is highly related to the linear eddy viscosity models. The isotropic limitation is only questionable
in the case of highly swirling flows and stress-driven secondary flows. In such cases, a Reynold
Stress Model (RSM) should be used.
Turbulence Model
The Wilcox k − ω model developed in 1988, is a model with great applicability on Low-Reynolds
Number (LRN) flows near wall regions. This model has two transport equations that represent the
turbulent properties of the flow. The first variable is the turbulent kinetic energy, k. The second
variable is the specific dissipation, ω. The first determines the energy of the turbulence, while the
second defines the scale of the turbulence. However, its main limitation is the lack of sensitivity in
the freestream zone of the flow (i.e. outside the shear layer).
Menter, in 1993, developed a model that successfully blends the Wilcox k−ω model (for treatment
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of wall regions) and the k−  model (for treatment of the freestream zone) [Men93]. It includes a
blending function that handles the transition between the two models, which was given the name
of SST k − ω model. Due to the nature of this study, this was the model of choice.
The Equations 3.12 and 3.13 allow the calculation of the turbulence transport parameters, k and
ω, respectively.
∂
∂t
(ρk) +
∂
∂xi
(ρkvi) =
∂
∂xj
(
Γk
∂k
∂xj
)
+Gk − Yk (3.12)
∂
∂t
(ρω) +
∂
∂xj
(ρωvj) =
∂
∂xj
(
Γω
∂ω
∂xj
)
+Gω − Yω +Dω (3.13)
In the Equations 3.14 and 3.15, Gk and Gω represent the generation of k and ω, respectively. S
represents the modulus of the mean rate-of-strain tensor and is defined by Equations 3.16 and
3.17. The turbulent viscosity, µt, is given by Equation 3.18.
Gk = µtS
2 (3.14)
Gω =
α
vt
Gk (3.15)
S ≡√2SijSij (3.16)
Sij =
1
2
(
∂vi
∂xj
+
∂vj
∂xi
)
(3.17)
µt =
ρk
ω
1
max
[
1
α∗ ,
SF2
α1ω
] (3.18)
A correction for LRN is introduced by means of α∗ that damps the turbulent viscosity (defined in
Equation 3.19). This is calculated using a turbulent Reynolds (Ret - defined in Equation 3.20), that
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will make α∗ become equal to 1 in high Reynolds number.
α∗ = α∗∞
(
0.024 + Ret/6
1 + Ret/6
)
(3.19)
where
Ret =
ρk
µω
(3.20)
In Equation 3.15, the value of α is given by Equation 3.21. Where α∗, α∞ and Ret are given be
Equations 3.19, 3.22 and 3.20, respectively.
α =
α∞
α∗
(
α0 + Ret/2.95
1 + Ret/2.95
)
(3.21)
α∞ = F1α∞,1 + (1− F1)α∞,2 (3.22)
where
α∞,1 =
βi,1
β∗∞
− 0.41
2
σω,1
√
β∗∞
(3.23)
α∞,2 =
βi,2
β∗∞
− 0.41
2
σω,2
√
β∗∞
(3.24)
In Equations 3.12 and 3.13, the terms Γk and Γω, which account for the effective diffusivity of k
and ω, respectively, are calculated by Equations 3.25 and 3.26.
Γk = µ+
µt
σk
(3.25)
Γω = µ+
µt
σω
(3.26)
whereas the turbulent Prandtl numbers, σk and σω, are calculated by Equations 3.27 and 3.28.
σk =
1
F1/σk,1 + (1− F1) /σk,2 (3.27)
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σω =
1
F1/σω,1 + (1− F1) /σω,2 (3.28)
In Equations 3.27 and 3.28 it can be found the blending functions previously referred, F1 and F2,
calculated accordingly to Equations 3.29 and 3.30. y is the distance to closest wall and D+ω is
the positive portion of the cross-diffusion term given be Equation 3.32.
F1 = tanh
(
Φ41
)
(3.29)
F2 = tanh
(
Φ22
)
(3.30)
Φ1 = min
[
max
( √
k
0.09ωy
,
500µ
ρy2ω
)
,
4ρk
σω,2D+ω y
2
]
(3.31)
D+ω = max
[
2ρ
1
σω,2
1
ω
∂k
∂xj
∂ω
∂xj
, 10−10
]
(3.32)
Φ2 = max
[
2
√
k
0.09ωy
,
500µ
ρy2ω
]
(3.33)
In Equations 3.12 and 3.13, Yk and Yω account for the turbulence dissipation of k and ω,
respectively, calculated by Equations 3.34 and 3.35.
Yk = ρβ
∗kω (3.34)
Yω = ρβω
2 (3.35)
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where β∗ is given by Equation 3.36.
β∗ = 0.09
(
4/15 + (Ret/8)
4
1 + (Ret/8)
4
)
(3.36)
and β is given by Equation 3.37.
β = F1βi,1 + (1− F1) βi,2 (3.37)
Cross-diffusion term, Dω, present in Equation 3.13, is defined accordingly to Equation 3.38. This
term provides the model with a procedure to blend the k − ε and the Wilcox k − ω models.
Dω = 2 (1− F1) ρ 1
ωσω,2
∂k
∂xj
∂ω
∂xj
(3.38)
The SST k− ω model is based in a few constants that are used throughout the model formulation
previously presented, and are defined as:
σk,1 = 1.176, σk,2 = 1.0, σω,1 = 2.0, σω,2 = 1.168, βi,1 = 0.075,
βi,2 = 0.0828, β
∗
∞ = 0.09, α1 = 0.31, α
∗
∞ = 1.0, α0 = 1/9
Curvature Correction
The SST k − ω model does not account for the streamline curvature, which in this particular
case is paramount. Smirnov and Menter (2009) developed a correction to provide the model with
sensitivity to streamline curvature, as described by Equation 3.39 [SM09].
frotation = (1 + Cr1)
2r∗
1 + r
[
1− Cr3 tan−1 (Cr2r˜)
]− Cr1 (3.39)
Equation 3.39 will be used to calculate a multiplier of the turbulence production term (previously
given by Equation 3.14) as described by Equations 3.40 through 3.42. WithCr1 = 1.0,Cr2 = 2.0
and Cr3 = 1.0.
Gk → Gk · fr (3.40)
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fr = max
[
0, 1 +
(
f˜r − 1
)]
(3.41)
f˜r = max [min [frotation, 1.25] , 0] (3.42)
This will limit the turbulence generation between 0 and 1.25, for cases of strong convex geometry
(stagnated flow) to cases of strong concave geometry (with high production of turbulence). r∗ and
r˜ are given by Equations 3.43 and 3.44, respectively.
r∗ =
S
Ω
(3.43)
r˜ = 2ΩikSjk
DSij
Dt
1
D˜
(3.44)
where the vorticity rate (Ω) is calculated by Equations 3.45 and 3.46, respectively.
Ω =
√
2ΩijΩij (3.45)
Ωij =
1
2
(
∂vi
∂xj
− ∂vj
∂xi
)
(3.46)
The value for D˜ is determined by Equations 3.47 and 3.48.
D˜ = ΩD3 (3.47)
where
D2 = max
[
S2, 0.09ω2
]
(3.48)
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Turbulence Production Limiters
Excess of turbulence energy, Gk, is generated in zones of flow stagnation. Limiting the generation
of turbulence energy is a way to avoid this problem for which there are two available methods in
the solver. One (see Equation 3.49) is based on the application of a coefficient of limitation, Clim,
which takes the value of 10.
Gk = min [Gk, Climρε] (3.49)
The second method (see Equation 3.50) is to recalculate the production of turbulence energy
considering the vorticity rate of the flow, that in stagnation zones will be very small.
Gk = µtSΩ (3.50)
When in the presence of a simple shear flow, S and Ω are equal and Equation 3.50 equals
Equation 3.14.
Wall Boundary Turbulence Treatment
Walls deeply influence the turbulence in the flow, the no-slip (i.e. zero velocity) condition at the
walls has to be satisfied and it will influence the mean velocity field of the flow. Additionally, the
turbulence is changed by the distance to the wall. When very close to it, viscous damping occurs
reducing the tangential velocity fluctuations and the normal velocity fluctuations are reduced by
kinematic blocking. As the distance from the wall increases, so the turbulence rapidly increases
by the production of kinetic energy (due to large mean velocity gradients).
Figure 3.1 illustrates the near-wall region divided into three layers: viscous sublayer (innermost -
with laminar behaviour), fully-turbulent layer (outermost - with the turbulence playing major role)
and the buffer sublayer (intermediate - where the viscosity and turbulence contribute equally).
The near-wall region (i.e. inner layer) is influenced by the viscosity in different degrees, accordingly
to the wall distance (y+ ≡ ρ
[√
τw/ρ
]
y
/
µ).
To correctly model the wall influence in the flow, semi-empirical functions (i.e. wall functions) are
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Figure 3.1: Wall law used in the flow regions of the inner layer
used to connect the near-wall region to the fully-turbulent region. Turbulence models will receive
modified terms that account for the wall presence and its influence in the turbulence generation.
This approach is adequate for coarse meshes with few refinement in the wall region (y+>15).
Another approach is to apply an adequate mesh refinement in the wall region (> 10 nodes) that
envelops the viscous and buffer sublayers. This method will resolve this near-wall region and the
turbulence models gain validity close to the wall. Obviously this is better for cases where the
near-wall phenomena are very important.
The solver (FLUENT) has an integrated approach when the k − ω turbulence model is used,
and will use by default a near-wall model known as Enhanced Wall Treatment (EWT) ω-Equation
(EWT-ω). This model integrates the ω-equation through the viscous sublayer without the need for
applying the two-layer approach. As it is insensitive to the value of y∗, it will blend the viscous
sublayer formulation with the logarithmic layer formulation based in the value of y∗.
The value of ω in the wall, ωw, is given by Equation 3.51, that depends on the value of ω+ which
can be assessed by Equation 3.52.
ωw =
ρ (v∗)2
µ
ω+ (3.51)
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ω+ =

6
β (y+)2
, for laminar layer
1√
β∗∞
dv+turb
dy+
, for turbulent layer
(3.52)
Gharbi and his team (2011) showed an interesting comparison of DNS data with three distinct
wall treatment models [EABB11]. Further discussion on this matter is given by Monticelli (2011)
[Mon11].
3.1.4 Heat Transfer
The energy balance in a fluid is described by Equation 3.53.
∂
∂t
(ρE) +∇ · (~v (ρE + p)) = ∇ ·
(
keff∇T −
∑
j
hj ~Jj
)
+ Sh (3.53)
being the effective conductivity, keff = k + kt. The turbulent thermal conductivity (kt) is defined
accordingly to the turbulence model used. The ~Jj represents the diffusion flux of the species j.
Fluid energy transfer by conduction is given by the term∇ · (keff∇T ). Species diffusion energy
is calculated by the term∇ ·
(∑
j hj
~Jj
)
. Sh represents the contribution of other heat sources,
such as, energy transfer from discrete phase. E is calculated by Equation 3.54.
E = h− p
ρ
+
v2
2
(3.54)
Here, the sensible enthalpy h is defined, for incompressible flow, in Equation 3.55. Yj represents
the mass fraction of species j, and hj given by Equation 3.56. Tref was assumed to be 298.15
K.
h =
∑
j
Yjhj +
p
ρ
(3.55)
hj =
∫ T
Tref
cp,jdT (3.56)
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3.1.5 Species Transport
When this model is used the fluid is considered to be composed by various species. It is then
possible to define different gases with specific mass fractions and properties. The ”air” was then
composed by N2, O2, H2O and HFA-134a. The solver calculates the conservation of the species
accordingly to Equation 3.57.
∂
∂t
(ρYi) +∇ · (ρ~vYi) = −∇ · ~Ji + Si (3.57)
where, Si is the rate of creation of species i by addition from the dispersed phase (i.e. vaporisation)
and any user-defined sources. This equation will be solved for N − 1 species where N is the
total number of species present in the fluid phase. Given the fact that the mass fraction of the
species must add to one, the mass fraction of the N th specie is calculated as one minus the
sum of the N − 1 solved mass. N2 was chosen as the N th since it possesses the largest mass
fraction, reducing the impact of numerical errors.
The mass diffusion, ~J , in turbulent flows is calculated by Equation 3.58, that arises from the
gradients of concentration and temperature. The ~Ji is the diffusion of each specie i, Sct is
the turbulent Schmidt number (considered as 0.7), the DT,i represents the thermal diffusion
coefficient, and Di,m represents the mass diffusion coefficient.
~Ji = −
(
ρDi,m +
µt
Sct
)
∇Yi −DT,i∇T
T
(3.58)
3.1.6 Discrete Phase Model (DPM)
The DPM model will treat the fluid as a continuum phase, for which the Navier-Stokes equations
were solved, and the discrete phase as a set of particles/droplets that are tracked along the
domain using an Euler-Lagrange approach. These discrete entities will exchange energy, mass
and momentum with the continuum phase. This approach is well suited for situations where the
interactions particle-particle are not dominant. For this to happen, the volume of particles has to
be lower than 10% of the domain’s volume.
Particles will be subjected to a force balance equation (3.59) that will be integrated over time. The
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resulting force, when applied to a particle during a time interval, will cause it to move a certain
distance.
d~vp
dt
= FD (~vf − ~vp) + ~g (ρp − ρf )
ρp
+ ~F (3.59)
where FD is the drag force given by Equation 3.60, ~g is the gravitational acceleration, and ~F is
an additional acceleration term that results from different formulation models available on the
solver (e.g. ”virtual mass” force, rotation of the reference frame, thermophoretic force), which can
be used accordingly to the phenomena in study. Additionally, this force can be provided by an
external calculation by means of a User-Defined Function (UDF).
FD =
18µ
ρpd2p
CDRep
24
(3.60)
where the Rep is given by Equation 3.61. The subscripts f and p indicate that a variable corresponds
to the fluid or particle/droplet, respectively.
Rep ≡ ρfdp |~vp − ~vf |
µf
(3.61)
The trajectory equations, as well as mass and energy transfer from/to the continuous phase, are
solved over time by integration using discretized time steps. Equation 3.62 predicts the trajectory of
the particle when integrated over time. Equation 3.63 is the generalized form of the Equation 3.59.
dxp
dt
= vp (3.62)
dvp
dt
=
1
τp
(vf − vp) + a (3.63)
where a represents the resultant acceleration given by the combination of all forces (except the drag
force) and τp indicates the particle relaxation time (i.e. the time a particle takes to aerodynamically
respond to a flow directional change) is given by Equation 3.64.
τp =
ρpd
2
p
18µf
(3.64)
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The analytical integration of the Equations 3.62 and 3.63 is given by Equations 3.65 and 3.66,
where the values for τp, a and v are constant during a certain time interval, where the superscripts
n + 1 and n indicate the present and previous position, respectively. These equations will be
solved numerically using the Euler implicit discretisation scheme, whose detailed information can
be found elsewhere [ANS13].
xn+1p = x
n
p +∆t
(
vnf + aτp
)
+ τp
(
1− e−∆tτp
) (
vnp − vnf − aτp
)
(3.65)
vn+1p = v
n
p + e
−∆t
τp
(
vnp − vnf
)− aτp (e−∆tτp − 1) (3.66)
Another methodology, is to compute Equations 3.62 and 3.63 using a Runge-Kutta scheme, where
the ordinary differential equations are solved in an integrated manner that will automatically chose
the best sub time step needed for each Runge-Kutta cycle to provide the result within an acceptable
error margin.
The solver (FLUENT) is equipped with an automatic routine for selecting the most adequate
methodology to integrate the equations for particle displacement and velocity. The decision is
based upon the variations in the forces acting on the particle at each time interval. The Runge-
Kutta routine is applied when the forces acting on the particle change along the integration step;
otherwise the Analytical approach is used.
Heat and Mass Exchange
FLUENT is equipped with specific laws for the handling of mass and heat exchange for droplets.
In this case, the droplet received heat, followed by evaporation, possible boiling and cooling . The
injected droplet is composed by HFA at -58 ◦C, liquid at this point, that suffers a rapid heating
(see Equation 3.67) when Tp < Tvap. This process can be called an inert heating since no mass
transfer occurs.
mpcp
dTp
dt
= hAp (T∞ − Tp) (3.67)
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wheremp is the mass of the particle, cp is the heat capacity of the particle, Ap is the surface area
of the particle, T∞ is the temperature of the continuous phase, h the convective heat transfer
coefficient.
As soon as the droplet temperature reaches the temperature of vaporisation, Tvap ≤ Tp < Tbp,
the process of mass transfer is initialised, and it is finalised when the boiling point is reached
or until the volatile fraction is totally consumed. This transfer was calculated using a diffusion
controlled model, which assumes that the vaporisation is slow and mainly controlled by the diffusion
gradient. Equation 3.68 defines the flux of vapour that is diffused into the continuous phase.
The vaporisation process stops if the Tp falls below the dew point. The solver does not take into
account condensation effects.
Ni = kc (Ci,s − Ci,∞) (3.68)
where the Ni represents the molar flux of vapour and kc is the mass transfer coefficient.
Ci,s is the vapour concentration at the droplet surface and is estimated using Equation 3.69,
assuming that the partial pressure of vapour ar the interface is equal to the saturated vapour
pressure, psat, at the droplet temperature, Tp.
Ci,s =
psat (Tp)
RTp
(3.69)
Ci,∞ is the vapour concentration in the bulk gas, given by Equation 3.70, where Xi represents
the local (i.e. cell) bulk mole fraction of species i, p is the absolute pressure andR is the universal
gas constant.
Ci,∞ =
Xip
RT∞
(3.70)
Equation 3.71 allows for the calculation of kc used in Equation 3.68, using a correlation based in
the Sherwood number (Sh). Sc represents the Schmidt number (Sc = µ/ρDi,m,p).
ShAB =
kcdp
Di,m,p
= 2.0 + 0.6Re1/2d Sc
1/3 (3.71)
The mass of the droplet is reduced over time accordingly to Equation 3.72, where Mw,i is
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the molecular weight of species i, and Di,m,p is the binary diffusion coefficient of the volatile
component in the droplet.
mp (t+∆t) = mp (t)−NiApMw,i∆t (3.72)
The heat transfer to the droplet during vaporisation process if given by Equation 3.73.
mpcp
dTp
dt
= hAp (T∞ − Tp)− dmpdt hfg (3.73)
where the hfg stands for latent heat that multiplies by the rate of evaporation, dmp/dt.
If Tp ≥ Tbp and the droplet mass exceeds the non-volatile fraction, a boiling process is initialised
by the solver, being the calculation governed by Equation 3.74.
d (dp)
dt
=
4k∞
ρpcp,∞dp
(
1 + 0.23
√
Red
)
ln
[
1 +
cp,∞ (T∞ − Tp)
hfg
]
(3.74)
where cp,∞ represents the heat capacity of the continuous phase and the k∞ is the thermal
conductivity of the continuous phase.
Particle Turbulent Dispersion
In a turbulent flow, the particle/droplet trajectory is affected by the turbulent fluctuations in the
velocity caused by the eddies. This is modelled by a stochastic tracking theory that takes into
account the turbulence influence by tracking several ”tries” paths for the same particle, obtaining
the averaged trajectory.
The solver (i.e. FLUENT) is equipped with a model to handle the particle dispersion named Discrete
Random Walk (DRW), that is actually the Eddy Interaction Model (EIM) developed by Gosman and
Ionnides (1983) [GL83]. Equation 3.75 defines the considered Lagrangean integral time (i.e. eddy
lifetime), TL, for the k − ω model, where CL was considered to be 0.3.
tL = CL
1
ω
(3.75)
The eddy length, Le, is given by Equation 3.76, where it was considered to be of random length,
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provided through a generation of a Gaussian random number (r) between 0 and 1.
Le = −tL ln (r) (3.76)
The time that a particle takes to cross an eddy is calculated using Equation 3.77, where τp is the
particle relaxation time (see Equation 3.64) and |vf − vp| is the relative velocity.
tcross = −τp ln
[
1−
(
Le
τ |vf − vp|
)]
(3.77)
The interaction between the continuous phase eddy and the particle is assumed to occur in the
smallest time between tL and tcross, as described by Equation 3.78. Subsequently, a new value
of instantaneous velocity is calculated.
min (tL, tcross) (3.78)
The turbulent isotropic behaviour of this model is present in the calculation method for the velocity
fluctuations for each velocity component, see Equations 3.79 to 3.82.√
v′12 =
√
v′22 =
√
v′32 =
√
2k
3
(3.79)
v′1 = ζ
√
v′12 (3.80)
v′2 = ζ
√
v′22 (3.81)
v′3 = ζ
√
v′32 (3.82)
where ζ is a normally distributed random number.
The RSM is a possible approach to overcome the isotropic assumption, through a considerable
computational cost. The EIM can give incorrect results for flows dominated by diffusion, where the
particles are not uniformly distributed. Particles smaller than a few microns, tend to deposit in
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zones of low turbulence (i.e. stagnation zones).
3.2 Geometry Definition
3.2.1 Valves Geometries
The eight VHC devices’ valves used in the present study were modelled in SolidWorks®, based
in dimensions obtained from direct measurement alongside with image measurements of open
valves (see chapter A.4). The 3-D models of the valves are represented in Figure 3.2, whereas
those designs can be grouped into four categories.
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Figure 3.2: Side and top views representation of the VHC’s valves used in the study, rendered in
an open position at 60 L/min
A Duck type is present in Nebuchamber, Optichamber and Vortex; Leaflets in A2A Spacer, Compact
Space Chamber and Space Chamber; Annulus Flap in Aerochamber; and a Coin in Volumatic.
Unique to its design, in the Coin valve type, the air flows around the valve, whereas for all the
others, the air passes through the valves (i.e. open-centre valve). This Coin concept presents a
larger obstacle for air flow like a bluff body, which shall lead to higher particle deposition on the
valve.
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3.2.2 VHC Geometries
Through direct measurements the VHCs’ bodies were rendered as depicted in Figure 3.3. The
devices were represented very close to their actual aspect, such as the material type and trans-
parency. All the devices mouthpiece are distinct from each other, except the Compact Space
Chamber and Space Chamber whose difference is in its body length.
A2A AC NC VOL
V CSC SC OCD
Figure 3.3: Geometrical representation of the eight VHC devices under assessment in this study,
in isometric perspective with all devices at the same scale factor
3.2.3 Complete Domain
The necessary computational fluid domain was obtained from the internal space of each geometry
combined with the USP IP internal volume and the pMDI mouthpiece. An example of the final
geometry is given in Figure 3.4, whereas the Cartesian origin point was placed at the location
of the pMDI nozzle for each assembly. To reduce the simulation time, only half of the domain
was represented, given that a symmetry plane was present along all the geometry. The symmetry
plane is represented by the gray area in Figure 3.4.
This procedure was repeated for all VHC devices geometries, with simplifications added to some
details of the geometry, such as the removal of small connection steps in junctions of large diameter.
These details would only increase the number of mesh elements without bringing any relevant
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influence for the flow field. Since most of those details were located in regions of fluid stagnation.
Because of their geometrical complexity, the Optichamber Diamond and the Vortex geometries
were not evaluated numerically, given the lack of computational resources.
Origin
Figure 3.4: Geometrical representation of the simulation domain for the A2A Spacer geometry
3.3 Mesh Generation
The numerical mesh, for all the geometries, was generated using Meshing software from ANSYS®.
Due to the complexity of the geometries used, it was not possible to create structured meshes.
Therefore, only unstructured meshes were used, being made up mostly by tetrahedral elements in
the bulk and prismatic elements near the wall. Specific VHC geometric details and highly varying
dimensions made it impossible to use a general element size, therefore automated algorithms for
mesh generation were applied. Those account for the proximity between surfaces, applying mesh
refinements in zones of reduced cross-section. Wall refinement was applied to all geometries by
means of an automated algorithm that required the definition of the number of prismatic layers
and the cell growth factor. The algorithm analyses the size of the surrounding elements and builds
the wall refinement layers by keeping the elements skewness in check. The height of the first layer
was provided in a way that the value of y+ was close to 1. In Table 3.1 it is provided some mesh
characteristics used in the creation of the numerical meshes.
Once the meshes were created some quality metrics can be used. This can give some insight into
the stability of the solution before numerical calculations. If a grid is full of highly skewed elements
it will lead to numerical problems and rounding errors in the calculations. Figure 3.5 provides
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the comparison between the different meshes on three relevant quality metrics. The vertical axis
represent the frequency of elements with various quality metric indexes. Results are presented
in the form of a normal statistical distribution, calculated upon the average, standard deviation,
minimum and maximum values for each mesh.
Table 3.1: General numerical mesh characteristics with averaged values obtained from the various
meshes produced
Feature Value
Mesh elements 89k - 883k
Boundary Layers 10 - 15
First Boundary Layer Height (mm) 0.02 – 0.05
Maximum Element Size (mm) 3.5 - 10.0
Minimum Element Size (mm) 0.126 – 0.220
Volume of Domain (mm3) 74k – 484k
The aspect ratio metric quantifies the ratio between the lengths of the element edges (a value of
1 refers for a perfect square). It is calculated by dividing the length of the longest edge by the
shortest edge. This is a metric that is important to evaluate the quality of prisms. The skewness
metric quantifies how close to ideal (an equiangular element) a cell is, being its value between
0 and 1. For tetrahedral elements, the equilateral volume index is applied and, it is obtained
by dividing the difference between an optimal cell size and the current cell size, by the optimal
cell size. Elements with skewness close to 0 are perfect while those close to 1 are of very poor
quality. Element quality provides an overall quality metric that ranges between 0 and 1. This
metric is based on the ratio of the element volume to the edge length (also a value of 1 indicates a
perfect square). Orthogonal quality of a cell is the minimum value that results from calculating the
normalized scalar product of the face’s area vector and a vector connecting the cell’s centroid to
the corresponding face; and the normalized scalar product of the face’s area vector and the vector
connecting the face and cell centroids. Therefore, the worst cells will have an orthogonal quality
closer to 0 while the best will have an orthogonal quality closer to 1.
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Figure 3.5: Mesh quality distribution for several meshes used in simulations according to four
quality metrics: Aspect Ratio, Skewness, Element Quality and Orthogonal Quality
The meshes obtained have an aspect ratio distributions averaging around 15, which is within the
acceptable range (high values are found in the elements in the boundary layer refinement). The
pMDI solo mesh has the highest average value of aspect ratio. The skewness distributions are
similar for all meshes, with an average around 0.35, which indicates a very good mesh quality.
All values are bellow 0.8, which means that all elements are above good quality. Element quality
metric distributions show that Volumatic has the best mesh (with average closer to 1), and the
worst is found for pMDI solo. Orthogonal quality has averages around 0.85, except for the CSC
(i.e. 0.8). The lowest value is ≈0.35, which is well above the minimum required for the solver (i.e.
0.1). An orthogonal quality above 0.2 indicates that the mesh is of good (or higher) quality.
69
Chapter 3. Development of the CFD Model
3.4 Gas Properties
The continuous phase was considered a mixture of four species (i.e. gases), in different mass
fractions: O2, H2O, HFA-134a and N2. Each component has its own properties, some of them
are dependent on the temperature, as described in Table 3.2. Mixing laws, weighted by the
mass fraction of each species, were used to assess the mixture density, specific heat, thermal
conductivity and viscosity.
3.5 Boundary Conditions
The boundary conditions present in the numerical domains were the same for all the geometries
tested, and they are defined in detail in Table 3.3. The pMDI mouthpiece was considered a wall
that would entrap all particles upon collision. The categorisation of each surface in a given group
allows for detailed post-processing analysis of the particles characteristics entrapped there.
The mid-plane surface (corresponding to the delimiting surfaces of positive z-axis) was considered
to be a symmetry condition. This forces the non-existence of a fluid gradient at that surface
and that a flow directed towards this surface is mirrored by a symmetrical stream with the same
characteristics. Mathematically, the solver assumes a zero flux for all quantities across a symmetry
boundary: there is no shear stress, no convective flux, the normal component of the velocity is
zero, and diffusion is not present across the symmetry.
The exit section was defined as an Outflow condition, meaning that the fluid reaching this boundary
will exit the domain without any variable being forced to meet a certain condition. This is advisable
to be used in cases whereas no knowledge is possessed downstream the domain and only in
regions where the flow is developed. For this reason, an extension of the exit section was added to
the geometries, before applying the outflow boundary condition.
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Table 3.2: Gas components properties
Name Properties Value
Oxygen, O2 Density, ρ (kg/m3) 1.2999
Specific Heat cp (J/kg.K)
834.8265+ 0.292958T −
1.495637E-4T 2 + 3.413885E-7T 3 −
2.278358E-10T 4
Thermal Conductivity, k (W/m.K) 0.0246
Viscosity, µ (kg/m.s) 1.919E-5
Molecular Weight,Mw (kg/kmol) 31.9988
Mass Diffusivity Coefficient (m2/s) 2.0E-5
Nitrogen, N2 Density, ρ (kg/m3) 1.138
Specific Heat cp (J/kg.K)
979.043+ 0.4179639T −
1.176279E-3T 2 + 1.674394E-6T 3 −
7.256297E-10T 4
Thermal Conductivity, k (W/m.K) 0.0242
Viscosity, µ (kg/m.s) 1.663E-5
Molecular Weight,Mw (kg/kmol) 28.0134
Mass Diffusivity Coefficient (m2/s) 1.8E− 5
Water Vapour, H2O Density, ρ (kg/m3) 0.5542
Specific Heat cp (J/kg.K)
1563.077+ 1.603755T −
2.932784E-3T 2 + 3.216101E-6T 3 −
1.156827E-9T 4
Thermal Conductivity, k (W/m.K) 0.0261
Viscosity, µ (kg/m.s) 1.34E-5
Molecular Weight,Mw (kg/kmol) 18.01534
Mass Diffusivity Coefficient (m2/s) 2.4E-5
Hydrofluoroalkane,
HFA-134a
Density, ρ (kg/m3) [LMF16]
2.844816E1− 1.973320E-1T +
5.593704E-4T 2 − 5.689913E-7T 3
Specific Heat cp (J/kg.K) [LMF16]
6.146563− 5.810724E-2T +
2.063815E-4T 2 − 2.383358E-7T 3
Thermal Conductivity, k (W/m.K) [LMF16]
−1.274201E-6+ 4.873137E-8T −
1.615986E-11T 2
Viscosity, µ (kg/m.s) [LMF16] −1.041363E-2+ 7.983640E-5T
Molecular Weight,Mw (kg/kmol) [Fin01] 102.03
Mass Diffusivity Coefficient (m2/s) [Fin01] −5.725646E-6+ 5.265307E-8T
T represents the temperature as a variable in the equations (value in Kelvin)
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Table 3.3: Boundary conditions and relevant input values for the models used
Name Type Value
Entrance (Velocity Inlet) Volumetric Flowrate (L/min) 60
Turbulence Intensity (%) 5
DPM Wall Condition Reflect
Temperature (K) 293.15
Mass Fraction O2 0.21
Mass Fraction H2O 0.0073
Mass Fraction HFA 0.0
Exit (Outflow) DPM Wall Condition Escape
VHC body and valve, Velocity (m/s) 0.0
USP, pMDI mouthpiece DPM Wall Condition see section 3.7.3
(No-Slip Walls) Temperature No heat exchange
Mass Fraction O2 No diffusive flux
Mass Fraction H2O No diffusive flux
Mass Fraction HFA No diffusive flux
3.6 Solver Configuration
The numerical simulations were performed using FLUENT 15.0 from ANSYS® as the solver.
According to the previously stated, the turbulence model used in the calculations was the k − ω
SST from Menter (1993) [Men93]. The solver used is pressure-based. This type of solver ensures
the mass conservation of the velocity field by solving the pressure equation. Specifically, the
pressure equation is obtained by derivation of the continuity and momentum equations (of the
corrected velocity field) by the pressure, while enforcing mass conservation. The governing
equations of the model are non-linear and are linked together in a way that the solution can only
be obtained through an iterative process. A segregated algorithm is employed to solve these
equations in a sequential way, one after the other, using the Semi-Implicit Method for Pressure-
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Linked Equations (SIMPLE) algorithm, fully described elsewhere [ANS13, VM95]. The spatial
discretisation scheme used in the simulations was the second order upwind scheme, applied to
solve the turbulence, species, energy and momentum equations [ANS13]. This procedure is in
accordance with the best practice guidelines for CFD simulations [Sul00]. Any iterative numerical
process needs a convergence criterion. For the energy it was assumed a value of 1E-6 and for all
other variables it was set at 1E-4. The simulations were carried out as unsteady over time where
the fluid was considered to be incompressible and Newtonian. The gravitational acceleration was
applied, downwards along the y-axis, with a magnitude value of 9.81 m/s2. An automated method
was used to decide the fluid time step accordingly to the convergence rate of the previous step.
This method is described elsewhere [ANS13]. Nonetheless, the values were limited between 5E-5
seconds and to 0.1 seconds.
3.7 pMDI Spray
The pMDI formulation of Ventolin is composed by drug particles (crystals) of salbutamol sulphate,
suspended in a propellant HFA-134a (liquid at the pressure of 3 atm). The solution is kept within
an aluminium canister that includes a metering chamber, which precisely doses a fixed volume
of content. The solution will rapidly expand upon contact with the atmospheric pressure (i.e. 1
atm). This is called the first atomisation process and occurs inside the metering chamber and
actuator channels. This evaporation process needs a high amount of heat to occur (this is a
reason for the need to wait between actuations), lack of energy will lead to formation of ice that
blocks the actuator nozzle. Several studies were carried out in close proximity to the nozzle orifice,
to measure the spray characteristics and behaviour, so those parameters can be of use to the
numerical modelling.
Accordingly to several studies, at the nozzle exit the spray exhibits a distribution of propellant
droplets, that can contain or not, one of more drug particles encapsulated in their volume [SSM12].
Some authors even point out the release of propellant gas bubbles in the centre of the nozzle
[MSDK+16].
For this study the spray behaviour is characterised by the secondary atomisation downstream the
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nozzle. FLUENT is very limited for modelling pharmaceutical sprays. So it was considered that all
the droplets had the same amount of propellant by defining a limit for evaporation process (i.e.
mass fraction of HFA is 99.05%). Once this value is reached the ”droplet” will retain its mass
being considered a solid particle (i.e. made solely of API drug) for wall collision purposes. The
evaporated mass will add to the gas species present in the continuous phase (i.e. HFA-134a gas).
This limitation, forces the injected particles with higher diameter to have higher amount of drug
mass, while smaller droplets have smaller drug mass. The following sections will focus on the
materials definition and models specific to the spray modelling.
3.7.1 Materials Properties
The droplet is composed by liquid propellant (i.e. HFA-134a) and its properties are given in Table
3.4. Additionally, the properties of salbutamol sulphate and wall materials found in VHC devices
are reported as well. When appropriate they will be used in wall-particle interaction models.
3.7.2 Drag Law
The aerodynamic interaction between the discrete phase and the continuous phase is assessed
through a drag law, that provides the Equation 3.60 with a drag coefficient which is a function
of the Reynolds number (see Equation 3.61) of the particle/droplet. A great deal of research
has been carried out over the last decades upon drag coefficient laws for droplets, bubbles and
particles; and the best compendium is given by Clift, Grace and Weber [CGW05]. Drag effects for
pharmaceutical particles are well documented by Finlay [Fin01]. Accordingly to Clift, droplets with
a high viscosity ratio between phases (i.e. κ = µp/µf , in this case is between 22 and 38) can be
considered non-deforming. Additionally, for droplets very small (i.e. under 1 µm) it was observed
that there is no formation of the Hill’s internal recirculation spherical vortex [CGW05], therefore
the spherical drag law for rigid spheres is the most adequate approach for handling the problem.
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Table 3.4: Properties of the spray droplets and surface materials
Name Properties Value
HFA-134a, liquid Density, ρ (kg/m3) [LMF16, KSZ07]
1.905004E3− 1.278338T −
3.479706E-3T 2 | 1300 (after
evaporation)
Specific Heat cp (J/kg.K) [LMF16]
1.298229− 2.121241E-3T +
8.294360E-6T 2
Latent Heat (J/kg) [Fin01] 3.883988E5− 7.025714E2T
Vaporisation Temperature (K)
[Fin01, BCLM11]
213.15
Boiling Temperature (K)
[LMF16, Dun97]
247.15
Volatile Fraction (%) 99.05
Saturation Vapour Pressure (Pa) [Fin01]
−9.802710E6+ 1.31117E5T −
5.931E2T 2 + 9.0939E-1T 3
Mass Diffusivity Coefficient (m2/s)
[Fin01]
−5.725646E-6+ 5.265307E-8T
Salbutamol Young Modulus (GPa) 3.38
Sulphate Poisson’s Ratio (-) 0.5
Aluminium Young Modulus (GPa) 69.0
Poisson’s Ratio (-) 0.334
Silicon Rubber Young Modulus (GPa) 0.05
Poisson’s Ratio (-) 0.48
ABS Young Modulus (GPa) 2.2
Poisson’s Ratio (-) 0.35
PC Young Modulus (GPa) 2.2
Poisson’s Ratio (-) 0.37
Stainless Steel Young Modulus (GPa) 180.0
Poisson’s Ratio (-) 0.305
T represents the temperature as a variable in the equations (value in Kelvin)
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The solver is equipped with the spherical drag law from Morsi and Alexander (1972) [MA72]. This
law is made by several branches applicable to specific intervals of Reynold number, as described
in Equation 3.83. Here are only reported the relevant intervals, by estimation of the maximum
Reynolds number, this should be close to 500 (considering the air velocity to be 0.01 m/s).
CD = A+
B
Rep
+
C
Re2p
(3.83)
where
Rep ≤ 0.1
A = 0.0
B = 24.0
C = 0.0
0.1 < Rep ≤ 1.0
A = 3.69
B = 22.730
C = 0.903
1.0 < Rep ≤ 10.0
A = 1.222
B = 29.1667
C = −3.8889
10.0 < Rep ≤ 100.0
A = 0.6167
B = 46.5
C = −116.67
100.0 < Rep ≤ 1000.0
A = 0.3644
B = 98.33
C = 2778.0
Several authors have used of this drag law in their numerical simulations [LHDX08, YIT15, GA04,
KHDL15, LV07]. However, a slip correction factor, Cc, for small diameters should be applied
[Hin99]. This factor takes into account that very small particles start being affected by the air
molecules that collide against its surface increasing the drag coefficient predicted for LRN. The
slip correction factor, (Cc - see Equation 3.84), was initially proposed by Cunningham (1910)
[Cun10] and it is based in the Knudsen number (Kn - see Equation 3.85) of the particle. Its value
becomes more relevant for submicrometer (dp ≤ 1.0 µm) particles [Cun10]. The parameter
λ represents the mean free path of a gas molecule and it was considered to be 65 nm for the
present temperature range. The value of α is given by Equation 3.86 and its coefficients (c1, c2,
c3) are empirical [AR85]. Based in the work of Longest (2007), the values used were c1 = 2.34,
c2 = 1.05 and c3 = −0.39 [LX07].
Cc = 1 + α · Kn (3.84)
76
3.7. pMDI Spray
Kn =
2λ
dp
(3.85)
α = c1 + c2 exp (c3/Kn) (3.86)
Once the propellant is fully evaporated, the resultant solid drug particle is not spherical at all. The
non-sphericity effect of the drag coefficient was not taken into account in the modelling due to lack
of accurate input parameters. Nevertheless, the work of Chhabra and his collaborators (1999)
provide a deep insight into this matter by comparing several drag laws available [CAS99]. Feng
and Kleinstreuer (2013) used CFD to model the transport of ellipsoidal particles along a pipe
flow. This work lead the way to a deeper understanding of the non-sphericity effect in the particle
rotation, drag and turbulence generation [FK13]. In Figure 3.6 it is shown the comparison of the
Stokes drag law versus that proposed by Morsi and Alexander, with or without the Cunningham
slip correction factor.
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Figure 3.6: Comparison of different drag laws and the effect of slip correction factor as a function
of the particle diameter
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The Stokes law is adequate for slow, viscous flows, where the Morsi and Alexander law follows
it closely. As the particle Reynolds number increases (Rep > 0.2), the two formulations rapidly
diverge. The slip correction based on particle diameter is negligible for diameters above 1 µm,
increasing rapidly as the particle diameter reduces.
3.7.3 Wall-Particle Interaction Models
The collision of droplets/particles against a solid wall is a complex matter that depends upon
an interaction of several forces requiring considerations to be made. Here, the discrete phase
was considered to be composed by liquid droplets or solid particles if the total evaporation of the
propellant has occurred. Distinct wall collision options were considered:
• Trap;
• Reflect;
• Critical velocity based model;
• Tangential lift-off ratio based model.
Trap
This model is already implemented in the solver and it is designed to entrap a droplet or particle that
collides onto the boundary. The discrete element is then removed from all tracking calculations.
Reflect
The reflect option, also included in the solver, will respond to a discrete element collision on the
boundary by recalculating the bouncing velocity components. It applies a restitution coefficient
(CR) to the particle velocity, that makes possible to stipulate a dampener factor for modelling
the energy lost during the collision. CR = 1.0 represents a perfectly elastic collision, in which no
kinetic energy is dissipated, while values of CR = 0.0 represents the opposite, a perfectly inelastic
collision, where all kinetic energy is dissipated and there is no separation between the bodies upon
contact (this is equivalent to the Trap model). In the models used in this work, it was considered
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that no energy was dissipated upon contact (CR = 1.0). However, the influence of this factor in
the results was not assessed, and additional models can be employed to estimate its value based
on the characteristics of the particles and walls [Tom06].
Critical Velocity Based Model
In this case all particles or droplets collisions were modelled accordingly to a model presented by
Brach and Dunn (1992) that predicts the particle deposition upon a ratio between the discrete
element normal velocity to the wall and its correspondingly critical velocity [BD92]. This model
was implemented in a numerical study of a DPI powder emission [MAK13]. The Dunn model,
considered in this work, treated the problem as a rigid body impact taking in account the following
assumptions [BD95]:
• The particle is considered to be spherical in the contact region and its centre of mass is
vertically aligned with the contact point;
• Non deforming bodies;
• The collision period is very short;
• Large contact forces;
• Finite velocity changes.
Figure 3.7 depicts the collision of a rigid particle with a rigid wall surface, in addition to the velocity
vector before (Vi) and after collision (Vf). The referential normal, n, and tangential, t, directions
are represented relatively to the wall orientation. Particle rotation is not considered in this work.
The determination of the critical velocity, VC ,is given by Equation 3.87. Particles with normal
component of the velocity before impact, Vn, less or equal to the VC value are entrapped. If the
initial velocity particle is so high that its normal component can overcome the critical velocity, the
particle will reflect accordingly to the Reflect model previously described (considering CR = 1.0).
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Figure 3.7: Velocity vectors representation of the particle wall collision along with the normal and
tangential referential
VC =
(
2E
dp
)10/7
(3.87)
where E is the effective stiffness parameter and is given by Equation 3.88:
E = 0.51
(
5pi2 (kw + kp)
4ρ
3/2
p
)2/5
(3.88)
The values of kw and kp are obtained by Equation 3.89:
kw =
1−ν2w
piEw
kp =
1−ν2p
piEp
(3.89)
where ν and E represent the Poisson’s ratio and Young Modulus, respectively. The subscripts
w and p, indicate whether the variable refers to the wall or particle, respectively. The relevant
properties are given in Table 3.4.
Tangential Lift-off Ratio Based Model
The model given by Shi and Bayless (2007) uses the forces ratios, acting on a particle when in
contact with the wall, as a correction for CFD prediction of powder deposition in a cyclone separator
[SB07]. This model was also reported by other studies [IDQ08]. The model was applied to the
angled surface of the cyclone funnel. The force calculation was simplified and the ratio equations
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were referred to the angle between the wall and the horizontal plane. Figure 3.8 represents the
forces acting on a particle resting in a surface angled with the horizontal plane.
t
n
FD,wall
FL
FA
0.7dp
Fg
θ
Figure 3.8: Representation of the forces acting on a particle upon contact with an angled (θ) wall
surface
In the case of the VHC geometry, the wall takes any possible orientation regarding the horizontal
plane. Shi model includes the ratio for vertical lift-off, the ratio for the sliding and the ratio for
the tangential lift-off. After an evaluation of the different ratios, the tangential lift-off ratio is the
dominant and is the only considered for particle reflection in this work. Equation 3.90 provides
the value of the tangential lift-off ratio (Rt).
Rt =
(0.7dp)FD,wall + AcFL + 0.5dpFg sin θ
Ac (FA + Fg cos θ)
(3.90)
where a is the area of contact, which depends of the material of the two bodies and is given by
Equation 3.91 [JKR71]:
Ac =
(
6pid2pσ
4K
)1/3
(3.91)
where the elastic constant K is given by Equation 3.92:
K =
4
3
(kw − kp)−1 (3.92)
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The forces present in Equation 3.90 are: gravity (Fg), drag (FD,wall), lift (FL) and adhesion (FA).
Equation 3.93 gives the value for Fg:
Fg = gmp (3.93)
The adhesion force is obtained through Equation 3.94, accordingly to the JKR model [JKR71],
where σ represents the surface energy (assumed to be equal to 0.001 J/m2).
FA =
3
4
piσdp (3.94)
The value of FD,wall was obtained from Equation 3.95 for particles resting on a plate accordingly
to O’Neill work [O’N68], being γ is the shear rate and f = 1.7009.
FD,wall = 6piµfγ
d2p
4
f (3.95)
The Lift force (FL) is given by Equation 3.96 from the work of Acrivos (1985) for spheres on a
resting plane at small Reynolds shear flow regime [LA85]. In this Equation, νf stands for the
kinematic viscosity of the fluid.
FL = 9.22
γµfd
2
p
4
γd2p
4νf
(3.96)
Other forces
Particle-wall interaction is a very complex matter and many theories are available in the literature.
In this work some effects were not possible to take into account, such as the electrostatic attraction
[Hin99, VLP09], the capillarity force from humidity in air [SMB00] or the contact force with
deformation [BD92], load and unloading cycles [Tom06].
3.7.4 Spray Distribution
The spray droplets were injected into the domain at the position corresponding to the pMDI actuator
nozzle. Since the primary atomisation was not modelled, it was necessary to program the droplets
spatial distribution at the nozzle exit. This was done by means of a Python language script that
provided the solver with an input file containing the characteristics of each ”stream” to be tracked.
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Alongside the distribution, it was also given other characteristics, such as: the temperature,
diameter, mass flow, velocity components and spatial position. The droplets were all assumed to
enter the domain at 215.15 K (-58 ◦C). This value is based on experimental studies of the Ventolin
spray plume passing through a set of thermocouple sensors [BCLM11, GSV99]. Accordingly to the
reported data, the spray temperature at the nozzle orifice can be lower than that considered here.
Another important parameter is the maximum spray plume velocity, although it is extremely difficult
to measure such quantity at the exact nozzle orifice position. Several data sources were taken into
consideration for defining the maximum velocity. Experimentally, the Ventolin spray was recorded
using a high-speed camera (the data being reported in section A.3). By image analysis, it is
possible to estimate a spray velocity of ≈50 m/s at 33 mm from the nozzle. Liu and his team
(2012) measured the Ventolin plume velocity, using PDA, at 54 mm from the nozzle and reported
it to be 10.3 m/s [LDG12]. Clark (1996) reports a peak velocity of 35 m/s at 50 mm from orifice
[Cla96]. Dunbar and his collaborators (1997) reported that the maximum velocity of a HFA-134a
plume is found along its axis with a value of ≈50 m/s at 25 mm from nozzle [DWM97]. Using
PIV technique, Crosland and his collaborators (2009), reported the Ventolin plume velocity field
over time, and showed a value of ≈63 m/s at 25 mm from the nozzle orifice at the beginning of
the actuation [CJM09]. Wigley, Versteeg and Hodson (2002) assessed the spray velocities at the
near-nozzle zone using a LDA/PDA system and reported a value of ≈90 m/s at 1 mm from the
nozzle [WVH02]. As the velocity decreases rapidly as the distance from the nozzle increases, so it
was assumed that the spray injection velocity had a value of 120 m/s.
The spray angle is another important parameter to model the spray plume. Using information
of the spray impaction pattern, from a plate located at 70 mm downstream from the nozzle,
Smyth and his team (2006) data suggested that the cone angle is ≈16 degrees [SHB+06]. A PIV
assessment on the spray cone angle made by Crosland and his collaborators (2009), reported a
value of 20.8 degrees [CJM09]. Dunbar (1996) measured the cone angle of a HFA-134a pMDI
spray and reported a value of 21.6 degrees [Dun96]. Given the fact that the pMDI plane-orifice
spray exits the orifice aperture rapidly, its high velocity jet expands radially. However, upon contact
with the slow velocity of the air, the angle reduces by friction with ambient air at periphery of the
spray. For modelling purposes, the full cone angle value was assumed to be 40 degrees.
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The nozzle diameter depends on the pMDI product actuator, and its dimension will strongly
influence the particle size distribution. Smaller nozzle diameters produce finer sprays [New05,
SSHM13, SBB+06]. Differences in the emitted mass between a flat, flat curved, cone and curved
cone nozzle designs were reported by Chen (2014) [CYF+14a]. Additionally, they reported the
effect of the electrostatic charge of the actuator material on the delivered mass [CYF+14b]. Cheng
and his team (2001) reported a value of 0.254 mm of nozzle diameter for an HFA-134a formulation
[CFYZ01]. Measurements of the pMDI Ventolin HFA-134a actuator used in the experimental tests
were conducted using a measuring microscope (Model 175-901 from Mitutoyo, Japan) with an
accuracy equal to 2 µm, and it was observed a nozzle diameter averaged 0.50(6)±0.01(0)mm.
The time duration of the spray can be assessed by high-speed image, by PIV, by laser measurements
over time or by impaction plate. Crosland (2009) reported a Ventolin spray duration of approximately
100 ms [CJM09]. Previously published work reported the value obtained by high-speed imaging to
be also 100 ms [OTT+12]. McCabe (2012) reported the Ventolin plume duration to be around
150 ms [MKBZ12]. Gabrio (1999) verified that the Ventolin spray plume duration had an average
of 94.5 ms [GSV99]. Based on this evidence, the spray modelled considers the spray duration to
be 100 ms.
The Ventolin label claims a dose per actuation of 100 µg. Using this value and the spray duration
of 100 ms mass flow rate of the spray was assumed to be 1E-6 kg/s.
The spray size distribution is the most relevant input for this model; it can be defined using
different statistical functions, whereas the literature reports that two of them have been widely
used in the pharmaceutical aerosol area: the Log-Normal (Equation 3.97) and the Rosin-Rammler
(Equation 3.98).
PDF (dp;µ, σ) =
1
dpσ
√
2pi
e−(ln(dp)−µ)
2/2σ2
CDF (dp;µ, σ) =
1
2
erfc
[
− ln (dp)− µ
σ
√
2
] (3.97)
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where the µ represents the mean diameter, σ is the geometric standard deviation and erfc is the
complementary error function.
PDF (dp;λ, k) =
k
λ
(
dp
λ
)k−1
e−(dp/λ)
k
CDF (dp;λ, k) = 1− e−(dp/λ)k
(3.98)
λ represents the mean diameter and k is the distribution spread.
Dunbar and Hickey (2000) studied the best distribution and fitting method for empirical data
obtained from a pMDI spray using an Andersen eight-stage cascade impactor. They concluded
that the best fitting method is through the nonlinear least squares of the PDF and that the Log-
Normal produced a better fit to the data than the Rosin-Rammler function [DH00]. However, these
distributions will approximate the spray by a unimodal function, when in reality, several peaks have
been identified [OTT+12]. Moreover, the spray size distribution is variable over time due to its
complex liquid-vapour movements inside the expansion chamber, with the addition of cavitation
effects near the nozzle orifice [WVH02, SBB+06].
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Figure 3.9: Measured spray size distribution and two corresponding statistical distribution
Given the fact that the spray distribution is modelled by means of an input file for the solver,
experimental particle size distribution data were obtained to be used as an input, removing the
need for mathematical modelling of the distribution. The spray was measured using the laser
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diffraction technique (particle sizer model 2600 from Malvern, UK), using a polynomial function
for data processing. The droplet diameter ranged from 1 µm to 60 µm. For comparison purposes,
the experimental data are plotted against the two distributions (see Figure 3.9) and differences are
observed [OTT+12]. A data fit was also carried out using the least squares methodology upon the
CDF functions.
Figure 3.10 shows the spray pattern at the nozzle orifice and the side view of the velocity vectors
for each injected droplets. As represented, the droplet spreading in the nozzle orifice was done
using a random generation algorithm that is independent of the droplet diameter. Further studies
are required for assessing the influence of the droplet pattern spatial distribution and its influence
in the deposition occurring inside the device. Other methods can be considered such as, randomly
spread the droplet by diameter along the radial direction.
This code allows the specification of the number of different diameters within the given distribution
as well as the number of random spatial positions at the nozzle. Each diameter is present at each
spatial position generated, multiplied by a fixed number of times. In the present simulations, the
total number of streams injected was 3600 per injection step.
Figure 3.10: Spray spatial distribution at the nozzle orifice
3.7.5 Tracking Model Configuration
The droplets were injected within 0.01 s apart during 0.1 s. Their interaction with the continuous
phase considered a two-way turbulence coupling, as well as mass and heat transfer. The tracking
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algorithm was performed at the beginning of each continuous phase time step. Apart from the
drag force, the Brownian motion and Saffman lift forces were also considered [ANS13].
The particle tracking had an stochastic model for predicting the influence of the turbulence
velocity fluctuations in the particles trajectories as described in section 3.1.6. As stated this
model has a limitation that it over estimates the normal component of the velocity fluctuations
close to a wall. This characteristic induces the simulation results with a small error, leading to
over deposition. Some corrections were developed to overcome this problem by modelling this
contribution according to the distance to the wall as proposed by Matida (2000) [MNT00]. The
equations are based in the work of Wang and James (1999) that was obtained by fitting DNS data
[WJ99]. Other authors had also followed this modelling technique [LHDX08, YIT15, LHCB07].
Dehbi (2008) approached the problem with a continuous random walk model, by applying the
normalized Langevin equations to determine the fluid fluctuations near wall [Deh08]. An application
of this model to a throat deposition CFD study was made in 2011 by Dehbi [Deh11].
3.8 Grid Discretisation Uncertainty Analysis
3.8.1 Methodology
A grid study for estimating the uncertainty due to the discretisation was carried out using the
Grid Convergence Method (GCI), which is based in the Richardson Extrapolation (RE) method
[CGR+08]. Currently, it is the most reliable method available; however its limitations are that the
prediction of local RE values do not exhibit a smooth monotonic dependence on the grid resolution.
Firstly, it is necessary to estimate a representing cell size (h). This can be done by using
Equation 3.99, that estimates an average mesh size for three-dimensional calculations.
h =
[
1
N
N∑
i=1
(∆Vi)
]1/3
(3.99)
where ∆Vi is the volume of the ith cell and the N is the total number of cells used.
Three grids should be created with different cell sizes (h1 < h2 < h3), whereas the refinement
factor (rmesh = hcoarse/hfine) should be greater than 1.3. The grid refinement was done
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automatically by changing the maximum cells size and keeping the boundary refinement unchanged.
A numerical solution shall be achieved for each grid, assessing the variables of relevance (φ) to
the problem.
Subsequently, it is calculated the apparent order (pm) of the method using the Equations 3.100
and 3.101, which can be solved together using a numerical method such as the fixed-point iteration.
pm =
1
ln (r21)
|ln |ε32/ε21|+ q (pm)| (3.100)
q (pm) = ln
[
rpm21 − (1 · sgn [ε32/ε21])
rpm32 − (1 · sgn [ε32/ε21])
]
(3.101)
ε32 = φ3 − φ2, ε21 = φ2 − φ1, and φk is the solution on the kth grid and r32 = h3/h2,
r21 = h2/h1.
The calculation of the extrapolated values is obtained by Equation 3.102.
φ21ext =
rpm21 φ1 − φ2
rpm21 − 1
(3.102)
The calculation of the approximate relative error is given by Equation 3.103, and Equation 3.104
that estimate the extrapolated relative error. The fine-grid convergence index is obtained through
Equation 3.105.
e21a =
∣∣∣∣φ1 − φ2φ1
∣∣∣∣ (3.103)
e21ext =
∣∣∣∣φ21ext − φ1φ21ext
∣∣∣∣ (3.104)
GCI21fine =
1.25e21a
rpm21 − 1
(3.105)
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3.8.2 pMDI Solo Grid
The grid uncertainty was evaluated for the pMDI solo geometry, using three sets of grids: 89.5k,
197.2k and 429.4k cells. The variable assessed was the velocity profile taken along the diameter
at four locations apart from the origin (see Figure 3.11).
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Figure 3.11: Locations of the velocity profiles for the pMDI solo domain
Figure 3.12 depicts the x-component velocity profiles for the three pMDI solo grids. The results
show some velocity differences between the grids in zones of high velocity gradient. The differences
appear to be higher for zones closer to the entrance.
Using the GCI methodology, the medium and fine grids velocity profiles are given in Figure 3.13,
along with the apparent order of the method and the averaged GCI value. The extrapolated absolute
error is given in the form of error bars, which identify the zones of highest uncertainty. It was
verified that the GCI decreases with the axial displacement, and that the uncertainty is small. This
result points out that a coarser mesh might be sufficient for the calculations in this geometry.
The most important variable to evaluate in the study is the amount of fine particles that exit the
domain after 2 seconds of simulation. Fine-grid GCI is 1.97% with an uncertainty of 0.81 µg, and
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medium-grid GCI is 0.60% with an uncertainty of 0.24 µg.
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Figure 3.12: Axial velocity profiles for the three pMDI solo grids, took at four locations from the
origin (t = 0.6 s)
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Figure 3.13: Extrapolated axial velocity profiles for the pMDI solo medium and fine grids, taken at
four locations from the origin (t = 0.6 s). The absolute extrapolated uncertainty is represented in
the form of error bars
3.8.3 CSC Grid
The grid uncertainty was evaluated for the CSC geometry using three sets of grids: 257.7k, 582.3k
and 1309.8k cells. The variable under study was the velocity profile taken along the diameter at
four locations apart from the origin (see Figure 3.14).
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Figure 3.14: Locations of the velocity profiles for the CSC domain
Figure 3.15 depicts the profile for the x-component of the velocity for the three CSC grids. The
results show velocity differences between the grids located in the centreline where velocity is
maximum. Similarly to the pMDI solo geometry, the highest differences are closer to the geometry
inlet section.
Using the GCI methodology, the medium and fine grids velocity profiles are given in Figure 3.16
along with the apparent order of the method and the averaged GCI value. The extrapolated absolute
error is given in the form of error bars, which identify the zones of the highest uncertainty. The
GCI decrease with the axial displacement up to the 75 mm, however closer to the valve (i.e.
100 mm) the uncertainty increases again. Despite that, the uncertainty is still within reasonable
intervals, which might be acceptable for the use of a coarser grid without much influence in the
drug deposition results.
The FPM exiting the domain after 4 seconds for the different grids shown a fine-grid GCI is 3.14%
with an uncertainty of 0.48 µg, and a medium-grid GCI is 7.94% with an uncertainty of 0.95 µg.
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(t = 0.6 s)
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4 Project of the Experimental Setup
4.1 Experimental Setups
In order to characterize the pMDI+VHC emitted dose, one can either assess the TEM (using a FD
setup) or detail regarding the plume aerodynamic size (using a CI setup).
4.1.1 Full Dose
Constant Flow
Initially some experimental tests were performed with the inhalation devices, at 30 L/min, using a
setup for capturing the full emitted dose as illustrated in Figure 4.1.
VHC Filter Casing Flow
meter
Needle
valve
Vacuum
Pump
Figure 4.1: Experimental setup schematic for tests at constant flow using a Full Dose collector
This setup includes a vacuum system with a ball valve for flow control, which is connected to a
rotameter and allows controlling of the air flow rate. The latter is connected to a house-made
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aluminium filter casing that has a geometry with dimensions similar to the upstream portion of the
USP IP (see section 4.2.5). The devices were connected to the filter casing, through a house-made
silicon universal adapter, for a leakage free fitting. The paper filter used in the experiments was
the MN 1674, whose characteristics are fully evaluated in section A.2. Tests were conducted by
firing 20 puffs into the setup for the VHC’s and 10 for the pMDI solo.
Variable Flow
Figure 4.2 depicts the experimental setup for testing the total emitted dose of the inhalation under
a breath pattern (described in section 4.3.1). The setup is composed by the device under test
that is connected to the filter casing, and the latter is directly connected to the breath simulator
(described in section 4.2.7). A paper filter MN 1674 was used for drug collection and a total of 20
puffs, actuated at the beginning of each inhalation phase, were fired into the VHC.
VHC Filter Casing Breath
Machine
Figure 4.2: Experimental setup schematic for tests at variable flow using a Full Dose collector
4.1.2 Cascade Impactor
Constant Flow
Experimental tests of the drug delivery by the VHC at constant flow rate (i.e. 60 L/min) required an
experimental setup that was able to replicate the lung deposition (see Figure 4.3). This is achieved
by collecting the drug through an impactor/impinger, specifically in this case, a 5-stage MSLI. The
impactor/impinger operation principle allows a mass separation by particle aerodynamic diameter
ranges.
The setup is constituted by a MSLI, which is connected to a vacuum system that allows a controlled
constant flow rate to be drawn through the impactor. A standardized induction port USP, connected
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to the MSLI entrance, allows for a rough replication of the throat deposition effect. The VHC
device under assessment is connected to the USP IP entrance, using an universal silicon adapter.
Constant flow rate is drawn through the VHC during the test while several pMDI puffs are fired
into the device. The collected mass at each part of the setup allows the quantification and the
evaluation of the device performance.
VHC
pMDI
USP Throat
Flow
meter
Ball
valve
Vacuum
Pump
3 Stage
rd
2 Stage
nd
1 Stage
st
4 Stage
th
5 Stage
th
(Filter)
Figure 4.3: Experimental setup schematic for tests at constant flow using a cascade impactor
Variable Flow
The variable flow setup was used for VHC devices experimental evaluation of the emitted dose
when the device is under a breath pattern. This approach is a more realistic way of testing VHC,
since these devices have in their constitution an one-way valve that only properly works when the
flow rate passing through it goes from zero to positive values and down again. This setup allows
the movement of the valve, making it able to test the device valve efficiency in the delivery of the
drug. In this experimental setup (see Figure 4.4), an MSLI was used for drug collection. The
impactor has the need to work at constant and controlled flow rate, to provide accurate results.
Therefore it is necessary to combine a variable flow rate pattern with the constant impactor flow
rate. This was firstly achieved by Finlay [Fin98] and Foss [FK99], whose research teams approach
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the problem by creating two flow circuits:
• a constant flow rate circuit between a compressed air source and the vacuum system that
passes through the impactor;
• a variable flow rate circuit that results from adding (exhalation) or subtracting (inhalation) a
flow pattern to the constant flow rate created by the compressed air source. At the impactor
entrance, a T-junction separates the variable from the constant flow. This allowed the
variable flow to be the only one reaching the VHC device that is connected to the IP.
An improvement to the typical T-junction was developed as a Mixer, for which geometric dimensions
were optimized to minimize the pressure drop and particle-wall interaction.
- L/min
Rotameter
Vacuum
Pump
Flow
regulator
Ball
valve
Pressure
regulator
Breath Machine
p + DeviceMDI VHC
USP Throat
Mixing
Cone
Inhalation
Exhalation
Impactor
Compressed
Air
60 L/min
60 L/min
Mass Flowmeter
Figure 4.4: Experimental setup schematic for tests at variable flow using a cascade impactor
Figure 4.5 depicts the two extreme situations whereas the variable flow is added or subtracted to
98
4.2. Main Experimental Setup Components
the constant flow rate circuit.
The introduction of a breath simulator machine is an essential part of this setup, which provides
the desired breath pattern that is used to evaluate the VHC device. A mechanical system was
developed based in a form-closed cam-follower mechanism, where a continuous spin motion is
converted to a variable linear motion, which is connect to a pneumatic piston rod that delivers a
specific airflow wave.
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Figure 4.5: Flow rate routes for two scenarios: (a) subtraction (i.e. inhalation) or (b) addition (i.e.
exhalation) of flow rate to the constant flow rate circuit
4.2 Main Experimental Setup Components
4.2.1 Vacuum System
The choice of the vacuum pump had to respect two important requirements: it could not be
lubricated with oil to ensure the non-contamination of the air during the experimental tests; on
the other hand it has to be able to overcome the pressure drop caused by the MSLI. In the MSLI
device, the high pressure drop is caused by the paper filter in the last stage; so it was essential to
start by evaluating different paper filters and choose the most adequate. This analysis is presented
in section A.2, whereas it was chosen the paper filter MN 619 (from Macherey-Nagel, Germany)
for usage with the MSLI.
Given a pressure drop of 37.7 kPa at 60 L/min, the vacuum pump needed, at least, to overcome
this value. Several pumps with different mechanisms were studied, although the most cost-effective
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and adequate choice was the oiless rotary vanes mechanism, more specifically the GS-6 model
from General Europe Vacuum, Italy (see Figure 4.6).
This equipment included a three-phase motor of 370 W that powered the vanes. This selected
equipment is capable to create a maximum flow of 123 L/min (at inlet atmospheric pressure) with
a ultimate vacuum of 150 mbar and it is equipped with a silencer (attached to the outlet) that
reduced the noise to 60 dB. Due to the pressure drop caused by the filter and the other setup
components, two GS-6 pumps were installed in parallel. An escape ball valve was also added, in a
T-junction, for flow rate control.
Figure 4.6: Vacuum system constituted by two GS-6 pumps in parallel
4.2.2 Compressed Air Source
The compressed air was obtained from the University pipe line, which was controlled through a
pressure regulator with a filter (Model N204-D00 from Camozzi, UK) where its value was fixed in 2
bar. Additionally, a flow regulator (Model FCA88 from Brooks, USA) was coupled to ensure a flow
rate of 60 L/min, measured in a rotameter (D10A11 from ABB, Switzerland). The objective of this
procedure is tho account for sudden grid pressure fluctuations. This allowed a constant flow rate
to be used in the variable flow experiments. The equipment used is displayed in Figure 4.7.
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Figure 4.7: Air compressed source with the assembly of the pressure regulator and flow regulator
4.2.3 Flow Meters
As previously described, a rotameter (see Figure 4.8) was used for constant flow measurements
in the setup, allowing for a control of the flow during the experiments. The latter was calibrated
using three methodologies fully described in the section A.1. The rotameter was installed in a
laboratory clamp universal support and it was placed in a vertical position. Percentage scale marks
allow the user to read the float position and thus the flow rate. Additionally, a mass flow meter
(Model 4043 from TSI, USA) was used for calibration and digital recording during the variable flow
experiments. The flow meter was calibrated by the manufacturer for different types of gas. This
device is composed by a hot-wire that estimates the flow rate based on voltage readings and by
correlation with several calibration curves incorporated in its microprocessor. Additionally, pressure
and temperature sensors allow to account for these variables influence and well as register them.
The equipment is shown in Figure 4.9.
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Figure 4.8: Rotameter used in the experimental setup
Figure 4.9: Mass flowmeter used in the rotameter calibration and in the variable flow setup
4.2.4 Mixing Cone
This device has the function to replace the classic T-junction, allowing for the smooth interaction
between the two intersecting flows. The upstream flow coming from the VHC, which transports
the drug particles, has a lower mean velocity than that delivered by the compressor plus breathing
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machine (Figure 4.4). This may result in the projection of the drug particles towards the ”Tee”
walls. To avoid this effect, it is necessary to gently mix both flows, keeping the particles in the core
of the jet.
Therefore, the device shall have a conical shape, similar to a cyclone separator, where a concentric
tube enters the funnel. The design of such device was based in the work of Miller [Mil02]. The
airflow, coming from the compressor plus breath machine, enters the funnel at the top (through
inlet ports) and it is forced downwards, pushing the air from the inner tube and keeping the particles
in the centre of the flow. This effect strongly reduces the drug deposition in this intersection, and
it minimizes the influence of this component in the drug assessment setup.
Through the use of CFD software, the dimensions and number of air inlet ports were assessed.
FLUENT® from ANSYS® [ANS13] was the software of choice for the study, where two flow cases
were tested: the maximum exhalation flow (60 L/min plus 22 L/min) and the maximum inspiration
flow (60 L/min minus 11 L/min). Due to the vacuum system function extracting air through the
MSLI at 60 L/min, the same flow condition was applied in the outlet boundary of the mixing cone
device. The top inlet of the concentric tube was kept at the atmospheric pressure and the flow
passing there was assessed, to verify if the design performs its function properly.
Taking into account that the top concentric tube inlet has a fixed diameter defined by the USP
throat (i.e. 25.4 mm) and the bottom outlet has also a fixed diameter (i.e. impactor entry26.8
mm), only the length of the concentric tube was assessed. Also, the influence of 1, 2 or 4 inlet
ports was studied in order to understand their impact in flow introduction at the top of the mixer
funnel.
Figure 4.10 shows an axial cross section of the mixing cone with the main dimensions. Amongst
them, the distance that was changed in the simulation study is marked with a red X. Although it is
an axisymmetric geometry, the inlet at the top has a circular section, and it is positioned evenly
spaced around the perimeter, accordingly to the number of inlet sections.
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Figure 4.10: Schematic revolution section cut of the mixer design
The two angled lines are identified with a parallel (//) symbol. As the X dimension increases,
the distance between those two parallel lines decreases. A sampling plane (parallel the bottom
exit and distancing 105-X mm) was created. In this location it occurs, the change in the flow
direction and mixing of both flows. The objective is to make this mixing as smoother as possible,
therefore, the velocity and direction at this point, are assessed. Also, the pressure drop coefficient
is evaluated for all the cases tested.
In order to identify the best dimensional value for X, a design analysis study was performed.
By varying the X distance between an upper and lower bounds (i.e. 25 mm and 70 mm), a
correlation function was obtained through 2nd order polynomial regression, for each output
parameter previously described. Both inhalation and exhalation cases were evaluated using the
ANSYS® software. The results are shown in Figure 4.11, and it can be observed that, the best
dimension for X is between the values of 35.0 and 50.0 mm, where the values of pressure drop
coefficient (K = (pin − pout) / (0.5ρfV 2in)) are the lowest.
In Figure 4.12, the results from the simulations for X=40 mm, for (a) exhalation and (b) inspiration,
are represented. The results are shown in the form of fluid streamlines and velocity magnitude
contours, in a quarter of geometry that includes the 4 inlets configuration. Results show a smooth
transition of the flow in inspiration and exhalation stages. The exit at the bottom shows an
undisturbed flow just upstream of the impactor. After post-processing of the results, the value for
pressure drop coefficient is 2.13 for inspiration and 3.67 for exhalation. The velocity field at the
sampling plane is similar for both cases in the bottom exit portion of the geometry.
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Also, the flow at the top exit has the expected values at both cases, i.e. the flow rate delivered by
the breath machine.
25 30 35 40 45 50 55 60 65 70
X Value [mm]
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
Pr
es
su
re
 D
ro
p 
C
oe
fic
ie
nt
 (K
) [
-]
Inhalation Peak: 22 L/min
Exhalation Peak: 11 L/min
Figure 4.11: Results of pressure drop for the mixer design upon several values for X dimension,
two curves represent the inspiration and exhalation points
A subsequent numerical assessment of the pressure drop coefficient results for 1, 2 or 4 entries
was made, with results respectively, 6.99, 3.52 and 2.11 for the inspiration phase. This suggests
that, the use of 4 inlets is the best configuration. Visual inspection of the results also showed a
more stable flow region close to the exit of the device, showing an axisymmetric flow.
This device was manufactured in aluminium with four side entries. However, latter on during
the testing procedure, it was found that using a triple T-junction connecting the four side entries
resulted in complications for the disassembly and washing procedures. Hence, the device was
modified to be used with only one side entrance.
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Figure 4.12: CFD results for the mixer chosen design of one quarter geometry: (a) exhalation and
(b) inspiration
4.2.5 USP IP
As depicted in Figure 4.3, the pMDI and the VHC were fitted into a home-made silicon universal
adapter, which was attached to the USP IP (made of aluminium accordingly to the standardized
dimensions present in US Pharmacopeia [US 14]), as depicted in Figure 4.13.
The standardized USP throat model (with a 90 degrees bend) is a fairly known representation of the
human throat. Nowadays, the latest standardized throat model is closer to a human physiologic
throat and it is known as the ”Alberta” idealized adult anatomic throat (AIT). Some studies point that
the AIT model shows a more correct drug deposition than the USP model [ZFM04, LHDX08, Che14].
Nevertheless, the AIT latest equipment was not available in the laboratory and due to economical
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reasons it was not feasible to acquire or produce it. Since USP model is still acceptable in the
Pharmacopoeia and fairly known, is was the device of choice.
Figure 4.13: USP IP aluminium model with the silicon universal adapter attached
The universal silicon adapter was based in the VHC actuator adapter design, made with a rubber
material that allowed for large deformations and that could create a tight seal around the different
VHC mouthpieces designs. It was designed using the CAD software SolidWorks®. A simple
deformation simulation (using explicit dynamics software LS-DYNA® from ANSYS®) was carried out
to study if the dimensions were able to tight seal around the Ventilan® pMDI actuator. Simulation
results proved that the design represent a feseable solution. Hence a two part aluminium mould
was produced by CNC milling so the liquid silicone (Smooth-Sil 950, Smooth-On from USA) could
be poured into it. Afterwards, the silicon sealed in the mould was exposed to a curing process
of 24 hours in an oven. The silicon universal adapter was then tested for mechanical resistance
to manual handling (by compressing and stretch). Afterwards it was also washed with a 0.01M
NaOH solution to a 20 mL flask to investigate the possibility of contamination. Results showed no
contamination (0.00 ± 0.00 abs at 244 nm).
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4.2.6 Multi-Stage Liquid Impinger (MSLI)
Impacting collectors have been used to measure particle size for a wide range of sprays. In
particular for inhaler derived aerosols, it has been the most widely used method [Mar04]. Mitchell
and Nagel have extensively reviewed this type of particle size analysers, their strengths and
limitations [MN03].
The theoretical principles of an impactor are based on the solution of the two dimensional Navier
Stokes equations of a fluid around a target oriented perpendicularly to the impinging flow. This
flow field is subsequently coupled with Newton’s equation of motion to model the trajectories of
particles/droplets through various stages and geometries. In its basic form, the impactor consists
of a jet of a known diameter that exits from an nozzle diameter (D) located at a certain distance
(S) from the flat target that acts as a collector (see Figure 4.14).
S
D
Figure 4.14: Schematic of the impactor working principle
As the flow exits the orifice, its streamlines diverge in the vicinity of the collection surface. The
high inertia particles move through the streamlines and impact on the target surface. The Stokes
number (Stk) defines the critical particle size (aerodynamic diameter dp) that will impact the
collection surface through Equation 4.1:
Stk =
ρpCcd
2
pUf
2µfD
(4.1)
where Cc is the Cunningham slip, ρp is the particle density, Uf is the gas velocity at the orifice
exit and µf is the fluid viscosity.
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The particle collection efficiency of an ideal impactor will increase in a step from 0 to 100% at a
critical Stk. For each impactor stage, the corresponding cut-off diameter (d50) can be calculated
through Equation 4.2.√
C50d50 =
[
9piµfnD
3
4ρpCcQ
](1/2)√
Stk50 (4.2)
where n accounts for the number of circular nozzle orifices, Q refers to the flow rate and subscript
50 identify conditions at 50% efficiency.
A cascade impactor consists of several stages with progressively decreasing cut sizes, assembled
in series, so that an aerosol is separated into various fractions according to the number of stages
assembled. The design of the CI can be tailored to measure the size down to sub-micron particles.
The Glass Twin Impinger is used to separate the large from the small particles. The former are
deposited in the upper tract of the respiratory system while the later are most likely to reach
the alveoli. For inhaler testing, it is desirable that at least 5 stages are assembled with cut off
aerodynamic diameters within the range 0.5 - 5.0 µm. One of the most widely used is the Anderson
type impactor with 8 stages. The testing of aerosols usually involves the operation at a constant
flow rate (i.e. 28 L/min) although this does not represent the conditions typical of a tidal respiratory
cycle.
The CI available in the laboratory was the 5-stage Multi-Stage Liquid Impinger (MSLI) (last calibrated
in 2014 by Westech, UK), see Figure 4.15. Although, this equipment has cut-off stage diameters
calibrated at 60 L/min, a simple formula (provided in the Pharmacopeia) can used to correct for
different flow rates (between 30 L/min and 100 L/min). The studies were conducted at 30 and
60 L/min, whereas the cut-off diameters are presented in Table 4.1.
Table 4.1: Cut-off diameters for all the stages at 30 and 60 L/min constant flow
Flow rate (L/min) Stage 2 Stage 3 Stage 4 Stage 5
30 18.4 9.6 4.4 2.4
60 13.0 6.8 3.1 1.7
Values come in micrometres (µm), except when indicated otherwise
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Figure 4.15: Pharmacopoeia 5-stage MSLI apparatus
4.2.7 Breathing Simulator
The breathing simulator has the purpose of replicating a human breath waveform by means of
a mechanical system. The system is composed by the spin motor that provides a continuous
rotation motion, two worm gear speed reducers coupled in tandem to reduce the motor Rotations
Per Minute (RPM) output, one form-closed cam-follower mechanism and a pneumatic cylinder. The
spin motor rotational movement actuates a cam, which transforms its movement to a non-uniform
linear translational follower’s displacement. The latter is connected to the pneumatic cylinder
piston. An overview of the house-made assembled mechanism is shown in Figure 4.16.
The cam-follower mechanism is fully dependent on the breath waveform that is intended to be
replicated. It is also limited by the pneumatic cylinder piston cross section area and the angular
velocity of the cam. Meaning that, this design can only reproduce a pre-defined waveform; a
different one would imply changing the spin velocity, cam plate and possibly the pneumatic piston.
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Figure 4.16: Photograph of the house-made breath simulator to deliver the designed breath
waveform
4.3 Design of the Breathing Simulator
4.3.1 Breath Profile
The first step in designing the breathing simulator mechanism is to define the respiratory profile,
which is the intended output. Thus, a target patient waveform was studied (i.e. an asthmatic
children under 6 years old).
An asthmatic child breathing profile shows certain characteristics that are different somehow
from a healthy child. The VHC use is intended for children and elder without the capacity for
breathing-actuation coordination. According to the Canadian normative for VHC testing (Dolovich
and Mitchell, 2008), a good simplified approach for the shape of the respiratory cycle (flow vs. time)
corresponds to a sinusoidal function [DM04, CZR08]. Also, other authors presented experimental
data that supports this assumption [JAC+05].
For a correct definition of the sinusoidal wave, it is of utmost importance to obtain the suitable
experimental data of breathing frequency BPM, duty cycle (ratio of inspiration time per total cycle
time) and tidal volume of inspired air. The respiratory frequency ranges from 20 to 30 BPM,
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and increases in the presence of asthma [DM04, BOS01, BP09, MGH+99]. It is known that the
duty cycle values for these children are approximately 0.44 [MGH+99, CAM+01, KCD+05], but
it decreases with the presence of a respiratory disease [BOS01, KCD+05]. Although the tidal
volume varies with height, weight, gender and with asthma pathology, data from various sources
show that it ranges from 150 to 180 L/min [DM04, BOS01, BP09].
Enlightened by these data, the following values were assumed to be the most adequate: a frequency
of 30 BPM, a duty cycle of 0.33 and a tidal volume of 150.0 mL. The breathing cycle used in the
simulations is represented in Figure 4.17.
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Figure 4.17: Breath profile developed to be used in the variable setup testing
The amplitude of the inspiratory sinus (21 L/min) was obtained by fitting the integral of a sine
function to the tidal volume. The same procedure was applied for the exhalation phase. A pause of
4 s after inspiration was added, to guarantee the sedimentation of drug particles inside the lungs.
This delay is recommended for improved efficacy in drug delivery. After the exhalation phase, a 2 s
pause was added, which is proposed by Mitchell and Dolovich, as well as, the Canadian normative
for VHC testing [CZR08, MD12]. This delay is intended to simulate the poor coordination of an
asthmatic patient using a VHC.
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4.3.2 Calculation of the Cam Tracks
Figure 4.17 depicts the initial condition for the design of the cam-follower profile. The piston shall
move accordingly to reproduce the flow rate as described. In the present case, the varying flow
rate of the respiratory cycle was obtained by the use of a cam/cylinder combination. This design
is robust and it can provide accurate flow profiles at a low construction cost. Alternatively the
volume flow rate could be delivered by a step motor driving the piston/cylinder. This option would
be more expensive to develop though with added flexibility of operation. However, as the current
study is focused on a particular group of patients, this limitation is not extremely severe.
After assuming the internal diameter of the cylinder, Dp, the corresponding circular area is
calculated. This area should be corrected by subtracting the cross section area of the internal
rod, Dr, if present inside the cylinder. Dividing the sine waves by the value of the piston cross
section area, the piston velocity is obtained. Through the integration of the velocity (y′) function,
the acceleration (y′′) is obtained, and from acceleration integration, the jerk (y′′′) is calculated.
In opposition, by derivation of the velocity, the displacement (y) function is obtained. The four
functions are shown in Figure 4.18, and they are essential to the definition of the follower path in
the cam. Using the profiles for the piston movement and the proper equations for form-closed
cam-follower calculation, the profile is obtained by the approximation of a curve tangent to the
position of the follower.
Equation 4.3 is used for the calculation of the follower movement, as [Flo09, Nor02]:
F (x, y, θ) = (x− xc)2 + (y − yc)2 −R2r = 0 (4.3)
where Rr is the radius of the contact roller (i.e. 19.0 mm) and (xc, yc) are the roller centre
coordinates, given by Equations 4.4 and 4.5 [Flo09, Nor02]:
xc = −(Rb +Rr + s) · sin θ (4.4)
yc = (Rb +Rr + s) · cos θ (4.5)
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Figure 4.18: Cam profiles (displacement, velocity, acceleration and jerk) calculated for the chosen
cam/cylinder dimensions
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In these equations Rb is the base radius of the cam, s is the displacement (see Figure 4.18).
Differentiating Equation 4.3 with respect to θ, Equation 4.6 is obtained [Flo09, Nor02]:
∂F
∂θ
= −2(x− xc)dxcdθ − 2(y − yc)
dyc
dθ
= 0 (4.6)
The derivatives of Equations 4.4 and 4.5 with respect to θ are given by Equations 4.7 and 4.8
[Flo09, Nor02]:
dxc
dθ
= −(Rb +Rr + s) cos θ − dsdθ sin θ (4.7)
dyc
dθ
= −(Rb +Rr + s) sin θ − dsdθ cos θ (4.8)
where ds/dθ represents the velocity of the follower (see Figure 4.18). Solving, simultaneously,
Equations 4.3 and 4.6, Equations 4.9 and 4.10 for cam profiles coordinates, are obtained [Flo09,
Nor02]:
x = xc ±Rr
(
dyc
dθ
)[(
dxc
dθ
)2
+
(
dyc
dθ
)2]− 12
(4.9)
y = yc ∓Rr
(
dxc
dθ
)[(
dxc
dθ
)2
+
(
dyc
dθ
)2]− 12
(4.10)
Equations 4.9 and 4.10 represent the inner and outer profiles for the cam, as shown in Figure 4.19.
All these calculations have been programmed using Python language and a script was computed.
Several dimensional configurations for the base diameter and piston diameter were assessed.
Also, the following constrains were introduced:
• cylinder feasible diameters could not be outside the manufacturer range;
• the maximum feasible displacement could not be outside the cylinder manufacturer range;
• cam outer profile could not be located at less than 6.0 mm to the maximum disk diameter
(i.e. 310.0 mm);
• cam inner profile could not be located at less than 5.0 mm to the disk bore diameter (i.e.
27.0 mm).
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Within such restrictions and the cylinder Dp manufacturer constrains, several possible combi-
nations were obtained. Amongst all the feasible solutions, those presenting the lower value for
pressure angle was selected (i.e. Base diameter: 250.0 mm and Piston diameter: 63.0 mm).
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Figure 4.19: Final design of the cam profile, showing the outer and inner profile tracks along with
the base diameter, the inner and outer borders
4.3.3 Cam Mechanism Performance Analysis
A cam follower mechanism performance can be numerically evaluated in the design phase, before
its experimental validation. This can be done using different metrics, herein were calculated the
pressure angle, curvature and backlash impact.
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In the contact point formed between the two curves (cam profile and roller), the force is transmitted
from cam to follower along the common normal (i.e. axis of transmission). The pressure angle is
defined by the angle between the direction of motion and the common normal. If the pressure
angle presents a value of zero, there is a perfect alignment between the both and therefore all
force goes into the movement. High pressure angle values, represent a part of the load not being
transformed into movement and results in tangential slip forces on the follower’s axis that can
lead to fracture. Equation 4.11 allows the calculation of the pressure angle profile along a cam
cycle [Flo09, Nor02]. Advisable values of pressure angle are within 30 degrees.
φ = tan−1
y
′
Rb +Rr + y
(4.11)
Curvature radius allows the evaluation of the cam profile curvature at each point of its cycle.
By using the general Equation 4.12 and applying it to Equations 4.4 and 4.5, the simplified
Equation 4.13 for radial cam with translating roller follower was used to calculate the curvature
radius. Its value is then compared with the roller radius (Rr) and a simple geometric analysis can
provide conclusions upon the type of cam profile: convex (ρp > Rr) or concave (ρp < 0). Design
combinations where the profile do not reproduce a desired solution are found when: 0 ≤ ρp ≤ Rr.
Undercutting problems can be found whereas the minimum positive curvature value is smaller
than the roller radius.
ρ =
[(
dx
dθ
)2
+
( dy
dθ
)2] 32
dx
dθ
d2y
dθ2 − dydθ d
2x
dθ2
(4.12)
ρp =
[
(Rb +Rr + y)
2 +
(
y
′)2] 32
(Rb +Rr + y)
2 + 2 (y′)2 − (Rb +Rr + y) y′′
(4.13)
The backlash impact force is resultant from the existence of backlash (i.e. the gap between the
moving parts whereas exists loss of contact), in cases where the cam angular velocity is very high
it is especially important to reduce the influence of this force. For the calculation of this force (see
Equation 4.14) is required to assume:
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• a backlash average value (i.e. ytol = 0.05 mm);
• the system equivalent mass (i.e. m = 0.48 kg);
• the system stiffness (i.e. k = 1.3E10 N/m).
Fc ∼=
[
1
2
(
d3y
dθ3
) 1
3
· (6 · ytol)
2
3
]√
m · k (4.14)
Whereas the system equivalent mass (i.e. m) is calculated through Equation 4.15 and the system
stiffness (i.e. k) is given by Equation 4.16.
m =
mcam ·mfollower
mcam +mfollower
(4.15)
Considering: mcam = 12.0 kg,mfollower = 0.5 kg.
k =
4 · √Rr
3 · 2 · (1− ν2
E
) (4.16)
Considering the Young Modulus (E = 1.9E11 Pa) and Poisson’s Ratio (ν = 0.27).
Figure 4.20 shows the performance analysis of the cam-follower mechanism, where it is re-
ported the pressure angle, curvature radius and backlash impact force.
Pressure angle reach a peak (i.e. 46.4◦) at 17◦, a second smaller peak (i.e. 27.7◦) is found
at the position 235.7◦; these values are within an acceptable range (hatched in red dash the
non-advisable limits) for the low angular velocity of this system (i.e. 7.5 RPM).
Regarding the curvature radius, it can be observed the existence of some peaks, coming in from
points where sharp corners are present. This could be mitigated by increasing the cylinder piston
diameter (or increasing the base diameter). Most important is the non-existence of undercutting
zones (hatched in red dash), for which the minimum curvature radius is 3 times higher than the
roller radius.
The backlash impact force reaches two peaks corresponding to the inspiration and exhalation
peaks. The peak values are 250 N and -120 N, and they play an important role for high angular
velocity systems which is not the case for the projected system, this effect can only be mitigated
by increasing the piston diameter.
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Figure 4.20: Performance profiles (pressure angle, curvature radius and backlash impact) calcu-
lated for the chosen cam design
4.3.4 Other Components and Assembly
The cam disk was manufactured by CNC milling of alloyed steel (UNE F-5303) with a surface
hardening nitriding process, to provide extra wear resistance. The disk has an outer diameter of
310.0 mm and an inner bore of 27.0 mm, with a thickness of 22.0 mm and a track depth of 10.0
mm.
The rotation movement transmitted to the cam is provided by a three-phase electric motor (model
TA713-4 from MEB) spinning at 1,380 RPM for a 50 Hz current. Therefore, two worm gears were
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sequentially coupled (model NMT040 from MEB) with a combined ratio of 1:75. To match the
RPM of the motor in order to reach the total breathing cycle time (i.e. 8 s per turn=7.5 RPM), it
was used a variable frequency drives (model SV008iC5-1 from LS). Such device also allows for
the study of other breathing patterns if required. A proper shaft union of the worm gear to the
cam axis was made (model flexible coupling union from TRASCO). This device allows a smoother
connection mainly in case of vibrations.
An adequate roller to run the form-closed profile of the cam was selected (model S24LW from RBC
bearings), which accounted for high levels of friction induced wear.
The roller was attached to a sliding guide, and this one to the cylinder rod. A guide with ball
bearings was selected (model REXROTH from BOSCH Group), so it did not added friction to the
system while ensured an accurate motion of the linear piston.
A pneumatic cylinder with a 63.0 mm internal diameter and 100.0 mm of stroke length (model
DSNU from FESTO) was chosen.
4.3.5 Breath Simulator Validation
The validation of the output generated by the designed breath machine, which is based in a
form-closed cam-follower mechanism, was executed by evaluating both the follower’s displacement
and the airflow output (see Figure 4.21).
The final configuration of the breath machine accounts for a constant flow rate of 60 L/min passing
through the pneumatic cylinder outlet port. However, this creates a positive pressure that the
mechanism needs to overcome. By placing the mass flow meter downstream of the junction of
both flow rates (i.e. constant 60 L/min plus the generated waveform) it allows a better evaluation
of the real breath pattern being generated.
The air flow rate was measured by the mass flow meter (Model 4043 from TSI, USA), and from
this data it was subsequently subtracted the constant air flow of 60 L/min, resulting the generated
waveform by the breath machine. The linear displacement was acquired by connecting a Linear
Variable Differential Transformer (LVDT) (DCTH2000 from RDP Electronics, UK) to the piston
rod. The LVDT sensor was connected to a data acquisition system (NI USB-6009 from National
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Instruments, USA) which was connected to the computer by USB interface, while the mass flow
meter was directly connected to the computer by Serial Port.
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Figure 4.21: Breath machine validation setup
The data from both sensors were processed in an instrumentation software (LabVIEW 2010 from
National Instruments, USA), and then were analysed and compared to the theoretical profiles of
displacement and flow rate (which were the input of the cam profile creation).
Comparison graphs are shown in Figures 4.22 and 4.23. Minimum differences were found for
the displacement profile (see Figure 4.22). However, the flow rate results presented an irrelevant
inconsistency in the peak of the inhalation (see Figure 4.23), which might be associated to backlash
caused by high curvature of the cam profile. That could be mitigated by increasing the base
diameter of the cam profile, which would not be fit within the existing metal framework dimensional
restrictions. Another possibility, would be the use of a custom-made pneumatic cylinder with larger
piston diameter.
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Figure 4.22: Displacement validation results from breath machine, comparing the theoretical with
the experimental profiles
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Figure 4.23: Flowrate validation results from breath machine, comparing the theoretical with the
experimental profiles
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5.1 Experimental Test Procedure
5.1.1 Washing Procedure
Each VHC was submerged in an anionic soap aqueous solution (1:250) during one hour and left
drying out for 24 hours, prior to the experimental procedure, as reported in the literature [FZ98].
This pre-treatment method was suggested by Mitchell and Nagel (2007), where the electrostatic
charge in VHC devices can be mitigated (mainly in those made of non-dissipative materials)
[MN07].
This procedure sets a baseline for all the different devices and reduces the inconsistency of the Total
Emitted Mass (TEM), caused by accumulated electrostatic charges. A soapy bath or initial priming,
are methodologies suggested by the majority of the VHC manufacturers to reduce electrostatic
charges. The service actuator that was used throughout all the tests was also immersed in the
soap solution, rinsed with tap water and left for drying during 24 hours, between each experimental
test.
This washing procedure, executed with all the devices, was thought to mimic the regular in-house
washing methodology performed by the patient. Since the main objective of the experimental
study is to obtain conclusions on how device’s geometric features affect the output performance,
the soapy bath will nullify the influence of the material type regarding electrostatic charges.
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5.1.2 Experimental Protocol
The experimental steps necessary to execute the assessment procedure at constant flow rate
are the following:
1. Once the experimental setup parts were all connected, the vacuum system was turned on
and the flow rate was set at the USP throat entrance, to the desired value. The flow rate
value was marked in the rotameter (D10A11 from ABB, Switzerland) placed between the
MSLI and the vacuum system.
2. The silicon universal adapter was fitted to the USP throat entrance and connected to the
device (e.g. VHC + pMDI or pMDI solo).
3. The pMDI canister was shaken during 5 seconds and fired twice to waste from the pMDI
original actuator.
4. Subsequently, the canister was placed in the service actuator, already attached to the VHC
(or directly attached to the universal throat adapter).
5. A total of 40 puffs were made (20 puff for the case when the pMDI was tested alone), while
shaking the canister for 5 seconds between each puff.
6. When the firing step was completed, the vacuum system was left running for 30 seconds
period and then it was turned off. The vacuum system was disconnected from the MSLI.
7. The pMDI canister was removed from the service actuator and stored in its original package.
8. Every stage of the experimental setup was washed with 0.01M NaOH solution [Fin98] into
volumetric flasks: primarily, the pMDI actuator into a 25 mL flask, then the VHC device into
a 100 mL flask, the USP throat to a 50 mL flask, each MSLI stage to a 20 mL flask, and
finally, the filter to a 50 mL flask. To improve the drug solubility and its release from the
filter, this was placed into an ultrasonic shaker for 5 minutes.
9. Each washing solution absorbance (λ=244 nm [Fin98]) was measured three time by means
of a UV-Vis spectrophotometer (UV-2401PC from Shimadzu Corporation®, Japan).
10. The concentration of each solution was estimated through the use of a calibration curve for
salbutamol sulphate in 0.01M NaOH (R2= 0.99996 from 0.01 to 2.0 abs).
11. At the end of each experiment, the MSLI was disassembled and its components were
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washed with tap water, rinsed with distilled water and dried in an oven at 60 ◦C. The
same procedure was followed for the rest of the laboratory glass material used. Silicon
components were dried outside the oven.
A minimum of six repetitions of each test were performed, in order to reduce protocol errors and
achieve low uncertainty.
All pMDI’s were stored, horizontally, in a cool and dry closet protected from light. The sequence of
steps for this procedure was implemented in Java programing language, in the form of a mobile
app for Android Operating System (OS), which allowed an easy interface and helped the operator
to follow the protocol closely without the possibility of any counting errors.
The determination of retained mass allowed an extensive analysis of the distribution of mass
deposition for each VHC device, as well as, the drug emitted by each device and its aerodynamic
characteristics. Values of the total mass collected in each test were also determined and used to
evaluate the accuracy of the test. Only tests with total mass recovery (i.e. sum of mass from all
zones) between 85% and 125% of the label claim were considered as valid [CZR08].
Experiments were conducted at an average temperature of 22.2 ± 0.3 ◦C and at an average
relative humidity of 38 ± 1%, measured with a weather station (W.155 Weather station from Ventus,
Denmark).
The assessment procedure at a variable flow rate, using a breath profile (see section 4.3.1), is
described below:
1. Once the experimental setup parts were all connected, the vacuum system was turned on
and the flow rate was set to 60 L/min at the USP throat entrance. The flow rate value was
marked in the rotameter (D10A11 from ABB, Switzerland) placed between the MSLI and
the vacuum system.
2. The compressed air source was open and, using the mass flowmeter (Model 4043 from
TSI, USA), the flow rate was set to 60 L/min by adjusting the flow regulator (FCA88 from
Brooks, USA).
3. The silicon universal adapter was fitted in the USP throat entrance and connected to the
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assessed device (e.g. VHC + pMDI or pMDI solo).
4. By initialising the breath simulator the system was operated with the necessary waveform
that was reproduced at the USP throat entrance. In some devices this could be verified by
observing the valve’s movement.
5. The pMDI canister was shaken during 8 seconds (i.e. duration of a full breath cycle) and
fired twice to waste from the pMDI original actuator.
6. Subsequently, the canister was placed in the service actuator, previously attached to the
VHC (or directly attached to the universal throat adapter).
7. A total of 40 puffs were made (20 puffs for the case where the pMDI was tested alone),
by firing once per cycle at the beginning of the inhalation, while shaking the canister for 8
seconds between each puff.
8. Once the firing step was completed, the assessed device was disconnected from the
universal throat adapter, the breath machine turned off, then the compressed air source
shut followed by the vacuum system. The connection between the mixer and the breath
machine was ceased, as well as, the vacuum system with the MSLI.
9. The pMDI canister was removed from the service actuator and stored in its original package.
10. Every stage of the experimental setup was washed with 0.01M NaOH solution [Fin98] and
the liquid collected into volumetric flasks: primarily, the pMDI actuator into a 25 mL flask,
then the VHC device into a 100 mL flask, the USP throat to a 50 mL flask, the Mixer to a
50 mL flask, each MSLI stages to a 20 mL flask, and finally, the filter to 50 mL flask. To
improve the drug solubility and its release from the filter, this was previously placed into an
ultrasonic shaker for 5 minutes.
11. Followed by steps 9 through 11 such as with constant flow rate procedure.
5.2 UV-Vis Spectrophotometry Analysis
Spectrophotometry is the interaction between light (i.e. electromagnetic radiation) and matter. A
photon is composed by both an electric (E) and a magnetic fields (M), oscillating perpendicularly to
each other. Wavelength (λ) is a characteristic of these fields, and it quantifies the distance between
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two wave peaks (measured in an adequate unit). The electromagnetic spectrum is composed by a
set of wavelengths ranging from radio (large wavelengths with low energy) to gamma ray waves
(small wavelengths with high energy).
There are several types of analytical spectroscopy: absorption, fluorescence, emission and reflec-
tion. The focus is on the absorption spectroscopy that quantifies the amount of electromagnetic
radiation absorbed by the matter, more specifically that within the UV wavelength range (185 - 400
nm).
At room temperature, the molecules of a certain substance are at the lowest energy levels (E0)
but when those molecules absorb UV light from electromagnetic radiation wave, the outmost pair
of electrons is raised to a higher energy level state (En). The difference between these energy
states is known as electronic transition (δE) [PLK01].
As a solution is crossed by a monochromatic radiation, the decrease in the incident radiation
intensity is directly proportional to the thickness of the illuminated solution (i.e. Lambert’s law).
This means that each solution layer (with equal thickness) absorbs the same amount of energy.
Beer’s law states that the energy absorbed by a solution with fixed thickness, is proportionally
related to its concentration [PLK01].
Beer-Lambert law is the main mathematical principle of absorption spectroscopy and it is described
by Equation 5.1:
A = ε · C · l (5.1)
Considering:
A – absorbance [−]
ε – molar absorptivity [dm3 ·mol−1 · cm−1]
C – concentration of substance [mol · dm−3]
l – thickness of solution [cm]
Each chemical structure of a substance has a specific absorbance spectrum, due to the distinct
bonds present in the structure. In a solution form, the drug structure is dissolved in a solvent,
which contributes to a modification of the drug structure that causes a shift in the absorbance
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peak shift. There are four main types of peak shifts: bathochromic, hypsochromic, hyperchromic
and hypochromic (see Figure 5.1) [PLK01].
Bathochromic shift (also known as red shift) is a movement of the absorbance spectrum from
short to longer wavelength, caused by the addition of a change of the solvent with an auxochrome
group (i.e. –OH, -OCH3).
Hypsochromic shift (also known as blue shift) is a movement of the absorbance spectrum from
long to shorter wavelength, caused by the addition of a change of the solvent with an acidic
medium.
Hyperchromic shift is characterised by an increase in the absorption intensity (ε), due to an
introduction of the auxochrome compound in the drug structure.
Hypochromic shift is characterised by a reduction in the absorption intensity (ε), due to a removal
of the auxochrome compound from the drug structure.
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Figure 5.1: Representation of the possible absorbance peak shifts
The drug salbutamol sulphate concentration is quantified by absorption spectroscopy. The Eu-
ropean Pharmacopeia describes a procedure to analyse this substance under absorption spec-
troscopy, which consists in a preparation of an acid solution (i.e. HCl) that will have an optimum
peak at 276 nm.
Because such solvents are not easy to obtain and handle, an alternative procedure, given in
literature, was explored. Firstly, distilled water was used as solvent which lead to fluctuations on
solution pH and peak shifts. A solution of 0.01M NaOH (Eka Pellets from AkzoNobel, Sweden) was
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prepared, accordingly to literature [FZ98, Fin98], and its pH value was controlled by measurements
(micropH 2000 from Crison, Spain) for each 6 L batches (showing 11.29 ± 0.05). It shows a
maximum absorbance peak at 244 nm, and the results (see Figure 5.2) show bathochromic and
hyperchromic shifts.
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Figure 5.2: Absorbance spectrum comparison of salbutamol sulphate dissolved in distilled water
and in 0.01M NaOH solution
The measurements were carried out in a UV-Vis spectrophotometer (UV-2401PC from Shimadzu
Corporation®, Japan) with double beam in space, which allows the direct comparison between a
reference cuvette and a sample cuvette (see Figure 5.3).
The radiation is originated from two possible sources (λ = 160 – 375 nm): a halogen lamp and a
deuterium lamp. The mirror rotation or lamp mount allows the selection of the lamp source that
goes into the monochromator. The latter is composed by an entrance slit, a collimating lens, a
diffraction grating (which causes the dispersion of the light in a discretized spectrum), a focusing
lens and an exit slit. Whereas, by adjustment of the lens position, only the desired wavelength
pass through the exit slit. The monochromatic beam passes through a beam splitter that divides
it into two identical beams. Each one crosses a cuvette measurement slot (whereas a sample
is positioned). Afterwards, both beams are steered to a photomultiplier detector, for differential
comparison of light intensity between the reference and sample. The resulting data is processed
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Figure 5.3: Simplified schematic of the UV-Vis spectrophotometer optical system
by computer software that provides the absorbance values, also allowing a spectrum range scan
of the sample substance [Shi97].
The cuvette (or sample cell) for the UV analysis, needs to be transparent to the wavelength range
of analysis, being quartz, the material of choice. A pair of cuvettes with calibrated path length is
important for a precise analysis, and its selection should be made accordingly to the amount of
sample available and to the equipment slot size. Cuvettes with longer path length are used for
increasing the measured absorbance (accordingly to Equation 5.1).
5.2.1 Measurement Protocol
The measurement protocol is composed by various steps that were defined by combining several
tests for a stable measurement methodology, and the equipment operating manual:
1. Turn on the UV-Vis equipment and the computer for data acquisition
2. Wait during 15 min for the equipment lamp to heat up and stabilizes
3. Setup the measurement software to the desired method and wavelength interval of scanning
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(i.e. 220 nm to 270 nm)
4. Put on latex gloves
5. Rinse twice both cuvettes (10 mm quartz vol. = 3.5 mL from Zuzi) with 0.01M NaOH
solution
6. Fill both cuvettes with 0.01M NaOH solution and place them into the sample and the
reference equipment slots
7. Execute a measurement for a reference baseline
8. Remove the sample cuvette and drain it to waste
9. Shake the measurement solution flask for a 1 minute period to improve homogenisation of
the solution.
10. Pour a sample into the cuvette and empty it to waste. Now pour again into the cuvette,
clean any droplets in the cuvette surfaces with laboratory soft paper, and place it into the
equipment measurement sample slot.
11. Take a measurement and save data through the data acquisition software
12. Repeat twice steps 8 through 11
13. Empty the cuvette
14. Rinse with 0.01M NaOH solution and empty it three times
15. Repeat the steps 8 through 14 for all unknown solutions
16. Turn off the equipment
The data were exported to .txt format files and the obtained curves were processed using a Python
code script. Each measurement curve was read and the averaged (of the three measurements)
absorbance value at 244 nm was calculated along with its corresponding error (halve of the
amplitude). The calibration curve parameters provided the means to obtain the corresponding
concentrations. Each solution concentration was then multiplied by the flask volume and the mass
was calculated.
These new data were saved to a file, whereas the setup stage name was included as well as its
salbutamol mass, number of puffs executed, total mass expected and total mass collected.
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5.2.2 Calibration Curve
A calibration curve is necessary for the calculation of the salbutamol sulphate drug concentration
in each solution was assessed UV-Vis absorption spectrophotometry. Since this assessment
method provides us with an absorption value at a certain light wavelength for a given unknown
concentration solution, it was necessary to get a calibration curve that relates the concentration
with the absorbance. To create such calibration curve, it was firstly necessary to create a stock
concentration solution that gave origin to several diluted solutions of smaller concentration. This
stock concentration solution was created by dissolving 99 mg of salbutamol sulphate into 1000
mL of 0.01M NaOH, giving origin to a concentration of 0.099 mg/mL. This solution was then
diluted into 13 smaller concentration solutions with concentrations that allowed the points to be
equally spaced over the range of interest. The measurement of the solutions was repeated three
times and the values of absorbance are shown in Figure 5.4. It shows the absorbance curve, for
each solution, along a span of light wavelength. The experimental uncertainty is represented as
error bars for each measurement point that compose each solution curve. It can be seen that no
error is found within the measured curves, which point to a well-executed measurement technique.
The wavelength value of 244 nm was selected; therefore those values will be used to create
the calibration curve, shown in Figure 5.5, along with the linear fitting parameters which were
calculated by least-squares method. The goodness of fit value is very high (i.e. R2 = 0.9999),
which indicates that a fair amount of linearity is found between the 0.009 and 1.844 of absorbance.
Hence, it is valid to use this curve for unknown concentration solutions with absorbance values
within this interval. This linear assumption allowed the calculation of the curve characteristics (i.e.
A - slop and B – y-intercept), that will be used in the determination of the concentration form an
absorbance measurement of unknown solutions from the setup stages.
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P11 - 0.032175 mg/mL
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Figure 5.4: Absorbance values obtained for the calibration curve solutions, including the experi-
mental uncertainty represented as error bars
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Figure 5.5: Calibration curve used for concentration determination from known absorbance
values at 244 nm of light wavelength for salbutamol sulphate in 0.01M NaOH solution. Linear fit
parameters are represented, along with the goodness of fit value
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5.3 Data analysis
Data analyses were performed using Excel® (Office 2010 from Microsoft, USA). The mass collected
in each solution was divided by the numbers of injected puffs. The following subsections explain
in detail the procedures for data treatment and mathematical operations used for data treatment
and presentation in the results section.
5.3.1 Uncertainty Analysis
Whenever the word ”error” is employed, it actually means uncertainty. These errors are not
mistakes and cannot be eliminated by being very careful during the measurement procedure.
The uncertainty is inevitable in all process of data gathering and sometimes are found to be
random or systematic (even both). The best that can be done is to estimate the uncertainty of our
measurements to the best of our knowledge. For that, several rules can be applied, most of them
are fairly well described in various literature sources. In the case of estimating the uncertainty of
experimental measurements John R. Taylor [Tay97] provides very good and intuitive guidelines on
how to deal with this matter.
By repeating the measurements, the uncertainty caused by random errors can be discovered; those
that cannot are known as systematic errors. Systematic errors are hard to find, and sometimes
expensive to eliminate. Usually they are originated in the usage of equipment with bad calibration
(e.g. the case of a ruler that suffered a stretching deformation). That can only be verified by
changing the equipment with a new/improved one. Also systematic operator wrong measurement
procedure can be a cause of a systematic error (e.g. parallax error by always looking on the same
wrong side of the equipment scale). Random errors can be caused by sudden power break that
leads to a failure in data gathering, mechanical vibrations, badly positioned equipment that caused
an unexpected flow leakage, parallax error that randomly overestimates and underestimated the
manometer needle. These errors can easily be spotted by repeating the measurement several
times, which eventually will cause them to be cancelled.
The most famous schematic example to describe the comparison between random and systematic
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errors is the target practice board described in Figure 5.6. Whereas the shooting board centre
stands for the true value, a shooter aim can be within four scenarios:
• (a) high precision (with small systematic error) and high accuracy (with small random error);
• (b) low precision (with large systematic error) and high accuracy (with small random error);
• (c) high precision (with small systematic error) and low accuracy (with large random error);
• (d) low precision (with large systematic error) and low accuracy (with large random error).
(a) (b) (c) (d)
Figure 5.6: Comparison between the random and systematic errors, using the example of target
practicing
In the experimental activity, measurements are only performed because the true value of a quantity
is unknown. Therefore if Figure 5.6 is visualized without the board, there is no way to be aware of
the existence of systematic errors neither their size.
The correct notification for presenting a measured value is given by the best estimate followed by
the uncertainty (δx) (see Equation 5.2).
x = xbest ± δx (5.2)
The calculation of the uncertainty, in a single measurement, is usually defined by halving the
difference between the two closest numbers (bellow and above) that can be evaluated with some
degree of certainty. This means that the value is found between xbest + δx and xbest − δx.
The calculation of the uncertainty from various measurements is calculated by the Standard
Deviation Of the Mean (SDOM), described in Equation 5.3.
σx¯ =
σx√
N
(5.3)
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Whereas the N stands for size of the sample and the σx for the sample standard deviation (see
Equation 5.4). The sample standard deviation is preferable in comparison to the population
standard deviation, since it is more accurate for small values of N .
σx =
√
1
N − 1
∑
(xi − x¯)2 (5.4)
considering the i as the ith measurement in the sample. The standard deviation provides us with
68% confidence that any measurement will fall within xbest + σx and xbest − σx.
Accordingly to the American Society of Mechanical Engineers (ASME) guidelines for test uncertainty
in instruments and apparatus [ASM98], it is advisable that the results are presented with a
uncertainty for a 95% confidence interval. Therefore, an expanded uncertainty should be calculated
through the multiplication of the SDOM by a expansion factor (B) (see Equation 5.5). This factor
is obtained by means of a t-student distribution for 95% and using the Degrees Of Freedom (DOF)
(i.e. DOF = N − 1).
δx = σx¯ ·B (5.5)
B - expansion coefficient
Concluding, the presented experimental data uncertainty was calculated by following two simple
rules, accordingly to the size of N :
• 2 6 N < 5 : δx = (maxx −minx)/2;
• N ≥ 5 : δx = σx¯ ·B.
Whenever it is necessary to combine two or more (x, ..., z) measurable variables (each with its
own uncertainty δx, ..., δz) in an equation (q), an general formula (see Equation 5.6) can be
applied to calculate the propagation of the uncertainty (δq).
δq =
√(
∂q
∂x
δx
)2
+ · · ·+
(
∂q
∂z
δz
)2
(5.6)
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5.3.2 Statistical Significance Analysis
Data were composed by two types of variables: nominal and measurement. Nominal variables are
such as Valve Design Type or Name of the Device. Measurement variables are all the other used,
from throat deposition to the performance metrics.
Statistical analysis (SPSS v21.0 from IBM, USA) is performed upon the reported data whenever is
needed for a comparison between two or more experimental data sets. The test of choice was the
one-way Analysis Of Variance (ANOVA). This statistical test is adequate with one nominal variable
and one measurement variable. Its null hypothesis states that the means of the measurement
variable are the same for all the different data sets. As example: is the mean throat deposition the
same for all VHC devices tested? One-way ANOVA will evaluate the null hypothesis and consider it
false if the P value is lower than 0.05.
This test is based in some assumptions:
• Data within each group are normally distributed
– The number of observations made is not big enough for this criterion to be met with
certainty. Although it has been reported that the one-way ANOVA is not very sensible
to deviations from the normality distributions [McD14].
• The data are homoscedastic (i.e. have similar standard deviation in the data sets)
– One-way ANOVA is not very sensitive to heteroscedasticity, unless the size of the data
sets is very different from each other. Given that the data sets have N < 10 and that
some of them have large standard deviations, the Welch’s ANOVA test was applied to
these cases distributions [McD14].
5.3.3 Devices Performance Analysis
The analysis of the experimental data was carried out in terms of indices that compare the efficiency
of the VHC in comparison to the use of pMDI solo. The procedure for the calculation of such
indices is presented below. The formulae described originates in the US Pharmacopeial Forum
as a stimulus for the USP revision: <1602> Spacers and valved holding chambers used with
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inhalation aerosols (USP38-NF33) [US 14].
The TEM by the device, is the sum of the drug mass present in all zones of the setup downstream
the device under testing. This includes the throat and all the stages of the impactor.
The FPM is the amount of mass present in the stages of the impactor with cut-off point below µm.
In the case that no stage cut-off point coincides with the 5 µm value, it is necessary to proceed
with the construction of the cumulative mass-weighted Aerodynamic Particle Size Distribution
(APSD) and interpolate it from there. That was the case for the impactor used in this study.
The Coarse Particle Mass (CPM) is calculated as the difference between the TEM and the FPM.
This assumes that the mass in the throat is all composed by coarse particles. Although it is not a
fully correct assumption, it is considered as acceptable.
The Extra-Fine Particle Mass (EFPM) is calculated as the mass of particles bellow 1 µm of diameter.
The procedure for the calculation was similar to the one used for the FPM calculation.
The Coarse Particle Fraction (CPF) is calculated in percentage according to Equation 5.7.
CPF =
[
CPM
TEM
]
× 100 (5.7)
Equation 5.8 presents the calculation of the Fine Particle Fraction (FPF) in percentage.
FPF =
[
FPM
TEM
]
× 100 (5.8)
The Extra-Fine Particle Fraction (EFPF) is given by Equation 5.9:
EFPF =
[
EFPM
TEM
]
× 100 (5.9)
The guidelines state that a properly functioning VHC shall have its FPF value above 60%, and CPF
below 40%. The EFPF is strongly related to the drug formulation APSD, however its value can vary
from < 20% to 50% FPF.
Three indices are used to evaluate the use of a VHC when compared to a pMDI solo. These ratios
compare the coarse mass (Rc), fine mass (Rf) and extra-fine mass (Re), and they are presented
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from Equation 5.10 to 5.12.
Rc =
CPMV HC
CPMMDI
(5.10)
Rf =
FPMV HC
FPMMDI
(5.11)
Re =
EPMV HC
EPMMDI
(5.12)
A properly functioning VHC shall operate within an Rc ≤ 0.6 and with both Rf and Re close to 1.0.
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6 Experimental Results
In this chapter, the obtained experimental results from the pMDI solo or attached to a VHC device
are presented and discussed. The tests were executed using a Full Dose setup and a Cascade
Impactor (i.e. MSLI) setup. The influence of air flow rate in the devices performance was assessed
at 30 L/min, 60 L/min and using a Breath Profile. The raw data is given by Tables B.1 to
B.5. Several performance metrics were used to make different conclusions about the device’s
performance and their relationship with the geometric features.
6.1 Full Dose Results
6.1.1 Constant Flow Rate (30 L/min)
Full Dose mass collection results at constant flow rate of 30 L/min are depicted in Figure 6.1,
along with the 95% confidence uncertainty represented in form of error bars. Mass was captured in
a MN 1674 paper filter, enclosed in the house-made aluminium filter casing. Detailed information
regarding the experimental setup can be found in section 4.1.1).
The mass deposition on the pMDI actuator appears to have a constant value of approximately 10
µg. Throat (i.e. filter casing) and filter deposition is greatly reduced by the usage of the pMDI
combined with a VHC. Some VHC devices present greater reduction than others: Nebuchamber,
Optichamber and Vortex (devices with the duck type valve) show higher throat deposition. As the
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air flow downstream the VHC valve is greatly dependent on the valve design, a duck type valve
might lead to higher velocities, which causes, instabilities in the flow (such as turbulence), resulting
in higher wall deposition.
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Figure 6.1: Salbutamol deposition mass (normalised for one actuation) in each setup zone for all
tested devices at 30 L/min
6.1.2 Breath Pattern
The full dose emitted by the VHC devices when exposed to a breath pattern (described in sec-
tion 4.3.1) is presented in Figure 6.2. The setup used in fully described in section 4.1.1.
Mass deposition in the pMDI actuator shows a value of approximately 20 µg, which is twice that
observed for a constant air flow of 30 L/min. This is an expected behaviour, since the air flow is
not in steady state, a higher amount of mass sediments on it. Throat (i.e. filter casing) and filter is
lower under a breath pattern than at constant flow rate. However, a higher throat deposition can
be found for duck type valved devices, which suggests that this effect is independent of the flow
rate.
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Figure 6.2: Salbutamol deposition mass (normalised for one actuation) in each setup zone for all
tested devices under a breath pattern
6.2 Cascade Impactor Results
6.2.1 Constant Flow Rate (30 L/min)
Results for the mass deposition using a constant flow setup (described in section 4.1.2) at 30
L/min are shown in Figure 6.3.
Actuator deposition is approximately 10 µg for all tested devices, with no statistical differences
between the devices (p>0.05). Analysing the TEM it is obvious that the pMDI solo emits a higher
amount of mass than the other devices (p<0.0001). However no statistical significant differences
were found between the VHC devices (p>0.05).
The usage of a VHC greatly reduces the mass deposition in the throat (i.e. induction port), which
is one of the main objectives of the VHC device. Some VHC devices are better at this function
than others (p<0.0001), as shown in Figure 6.4, where the percentage reduction of mass throat
deposition in comparison to pMDI solo usage is presented.
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Figure 6.3: Salbutamol deposition mass (normalised for one actuation) in each setup zone for all
tested devices at 30 L/min using the MSLI. Error bars indicates the limits of the uncertainty within
a 95% confidence interval
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Figure 6.4: Percentage reduction in mass throat deposition in comparison with the pMDI solo at
30 L/min. Error bars indicates the limits of the uncertainty within a 95% confidence interval
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Deposition of salbutamol in the throat is reduced between 95% and 82% when the pMDI is used
coupled to a VHC. The Nebuchamber, Optichamber and Vortex have the lowest reduction (all
devices from Duck valve type group, p>0.05), while the highest reduction is found for Volumatic
(Coin type valve), followed by the Leaflets valve type devices (p>0.05) and the Aerochamber
(Annulus Flap valve type). The results suggest that throat deposition is highly related to the valve
type, whereas statistical significant differences were found between all valve type groups (p<0.05).
Using the MSLI 4 last stages (i.e. 2nd to 5th stage), the sum of these masses corresponds
to the Sizable Mass (SM) in the impactor. Cumulative fractions were then calculated by incremen-
tally add the mass in the stages (starting on the 5th) and dividing it by the SM. The cumulative
mass fraction chart is created by plotting these fractions against the cut-off particle aerodynamic
diameters of each corresponding stage (see Figure 6.5). The procedure for creating such graph is
fully described in Pharmacopeia and referenced in section 5.3.3.
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Figure 6.5: Cumulative mass fraction versus the aerodynamic particle diameter for tested devices
at 30 L/min. Error bars indicates the limits of the uncertainty within a 95% confidence interval
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Figure 6.5 allows to conclude that, for pMDI emitted plume, approximately 50% of the SM is
composed by particles with aerodynamic diameter below 2.4 µm. As shown in Figure 6.5, the
usage of any VHC coupled to the pMDI increases the fraction of particles lower than 2.4 µm
available to the patient. These values were normalised for each device SM emitted.
The fine particles (i.e. 4.7 µm) mass fraction was interpolated from those curves and then
multiplied by the corresponding SM value, giving the FPM emitted. The results are depicted in
Figure 6.6.
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Figure 6.6: Emitted FPM at 30 L/min for the devices various. Error bars indicate the experimental
uncertainty for 95% confidence intervals
It is evident that using a VHC coupled to the pMDI is an advantage to the patient inhalation
treatment, because it provides an increase of the FPM in comparison to the use of pMDI solo,
except for Optichamber and A2A. The FPM emitted from the VHC devices shows no statistically
significant differences (p>0.05) when compared to the pMDI solo. There is not statistical evidence
that valve type is related to the emitted FPM at 30 L/min (p>0.05).
The values of the MMAD can be determined by interpolation of the cumulative fraction curves. It
represents the aerodynamic diameter at which 50% of the SM is found. Results for the calculated
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MMAD are given in Figure 6.7.
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Figure 6.7: Emitted plume MMAD at 30 L/min for the tested devices. Error bars indicate the
experimental uncertainty for 95% confidence intervals
The results show a slightly reduction of the plume aerodynamic size when using a VHC in compari-
son to the pMDI solo. This observation suggests that the VHC design is capable of reducing the
plume coarse fraction. However this impactor apparatus (i.e. MSLI), being constituted by 5 stages,
does not allow a very accurate assessment of this metric, whereas the interpolation was calculated
between an experimental and an assumed value (i.e. of zero for particles lower than 0.1 µm).
The MMAD emitted from the pMDI solo is statistically different from the A2A Spacer (p<0.05) and
from the Nebuchamber (p<0.01), while no statistical differences were found between the other
devices (p>0.05).
FPF is the ratio of FPM in relation to the TEM for each device and the same procedure is done for
the EFPF by using the ratio of EFPM. Those metrics allow to evaluate the amount of fine particles
in the emitted plume mass (the guidelines advise its value (for VHC’s) to be above 60%). EFPF is
related to the drug formulation itself and its value shall be between 20% FPF and 50% FPF. The
results for CPF are not depicted in Figure 6.8, because this metric is complementary to the FPF.
The FPF and EFPF metrics are above 60% for all VHC with the exception for the Optichamber. The
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highest FPF value is found for the Volumatic (69.9%) and the lowest for the Optichamber (51.5%).
EFPF metrics are between 27% and 30% of its corresponding FPF value. pMDI solo shows a FPF
value of approximately 27%, hence the pMDI solo has lower fraction of fine particles in its emitted
plume than pMDI coupled with VHC (p<0.0001). This indicates that VHC emitted plume has a
lower amount of coarse particles than it has of fine particles. Therefore the VHC accomplish well
its objective in reducing the coarse fraction. Devices within the Leaflets valve type group show
no statistically significant differences (p>0.05). However, the Optichamber FPF is distinct from
the other VHC devices (p<0.05). There is no statistical evidence suggesting that the valve type is
correlated with the FPF (p>0.05). Figure 6.8 depicts the FPF and EFPF.
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Figure 6.8: FPF and EFPF metrics of the emitted plume for each tested device at 30 L/min. Error
bars indicate the experimental uncertainty for 95% confidence intervals
Given the CPM, calculated by section 5.3.3, Rc can be assessed of how much CPM reduction is
due to the VHC use instead of pMDI solo. Results are depicted in Figure 6.9.
The guideline reference value for Rc should be lower than 0.3, which is observable for all tested
VHC devices. These results assures that all the tested devices are in agreement with the guidelines,
and they are able to reduce the coarse fraction by more than 70% in comparison with the solo
pMDI usage. The Volumatic has the best capacity to reduce the CPM of the emitted plume, which
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might be related to the large inner surface area when compared to the other devices. Also the Coin
type valve, in Volumatic, contributes to the high reduction of coarse particles by acting as a bluff
body for the air and particles stream flow. The Optichamber is the VHC with the lowest capacity to
reduce the coarse fraction of the plume, along with the Vortex and Nebuchamber (all three devices
have the Duck type valve, p>0.05). No statistically significant differences were found between the
Leaflets valve type devices regarding the Rc metric (p>0.05). The results suggest that valve type
design greatly affects the coarse particle reduction, which can be ranked as: Coin > Leaflets >
Annulus Flap > Duck. The Duck type valve devices have significant differences (p<0.0001), in
comparison to the other valve groups (p>0.05).
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Figure 6.9: Coarse fraction reduction metric (Rc) results at 30 L/min for the tested devices. Error
bars indicate the experimental uncertainty for 95% confidence intervals
The increase of FPM and EFPM in comparison to the pMDI solo is assessed through Rf and Re
metrics, correspondingly. Results are shown in Figure 6.10.
The guidelines recommend that Rf and Re should be approximately 1.0, which means that using
the VHC do not greatly affect the amount of FPM and EFPM available to the patient in comparison
to the pMDI plume. The main reason for this guideline is that a VHC device coupled to a pMDI has
to be bioequivalence to the pMDI solo. Meaning that if the VHC greatly increases the amount of
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FPM to the patient, different therapeutic dosage will be delivered which can cause adverse effects
[SM14]. This would require that the VHC plus pMDI and formulation to go under reassessment
and recertification to be put again in the market. However, VHC act as a add-on device for the
commercial pMDI’s, has a simpler certification process. Results of Rf and Re are found to be
between 0.8 and 1.3. All VHC devices have a similar output (p>0.05); however the Volumatic has
the highest values and the Optichamber the lowest, whose comparison is statistically meaningful
(p<0.05). All VHC devices increase (from 4% to 29%) the FPM in comparison to the pMDI solo,
except for the Optichamber that reduces its value in 20% and the A2A Spacer that does not provide
any change.
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Figure 6.10: Results for the fine fraction increase metric (Rf) extra-fine fraction increase metric
(Re) results at 30 L/min for the tested devices. Error bars indicate the experimental uncertainty
for 95% confidence intervals
Figure 6.11 shows a comparison between the FPM emitted in each SM recovered. The dashed
line represents the maximum theoretical values possible for the FPM in a certain amount of
SM, logically it is impossible to the FPM be higher than the SM. All devices follow a linear trend
(represented by a solid line), meaning that for a greater emitted SM, a higher amount of FPM
is present. This is a logical conclusion since the FPM is obtained from the multiplication of the
Fine Particle Dose (FPD) by the SM. Therefore, the trendline slope corresponds to the FPD for the
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VHCs (i.e. ≈0.80). The pMDI solo shows similar results when compared to the VHCs. Figure 6.12
shows a comparison between the emitted FPM in each TEM recovered.
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Figure 6.11: FPM versus the SM emitted by each device tested at 30 L/min. Error bars indicates
the limits of the uncertainty within a 95% confidence interval
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Figure 6.12: FPM versus the TEM emitted by each device tested at 30 L/min. Error bars indicates
the limits of the uncertainty within a 95% confidence interval
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Results show a comparison of the emitted FPM and the TEM for each device. As expected, pMDI
solo has higher TEM than using a VHC. The linear trendlines for both types of devices are shown
in black lines. The slope of these lines is, for all purposes, the ratio between the FPM and the
TEM which is the correspondent to the FPF metric. This metric can never be higher than 1.0
(corresponding to a 45◦ slope), hence the dashed line. Although the VHC entrap a high amount
of mass, the fraction of FPM of the emitted plume is higher than when the pMDI solo is used,
proving the capacity of the VHC devices to entrap mostly the coarse particles of the pMDI plume.
6.2.2 Constant Flow Rate (60 L/min)
Results for the mass deposition using a constant flow setup (described in section 4.1.2) at 60
L/min are shown in Figure 6.13.
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Figure 6.13: Salbutamol deposition mass (normalised for one actuation) in each setup zone for all
tested devices at 60 L/min using the MSLI. Error bars indicates the limits of the uncertainty within
a 95% confidence interval
It can be seen that the pMDI actuator deposition is approximately 10 µg, approximately constant
for all tested devices (p>0.05), which is also observed with tests at 30 L/min. Analysing the TEM
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it is obvious that the pMDI solo emits a higher amount of mass than the other devices (p<0.0001)
also, there is statistically significant differences between the VHC’s (p<0.0001). The throat mass
deposition is greatly reduced by coupling a VHC device to the pMDI.
Figure 6.14 provides information regarding the percentage reduction of mass deposition in the
throat in comparison to pMDI solo usage.
VOL A2A CSC SC AC V OCD NC
0
20
40
60
80
100
Th
ro
at
 R
ed
uc
tio
n 
[%
]
93
89 88 88 84
72 72
64
Figure 6.14: Percentage reduction in mass throat deposition in comparison with the pMDI solo at
60 L/min. Error bars indicates the limits of the uncertainty within a 95% confidence interval
Deposition of salbutamol in the throat is reduced between 94% and 65% when the pMDI is used
coupled to a VHC, being distinct between them (p<0.0001). The Nebuchamber, Optichamber
and Vortex have the lowest reduction (all with valve type Duck), whereas the Nebuchamber is
statistically distinct from the other two (p<0.0001). While the highest reduction is found for the
Volumatic (coin valve type), followed by the A2A Spacer and the Compact Space Chamber and
Space Chamber (devices from the Leaflets valve type group, p>0.05). The results suggest that
throat mass deposition is strongly related to the VHC valve type, ranked as: Coin < Leaflets <
Annulus Flap < Duck. Statistical analysis show that the throat reduction for each valve type group
is distinct from the others (p<0.0001).
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Figure 6.15 depicts the cumulative mass curves for all tested devices. It shows that 50% of the SM
is composed by particles with aerodynamic diameter smaller than 3.0 µm.
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Figure 6.15: Cumulative mass fraction versus the aerodynamic particle diameter for tested devices
at 60 L/min. Error bars indicates the limits of the uncertainty within a 95% confidence interval
The FPM results are depicted in Figure 6.16, and it is shown that all VHC’s provide higher amount
of fine particles to the patient lungs, except the A2A Spacer. The Aerochamber, Vortex and Space
Chamber are the devices that emit the highest amount of FPM, while the A2A Spacer, Optichamber,
and Nebuchamber emit the lowest value. The FPM emitted from all devices has statistically
significant differences (p<0.0001) and the same is verified among the VHC’s (p<0.0001). Similarity
is found between the FPM emitted by the pMDI solo and these VHCs: A2A Spacer, Optichamber,
Nebuchamber and Compact Space Chamber (p>0.05). Statistical analysis show that devices from
Leaflets and Annulus Flap groups are distinct (p<0.05), however no significant differences were
found (p>0.05) between the other valve type groups. Therefore, based on the observations drawn
from the statistical analysis, a relationship can be found between the valve type and the FPM
emitted by the VHC.
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Figure 6.16: Emitted FPM at 60 L/min for the tested devices. Error bars indicate the experimental
uncertainty for 95% confidence intervals
Figure 6.17 shows the calculated values for the MMAD, from the mass fraction cumulative curves
depicted in Figure 6.15. As expected, the highest MMAD value can be found for the pMDI solo
and the lowest one is obtained for the Nebuchamber. Nevertheless, the MMAD values for all VHC
devices are very similar and lower than the pMDI solo. Therefore, it can be concluded that the
commercial VHC devices (p>0.05) are able the actively reduce the coarse fraction in the emitted
plume in comparison to the pMDI solo (p<0.001). The MMAD results, for the pMDI solo, has
no statistically significant differences when compared with the Vortex, Space Chamber, Compact
Space Chamber, Aerochamber and Optichamber (p>0.05).
The FPF and EFPF are depicted in the Figure 6.18. The calculated FPF values for the VHC’s are
above 60%, as advised in the guidelines, except for the Vortex, Nebuchamber and Optichamber
devices (all with Duck type valve, p<0.05). The highest FPF value is found for the Volumatic and
the lowest for the Optichamber (p<0.0001). Contrarily to the pMDI solo (p<0.0001), the VHC
FPF indicates that the emitted plume mostly made up by fine particles. Devices with Annulus
Flap valve type and Leaflets show no statistically significant differences (p>0.05) in terms of FPF
results. The EFPF values are between 28% and 30% of the corresponding FPF value, which are
within the guidelines reference values. Similarly with the results at 30 L/min, this parameter is
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highly dependent on the formulation and not in the device.
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Figure 6.17: Emitted plume MMAD at 60 L/min for the tested devices. Error bars indicate the
experimental uncertainty for 95% confidence intervals
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Figure 6.18: FPF and EFPF metrics of the emitted plume for each tested device at 60 L/min. Error
bars indicate the experimental uncertainty for 95% confidence intervals
The Rc metric results, representing the ratio of CPM between the pMDI coupled to the VHC
and the pMDI solo, are depicted in Figure 6.19. The Rc is statistically different for the tested
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VHC’s (p<0.0001). Results are highest for the Duck type valve devices (i.e. Optichamber, Vortex,
Nebuchamber, p<0.001) and lowest for the Coin type valve (i.e. Volumatic). The results seem to
be related to the valve type, ranked as: Coin < Leaflets < Annulus Flap < Duck. In fact, there is
statistical significant differences between all valve groups (p<0.001), and even within the Leaflets
(p<0.01) and Duck (p<0.001) groups differences were verified.
The Aerochamber, Nebuchamber, Vortex and Optichamber are slightly above the reference value
of 0.3, the rest of the VHC’s are within the guideline. Results point out that Volumatic has the
capacity to reduce 80% of the coarse fraction emitted by the pMDI.
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Figure 6.19: Coarse fraction reduction metric (Rc) results at 60 L/min for the tested devices. Error
bars indicate the experimental uncertainty for 95% confidence intervals
The results for both the Rf and the Re metrics, are shown in Figure 6.20. It can be seen that Rf and
Re are between 0.97 and 1.32, in agreement with the guideline reference. The Aerochamber has
the highest Rf (increasing the delivered FPM in 32%), and the A2A Spacer has the lowest (reducing
the emitted FPM in 3%). All VHC Rf values are distinct (p<0.0001), however the Aerochamber,
Vortex, Volumatic, Space Chamber, Compact Space Chamber show no statistically significant
differences (p>0.05). The Re values range between 1.00 and 1.26, however this metric is based in
the EFPM which, due to the resolution of the impactor, is not estimated with the required accuracy.
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Figure 6.20: Results for the fine fraction increase metric (Rf) extra-fine fraction increase metric
(Re) results at 60 L/min for the tested devices. Error bars indicate the experimental uncertainty
for 95% confidence intervals
Figure 6.21 shows a comparison between the FPM emitted in each SM recovered, at 60 L/min for
all the tested devices (categorised in two groups: VHC and pMDI). The dashed line delimits the
upper zone, whereas no possible combinations of FPM versus SM exist (FPM cannot be higher than
SM). A black line illustrates the linear trend of the VHC results, which has slope of approximately
0.8 (similar result found at 30 L/min). This value is highly related to the FPD metric previously
calculated from Figure 6.15 and the results suggest that the pMDI spray technology has a typical
linear trend of delivered FPM for a certain amount of SM emitted.
Figure 6.22 shows a comparison between the FPM emitted for each TEM recovered. The dashed
line delimits the feasible results, and the two solid lines identify linear trends. These results show
how much of the TEM is composed by FPM, which is highly related to the FPF metric. More
specifically, the trend line slope is correspondent to the averaged FPF of each device type. When
the FPM delivered by the use of VHC and by the pMDI solo are similar, the TEM is quite distinct
(due to the removed coarse fraction performed by the VHC technology). VHC devices located
above the trend line have better performance than the others bellow.
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Figure 6.21: FPM versus the SM emitted by each device tested at 60 L/min. Error bars indicates
the limits of the uncertainty within a 95% confidence interval
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Figure 6.22: FPM versus the TEM emitted by each device tested at 60 L/min. Error bars indicates
the limits of the uncertainty within a 95% confidence interval
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6.2.3 Breath Pattern
Results for the mass deposition using a variable flow setup (described in section 4.1.2) are shown
in Figure 6.23. Herein are reported the results for the pMDI solo and combined with four VHC
devices: Aerochamber, Compact Space Chamber, Vortex and Volumatic. One from each valve
design type group.
Spray injection was executed in the beginning of the inhalation phase. Only four VHC devices
were tested, each one with a different valve type. The actuator mass deposition is ≈17 µg for
the tested devices (p>0.05) and, as observed for other results at constant flow, is related with the
actuator geometry. The drug deposition in the VHC is higher (i.e. ≈72 µg) than at constant air
flow (i.e. ≈26 µg to ≈50 µg, at 30 L/min), which is expected since only a small volume of air
passes through the device (i.e. tidal volume of 150 mL) during the inhalation. The TEM from the
pMDI is statistically different from that emitted from the VHC devices (p<0.0001), however it is
similar among the VHC’s (p>0.05).
The throat deposition is greatly affected by the use of a VHC device when compared with the pMDI
solo; however the reduction of the mass throat deposition depends on the device, as can be seen
in Figure 6.24. Deposition of salbutamol in the throat is reduced between 95% and 88% when
the pMDI is used coupled to a VHC device. The Volumatic has the highest reduction, while the
lowest reduction is found for Vortex. Throat reduction has significant differences between the
VHC’s (p<0.0001), due to the fact that the mass reduction at Volumatic is distinct from that found
in other VHC devices (p>0.05). The results suggest that throat mass deposition is related to the
VHC valve type, ranked as: Coin < Leaflets < Annulus Flap < Duck. Similar observations were
found for the results obtained at 60 L/min flow rate.
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Figure 6.23: Salbutamol deposition mass (normalised for one actuation) in each setup zone for
all tested devices under a breath pattern using the MSLI. Error bars indicates the limits of the
uncertainty within a 95% confidence interval
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Figure 6.24: Percentage reduction in mass throat deposition in comparison with the pMDI solo
under a breath pattern. Error bars indicates the limits of the uncertainty within a 95% confidence
interval
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Figure 6.25 depicts the cumulative mass curves for all tested devices. This graph shows that 50%
of the SM is composed by particles with aerodynamic diameter smaller than 2.0 µm.
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Figure 6.25: Cumulative mass fraction versus the aerodynamic particle diameter for tested devices
under a breath pattern. Error bars indicates the limits of the uncertainty within a 95% confidence
interval
The FPM results shown in Figure 6.26 indicate that, under a breath pattern, the FPM emitted
by the VHC devices is highly reduced. This is not in according to the literature, and might be
explained by the low tidal volume of the breath pattern. pMDI delivers the highest FPM (14%)
and the Vortex emits the lowest (6%). FPM emitted from the pMDI solo is distinct from the VHC’s
(p<0.0001). However, the FPM emitted from the VHC devices have no statistically significant
differences (p>0.05).
Figure 6.27 shows the calculated values for the MMAD, from the mass fraction cumulative curves
depicted in Figure 6.25. The highest value for the MMAD can be found for the pMDI solo, as
expected, although this parameter is very close to all the tested devices (p>0.05).
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Figure 6.26: Emitted FPM under a breath pattern for the tested devices. Error bars indicate the
experimental uncertainty for 95% confidence intervals
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Figure 6.27: Emitted plume MMAD under a breath pattern for the tested devices. Error bars
indicate the experimental uncertainty for 95% confidence intervals
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Figure 6.28 depicts the FPF and EFPF emitted for each tested device under a breath pattern. The
calculated FPF for the VHC’s are above 40%. The Volumatic has the highest (i.e. 59%) FPF value
and the pMDI the lowest (i.e. 19%). FPF from VHC is distinct from the pMDI solo (p<0.0001). The
Volumatic emits a FPF statistically distinct (p<0.0001), to all other VHC’s (p>0.05). A trend is
noticeable among the type of valves and the FPF, ranked as follows: Coin > Leaflets > Annulus
Flap > Duck. EFPF values are between 31% and 33% of the corresponding FPF value, which is
within the guidelines reference.
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Figure 6.28: FPF and EFPF metrics of the emitted plume for each tested device under a breath
pattern. Error bars indicate the experimental uncertainty for 95% confidence intervals
The Rc metric results are shown in Figure 6.29. All results are below 0.3, although the value is
highest for the Compact Space Chamber (i.e. 0.15) and lowest is achieved for the Volumatic (i.e.
0.09). Results point out that the Volumatic has the ability to reduce 91% of the coarse fraction
emitted by the pMDI. The Rc metric show no statistically significant differences among the VHC
devices (p>0.05), whereas the Aerochamber, the Vortex and the Compact Space Chamber show
closer average Rc values (p>0.05).
The results for both the Rf and the Re metrics, are shown in Figure 6.30. It can be seen that Rf
and Re values vary between 0.41 and 0.62, which are outside the guideline reference values. The
calculated Rf values show no statistically significant differences (p>0.05) when comparing the VHC
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devices. The Compact Space Chamber has the highest Rf value (reducing the delivered FPM in
38%), and Vortex has the lowest one (reducing the emitted FPM in 59%). Re values range between
0.42 and 0.61, however this metric is based in the EFPM which, due to the limited number of
stages of the impactor, cannot be estimated with great accuracy.
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Figure 6.29: Coarse fraction reduction metric (Rc) results under a breath pattern for the tested
devices. Error bars indicate the experimental uncertainty for 95% confidence intervals
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Figure 6.30: Results for the fine fraction increase metric (Rf) and extra-fine fraction increase metric
(Re) results under a breath pattern for the tested devices. Error bars indicate the experimental
uncertainty for 95% confidence intervals
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Figure 6.31 shows a comparison between the FPM emitted in each SM recovered, under a breath
pattern for all the tested devices (categorised in two groups: VHC and pMDI). The dashed line
delimits the upper zone, whereas no possible combinations of FPM versus SM exist. A solid line
illustrates the linear trend of the VHC results, which has slope value of approximately 0.8 (similar
to the results found at 30 L/min and at 60 L/min). This value is highly related to the FPD metric
previously calculated from Figure 6.25 and the results suggest that the pMDI spray technology has
a typical linear trend of delivered FPM for a certain amount of SM emitted.
Figure 6.32 shows a comparison between the FPM emitted in each TEM recovered. The dashed
line delimits the feasible results, while the two solid lines identify linear trends. These results
are highly related to the FPF metric. More specifically, the trend line slope is correspondent to
the averaged FPF of each device type. Whereas the FPM delivered by the use of VHC and the
pMDI solo are similar, the TEM is quite distinct. VHC data above the trend line indicate a better
performance than those bellow.
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Figure 6.31: FPM versus the SM emitted by each device tested under a breath pattern. Error bars
indicates the limits of the uncertainty within a 95% confidence interval
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Figure 6.32: FPM versus the TEM emitted by each device tested under a breath pattern. Error
bars indicates the limits of the uncertainty within a 95% confidence interval
6.3 Evaluation of the Flow Rate Effect
The following section reports the effect of flow rate in the various performance parameters, such
as, the Total Emitted Mass, Fine Particle Mass, coarse and fine particles ratios.
6.3.1 Total Emitted Mass
The TEM value for the MSLI and Full Dose setups at different flow rates are presented in Figure 6.33,
whereas the uncertainty within a 95% confidence interval is represented as error bars. Results
show a clear reduced TEM trend with the reduction of flow rate. Higher air velocities inside the
VHC reduce the deposition onto it. The results of FD setup are similar to the MSLI at the same
flow rate.
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Figure 6.33: TEM values for each device tested at MSLI and FD setups under different flow rates
6.3.2 Fine Particle Mass
Figure 6.34 depicts the FPM emitted by several devices under different flow rate conditions and
error bars represent the uncertainty confidence interval of 95%. Results suggest the diminishing of
the FPM upon the reduction of the flow rate. Because the FPM is based in the value of SM, which
is a part of the TEM, some correlation with the TEM are expected.
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Figure 6.34: FPM values for each device tested at MSLI setup under different flow rates
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Figures 6.35 and 6.36 provide further insight into the influence of the flow rate upon the FPM
when compared to the SM and TEM values. A trend solid line shows that salbutamol sulphate
delivered by pMDI, with or without a VHC coupled, has a linear relation between the SM and the
FPM emitted which is independent of the flow rate. This indicates that the commercial VHCs are
bioequivalent to the pMDI solo. The line slope represents the mass fraction of fine particles in the
APSD cumulative graph, which seems to be independent from the flow rate.
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Figure 6.35: FPM versus SM for each device at different flow rates
When the FPM is plotted as a function of the TEM value two trend lines arise: a black solid one
indicates the VHC results and a grey solid one for the pMDI results. Both line slopes are related to
the FPF value of each corresponding device technology. Results show that FPM and TEM values
increase with the flow rate, which was previously discussed.
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Figure 6.36: FPM versus TEM for each device at different flow rates
6.3.3 Evaluation of Rc and Rf Parameters
Figures 6.37 and 6.38 show the variation of the Rc and Rf metrics for different flow rates.
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Figure 6.37: Rc metric values for several devices under different flow rates
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Figure 6.38: Rf metric values for several devices under different flow rates
Results suggest that Rc decreases with the reduction of the flow rate, as observable for the Rf
metric results. The variation is higher in some devices than in others, although a trend is present.
6.4 Metrics Comparison
In this section, several other variables are compared, being categorised for the flow rate value
and/or valve design type. Only variables that presented unequivocal of correlation were included
in this section.
6.4.1 Throat Deposition versus FPM
An analysis of the Throat salbutamol deposition versus the FPM emitted by each device and
categorised by valve type and flow rate, is depicted in Figure 6.39. Dashed lines indicate the linear
correlation for devices with the same type of valve design. Results show distinct FPM data that
increases with flow rate as previously discussed. Furthermore, the Duck type valve design seems
to favour the throat deposition with increasing flow rate, though other types of valve do not present
such effect. Throat deposition is higher for Duck valve devices independently of the flow rate,
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followed by the Annulus Flap > Leaflets > Coin valve type,«. Such conclusions already have been
observed previously in this chapter.
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Figure 6.39: Comparison of the Throat deposition versus the FPM, categorised by valve design
and flow rate value
6.4.2 MMAD versus FPM
Figure 6.40 shows the comparison of the calculated MMAD versus the FPM of the spray plume,
with categorisation by the flow rate. The linear correlation of the results (dashed line) suggests
that the MMAD and FPM increase with the flow rate. A higher flow rate passing through a VHC
delivers more FPM to the lungs, however this plume is coarser.
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Figure 6.40: MMAD versus FPM emitted by several devices under different flow rate testing
conditions
6.4.3 Device Volume versus FPM
In Figure 6.41 is depicted the salbutamol FPM against the VHC volume at 60 L/min, categorised
by valve type. Additionally, the data correlation (FPM = 0.0397492 ∗ ln (V olume)− 0.147937,
R2 = 0.84349) from Barry and O’Callaghan (1995), is also shown and represented through the
dashed line. This correlation was obtained from a study on sodium cromoglycate FPM emitted
from tubular spacers and assessed using a glass MSLI at 60 L/min [BO95]. Results indicate that
VHC devices show a distinct behaviour from an open tubular spacer, where the Volumatic (with
750 mL) should emit a higher amount of FPM. Furthermore, based in the previously discussed
results, the VHC valve design seems to be more influential than the chamber body volume or
the VHC shape itself. No apparent relation can be found between the valve design type and the
reported results in Figure 6.41.
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Figure 6.41: FPM versus VHC volume at 60 L/min
6.4.4 FPF and Throat Deposition versus Air Volume Drawn
Analysing the FPF (Figure 6.42) and the percentage of throat deposition regarding the TEM values
(Figure 6.43), against the volume of air drawn through the device in one actuation, can provide
further insight. Given the fact that some experimental data comes from unsteady flow rate setup
and other part from constant flow rate, the best way to correlate them is by calculating the volume
of air drawn in each actuation. The time between actuations at constant flow rate procedure was
5 s during 40 actuations plus 30 s at the end of the procedure, giving an average volume of
2875 mL for 30 L/min and 5750 mL for 60 L/min. Under the breath profile the value equals
the tidal volume, i.e. 150 mL. The FPF (i.e. FPF = FPM/TEM) was plotted against the volume of
air drawn during one actuation. Logarithmic correlations were be found for each valve category,
represented by solid lines. There is a high degree of correlation (R2 > 0.78) between the data
and the logarithmic trends. Results point out that FPF increases with the amount of air drawn,
whereas the valve type has clear influence in the FPF values ranked as: Coin > Leaflets > Annulus
Flap > Duck. In Figure 6.43 the results reported that the mass fraction of salbutamol deposited
in the throat is reduced with the volume of air passing through the VHC. Also, the valve design
seems to influence this matter greatly, ranked as: Duck > Annulus Flap > Leaflets > Coin. There
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is a high degree of correlation (R2 > 0.73) between the data and the logarithmic trends.
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Figure 6.42: FPF versus Air Volume Drawn categorised by valve design type
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Figure 6.43: Throat mass per TEM versus Air Volume Drawn categorised by valve design type
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6.5 Patient Relevant Metrics
In an effort to relate commercial devices in a friendly manner for the patient, several metrics were
developed. These metrics process a certain degree of subjectivity and which are far from being
universally accepted. Nevertheless they relate the device weight, volume necessary to transport
it, features of interest against the price and the performance. These metrics are an attempt to
facilitate the comparison between widely varying market alternatives using objective parameters.
Figure 6.44 depicts the relation between the commercial VHCs weight with the transport volume
(given by the volume of a cylinder that enclosures the VHC when disassembled/unmounted for
transport). Devices are categorised by valve type, majority of the market devices have a transport
volume between 200 and 400 mL and a weight between 40 and 80 g. However some VHC devices
have high volume and high weight (i.e. Volumatic) or; in opposition to low volume and high weight
(i.e. Nebuchamber – made of stainless steel).
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Figure 6.44: VHC weight versus transport volume, categorised by valve type
A Handling metric can be calculated by Equation 6.1, using the weight and the transport volume
of the device. Higher the Handling value means that the weight and/or the transport volume are
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lower.
Handling =
1
Weight · Transport Volume (6.1)
The Attractiveness of a device is averaged by the subjective evaluation given by each device
characteristics, rated from 0.1 to 1.0 (bad to good), see Table 6.1. The considered features of
interest were:
• existence of a universal adapter for all type of pMDI’s;
• existence of an exhalation one-way valve;
• collapsibility of the device for transport;
• existence of a flow whistle for patient inspiration control;
• visibility of the valve functioning.
Table 6.1: VHC features evaluation rating
Device
Valve
visibility
Flow
whistle
Exhalation
valve
Universal
adapter
Modular
transport
Attractiveness
Metric
A2A 1.0 0.1 0.1 0.5 1.0 0.54
AC 0.5 1.0 1.0 1.0 0.1 0.72
CSC 1.0 0.1 1.0 1.0 0.1 0.64
NC 0.5 0.1 1.0 0.1 0.5 0.44
OCD 0.5 1.0 1.0 1.0 0.1 0.72
SC 1.0 0.1 1.0 1.0 0.1 0.64
VOL 0.5 0.1 0.1 0.1 0.5 0.26
V 1.0 0.1 1.0 1.0 0.1 0.64
Figure 6.45 depicts the comparison between the Handling and the Attractiveness metrics. Devices
with low Handling are rated with poor Attractiveness. Combining these two metrics, an overall
measure of patient interest in the device can be obtained. This graph indicates that devices with
high volume or weight (i.e. Volumatic and Nebuchamber) also have poor features which make
them unattractive.
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Figure 6.45: Attractiveness versus Handling metrics for VHCs
Another approach for the device evaluation is concerned to its efficiency, as one can assess the
VHC by the cost of the daily therapy. The British pound (£) was the chosen monetary unit for
this evaluation due to the fact that some of these devices are not available in Portugal. If a given
patient uses the device twice a day, firing it twice, he uses 4 actuations per day (considering that
a canister of 200 doses of salbutamol costs around 1.5 £) therefore the daily treatment cost is
around 0.03 £. Adding this value to the daily cost of having a VHC (i.e. divide the device price by
12 months of advisable maximum usage), a measure of the cost of treatment is obtained. Taking
the effective amount of drug inhaled daily (i.e. 4 times the FPM) and dividing it by the daily cost of
treatment an interesting metric can be obtained. This gives the amount of drug per pound that a
patient will obtain using that particular VHC device.
Figure 6.46 reports the comparison between these two patient relevant metrics for the four tested
devices under breath simulated conditions. The most interesting devices are found in the right
upper corner, while the least are found in the opposite corner. Volumatic is the device with the
lowest handling and attractiveness; however it delivers a high amount of salbutamol per pound.
The Vortex has a reasonable handling and attractiveness value and delivers the lesser amount of
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salbutamol per pound in a daily treatment. The highest handling is found for the Aerochamber,
although the cost of the device makes the daily treatment more expensive than other market
alternatives.
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Figure 6.46: Salbutamol per pound of daily treatment versus Handling for the VHC tested under
breath simulated conditions
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7 Numerical Results
This chapter focus in the presentation and discussion of the numerical results obtained through
the CFD simulations. These are focused on the analysis of various geometries. The results are
organised into velocity, evaporation, validation and drug delivery. They can be depicted as:
• contours of a cross-section plane or surface within the geometries;
• profiles obtained from data sample along domain section lines;
• drug deposition information processed from collection files located at the boundaries of the
domain;
• efficiency deposition device curve.
7.1 Velocity
The simulations were initialised with the boundary conditions defined in section 3.5, and the axial
velocity profiles were assessed, over time, in different zones of the domain until a convergence of
the field was reached. Convergence was obtained within 0.6 seconds and the velocity results were
all took from at this moment (t = 0.6 s).
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7.1.1 Contours and Streamlines
Figure 7.1 depicts the velocity magnitude contours along the symmetry plane for all the devices
assessed. The contours are represented as a logarithmic greyscale for better representation of the
low velocity zones (units are presented in m/s).
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Figure 7.1: Compared velocity magnitude contours along the symmetry plane for all devices
assessed (t = 0.6 s)
In the pMDI solo geometry, the air enters the domain at a relatively high velocity (i.e. ≈3.2 m/s),
and upon a sudden expansion of the USP throat the velocity slightly decreases, before reaching
a new maximum of 5.3 m/s at the 90 degrees bend. At this location the flow becomes very
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complex due to the boundary layer detachment that leads to recirculation zones near the sharp
corners of the bend. Downstream the cross-section of the USP throat increases in diameter and
the flow stabilizes reducing the recirculation zones, also lowering the velocity. At the bend, the
air stream is directed towards the outside descending wall and this is the major reason for the
particle impaction on this wall. Stagnation zones can be found at the entrance walls of the USP
throat, whereas the velocity magnitude is close to zero.
Results for the VHCs are somewhat different, mostly due to the existence of a valve zone that greatly
reduces the air flow cross-section, as a consequence increases the air velocity. The maximum
velocity is found for the Nebuchamber (i.e. ≈37 m/s), followed by the Aerochamber (i.e. ≈30
m/s), A2A Spacer (i.e. ≈27 m/s), Volumatic (i.e. ≈24 m/s) and both Space Chambers (i.e. ≈22
m/s). As previously noted the measurement of the open valve position (for the corresponding flow
rate) was not very accurate in the case of the Aerochamber and Volumatic. This influences the
domain drawing and the cross-section at the valve zone, which might lead to misleading values of
velocity in this zone. Therefore the validity of the results should be gauged within such limitations.
The velocity contours in the VHC bodies are similar between them, whereas a high velocity air
jet is found along the centreline of the body and lower air velocities near the walls (i.e. close to
zero). Further analysis of the centre jet contours, shows it is possible to observe that for both the
Compact Space Chamber and the Space Chamber, the air jet velocity reduces with the increase
of the body length. The increase in the length might lead to improved particle evaporation and
emission of finer spray plumes. The Volumatic presents similar contours due to the higher body
length and volume.
As the throat deposition might depend on the air jet downstream the valve. The Aerochamber,
Space Chambers and Volumatic appear to present the most symmetric and uniform pattern.
Whereas, the Nebuchamber mouthpiece design yields a misalignment of the air jet with the throat
centreline, which might lead to higher throat deposition.
Figure 7.2 depicts the velocity magnitude contours of half of the symmetry plane and the per-
pendicular plane both intersecting at the geometry centreline (i.e. x-axis). On the upper portion
of the geometry (i.e. y > 0) several air flow streamlines were represented to illustrate the three
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dimensional air flow patterns. The streamlines are coloured in black and the velocity contours are
coloured in a logarithmic greyscale; units in m/s. The wall surfaces are represented in solid grey,
and the valve surfaces are set with a transparency of 60%.
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Figure 7.2: Velocity magnitude contours in two perpendicular planes (XY and XZ) intersecting in
the centreline along with air flow streamlines, for all VHC devices numerically assessed (t = 0.6 s)
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The results bring more three-dimensional detail into the velocity contours, specifically in cases
where the geometry of the valve is not easily understood from the 2-D views (i.e. A2A Spacer,
Space Chambers, Aerochamber). Valve’s designs based in an obstacle (i.e. those without a open
centre design) such as, Coin (i.e. Volumatic) and Annulus Flap (i.e. Aerochamber) or when an
impaction zone is added downstream the valve (i.e. A2A Spacer), result in recirculation patterns
downstream the cross-section contraction zone. These recirculation zones can lead to higher
entrapment of drug particles and generation of turbulence, which can potentially be mitigated by
removing obstacles downstream and smoothing the valve downstream design for later boundary
layer reattachment, as suggested by designs from Oliveira (2012) [OTS+12].
7.1.2 Profiles
Figure 7.3 depicts the axial velocity along the centreline (i.e. x-axis) for each VHC domain. The
axial distance was normalised and two grey shadowed areas identify the regions corresponding
to the VHC body length and USP throat zone. The velocity units are m/s and the white region
corresponds to the valve zone.
The velocity centreline profiles are relatively low in the VHC body, as previously observed in the
contours, and rapidly increase to a maximum in the valve region. Negative values indicate that
recirculation is present, which is noticeable for the A2A Spacer, Aerochamber and Volumatic (as
previously observed in the streamlines behaviour). The Nebuchamber is the VHC with highest
velocity at the valve centreline. Downstream of the valve, the axial velocity gradually reduces until
it reaches a zero, which corresponds to the 90 degrees bend of the throat, where the flow changes
direction. Results from A2A Spacer are the hardest to analyse. Due to the geometric configuration.
In fact, the existence of several obstacles along the centreline, diverts the flow to go around them,
making the centreline axial velocity extremely low.
Figure 7.4 shows the axial velocity took along three vertical lines, each one corresponding to a
portion of the VHC body length (i.e. X/L = 0.3, 0.6 and 0.9). The radial coordinate was normalised
by the local radius and the velocity is in m/s.
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Figure 7.3: Axial velocity for six VHC, normalised along the centreline axis of each geometry.
Shadowed grey areas represent the VHC body and USP throat lengths (t = 0.6 s)
-1.0
-0.5
0.0
0.5
1.0
Y/
R 
[-]
A2A AC CSC
-1 0 1 2 3
-1.0
-0.5
0.0
0.5
1.0
Y/
R 
[-]
SC
-1 0 1 2 3
Axial Velocity [m/s]
NC
-1 0 1 2 3
VOL
X/L = 0.3
X/L = 0.6
X/L = 0.9
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at three distances (t = 0.6 s)
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The velocity profiles along cross sections of the VHC body enables a rapid assessment of the
proportion of the domain under recirculation, by the negative axial velocity values. It was verified
that the recirculation zone tend to diminish along the body length. The Volumatic geometry has the
greatest recirculation zone, followed by the Aerochamber, both Space Chambers, the Nebuchamber
and the A2A Spacer. The profiles also identify that the flow inside the VHC bodies is practically
symmetrical, whereas it slightly deviates for devices with non-axisymmetric geometry (i.e. A2A
Spacer). Also it can also be identified a reduction of the axial velocity along the body length.
7.2 Evaporation
7.2.1 Profiles
For understanding the evaporation process during the spray release inside the VHC devices, the
volume averaged HFA gas mass fraction was assessed over the time.
Results are depicted in Figure 7.5 for the Aerochamber, A2A Spacer and Volumatic devices. The
shadowed area represents the duration of the pMDI spray injection. The HFA rapidly increases
during the injection period where the peak is reached. Subsequently the propellant mass fraction
inside the domain starts to diminish caused by the air renovation (i.e. at 60 L/min). The ratio on
which the HFA leaves the domain clearly depends on the geometry shape and, mostly, of the VHC
volume. The A2A Spacer and the Aerochamber have a similar rate of HFA decay, since they have
similar volumes. However, the Volumatic high volume makes it harder for the HFA to rapidly leave
the domain. This is identified by the instant at which the HFA reaches zero, which happens at 2.0
s for the Aerochamber, 2.8 s for the A2A Spacer and >4.0 s for the Volumatic.
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Figure 7.5: The variation of HFA mass fraction averaged over volume for the Volumatic, A2A Spacer
and Aerochamber
7.2.2 Contours
Figure 7.6 depicts time evolution of the HFAmass fraction contours for the A2A Spacer, Aerochamber
and Volumatic domain. The contours are displayed in a linear greyscale to a maximum of 0.15%,
whereas in the initial injection moments the high values (i.e. up to 2%) saturate the contours.
During the initial moments of the injection, the HFA rapidly expands throughout the domain. At the
end of the injection (i.e. t = 0.69 s) all the Aerochamber volume contain HFA gas, which is due to
the elevated recirculation velocities within this device and its small volume. When compared with
the A2A Spacer, the region behind the spray injection cone is absent of HFA (t = 0.69 s), which
only diffuses later (t = 0.8 s). For the Volumatic this is only verified much later (t = 1.5 s). The HFA
reaches the lower portion of the throat firstly for the Aerochamber, followed by the A2A Spacer and
finally the Volumatic. The upper portion of the throat is more densely filled with HFA in the case of
the A2A Spacer, which may be related with the valve design (i.e. Leaflets - open centre design).
The Aerochamber impaction cup, forces the HFA evaporation to occur mostly inside the VHC body,
reducing the high concentration of the propellant in the throat zone (t = 0.69 s). At 4.0 s, the
Volumatic still shows some concentration of propellant, while Aerochamber HFA concentration
reaches a minimum at 1.5 s, as previously discussed (see Figure 7.5).
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Figure 7.6: HFA gas contours over time for the Volumatic, A2A Spacer and Aerochamber from left
to right, respectively
189
Chapter 7. Numerical Results
7.3 Validation
This section reports the comparison between the CFD results and the experimental data presented
in chapter 6.2.2. Also, some numerical results are compared with available data (experimental
and numerical) from the literature.
7.3.1 CFD versus Literature
Impaction Parameter vs Deposition Efficiency
The numerical results were compared against several literature sources in terms of Impact Param-
eter versus the Deposition Efficiency defined as in Equation 7.1.
Deposition Efficiency =
Entraped Mass
Total Mass
(7.1)
For a particle size distribution injected into the domain, the mass of a certain particle size trapped
in a surface (i.e. USP IP) is evaluated and divided by the mass injected for the same particle
size. This ratio provides the efficiency of deposition for a certain particle diameter crossing that
particular geometry. The Impaction Parameter is simply the air flow rate multiplied by square
of the particle diameter (d2p ·Q - µm2 · L · min−1). This shall result in a sigmoid shaped curve,
which represents free passage of particles with a small Impaction Parameter and the entrapment
of particles with high Impact Parameter values. This curve is characteristic for a given geometry.
Figure 7.7 reports the pMDI solo CFD data using a USP IP geometry and its corresponding data
fitting curve using a Weibull function. Additionally, it can be found the results for a CFD simulation
of a USP IP by Longest (2008) [LHDX08], and the experimental results from Cheng (2015) with
the same geometry [CZS15]. Other numerical results for Realistic Casts of the human throat made
with anatomical data [LHDX08, ZKKC04, FWZS07] and numerical prediction for an AIT geometry
[MFLG04], were added.
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Figure 7.7: Deposition Efficiency versus Impaction Parameter for the USP IP against literature data
The CFD results from this work seems to make a fairly good prediction in comparison to the
USP IP data from literature. However, the numerical predictions are globally underestimating
the deposition of particles with small impaction parameter. The data fitting curve has a good
coefficient of determination (i.e. R2 = 0.9905).
Stokes Number versus Deposition Efficiency
The CFD data were compared against Cheng (2015) experimental assessment of the USP IP
geometry in terms of deposition efficiency versus Stokes number (Stk) (see Equation 7.2).
Stk =
ρpCcd
2
pUinlet
9µfDmin
(7.2)
Where the Uinlet = 4Q/piD2inlet is the estimated velocity at the entrance of the geometry and
Cc stands for the Cunningham slip correction factor (see Equation 3.84).
Figure 7.8 depicts the numerical results of this study versus the experimental data of Cheng (2015)
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[CZS15]. The curve fit of the CFD data was made using a Weibull function and the coefficient of
determination indicates a good fit (i.e. R2 = 0.9905). The numerical prediction shows lower
deposition efficiency for higher Stokes numbers, underestimating the deposition data from Cheng.
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Figure 7.8: Stokes Number versus Deposition Efficiency for the USP IP against literature data
7.3.2 Experimental versus Numerical
In this section it is reported the comparison between experimental data and the numerical
predictions, firstly regarding the different wall models used for handling the particle collision
phenomena and lastly the drug deposition in the VHCs, throat and SM.
Comparison of Wall Models
The wall-particle interaction models tested were:
• (1) Reflect;
• (2) Trap;
• (3) Evaporation Model (any particle not fully evaporated, would behave like Trap, otherwise
would be Reflect);
• (4) Evaporation Model plus Tangential Lift-off Ratio Model (any particle not fully evaporated
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or with Tangential Lift-off Ratio ≥ 1.0, would be Trap otherwise Reflect);
• (5) Evaporation Model plus Critical Velocity Model (any particle not fully evaporated or with
wall normal velocity component ≤ than the critical velocity, would be Trap otherwise Reflect);
Figure 7.9 shows the SM emitted by the pMDI solo and the Compact Space Chamber geometries,
when five different types of wall configurations were used to handle the wall-particle interaction.
Additionally, the experimental data along with its corresponding uncertainty, is given.
Using Reflect condition leads to the highest output of mass from the domain, as expected. Whereas
the difference in mass (i.e. the missing injected mass to reach 100 µg) suggests that several drug
particles are inside recirculation zones or hovering above lower horizontal surfaces, given the fact
that no particle entrapment occurs at any surface of the domain. In the case of the pMDI solo, the
rank of the closest to experimental data is: (2) – (3) – (4) – (5) – (1). Whereas in the case of the
Compact Space Chamber the rank is: (3) – (5) – (2) – (4) – (1). Upon these data, the best wall
model for the SM is (2 – Trap) or (3 – Evaporation Model).
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Figure 7.9: SM exited the domain using different particle-wall collision models
Figure 7.10 depicts the influence of the same wall models on the mass entrapped on the USP
IP walls. The Reflect option is expected to provide zero deposition by definition. On the other
side, the other wall models will vary between: the undiscriminating entrapment of any particle
that collides, passing by the solely collection of liquid droplets, to the collection of liquid droplets
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and solid particles of low wall normal velocity or upon the assessment of the forces equilibrium.
For the pMDI solo case, the models rank as: (3) – (2) – (4) – (5) – (1). For the Compact Space
Chamber case, they rank as: (3) – (2) – (5) – (4) – (1). Model (3) might be the best option for the
prediction of drug entrapment in the USP throat surfaces.
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Figure 7.10: Mass entrapped in the USP throat using different particle-wall collision models
Based on the previous comparisons, the best model to be used in the simulations seems to be
the Evaporation criteria, which will only entrap droplets whose evaporation process is not fully
completed.
Figure 7.11 depicts the Deposition Efficiency versus the Impaction Parameter in the case of
pMDI solo, for each wall-particle interaction model tested. A curve fit from Cheng (2015) experi-
mental data was added to estimate the accuracy of each wall model [CZS15]. These results indicate
that the previous conclusions, regarding the best wall model (3 - Evaporation), are not supported.
This approach sets a threshold on the collection efficiency, based on the evaporation process
being completed or not, resulting in a underestimation for particles with Impaction Parameter
values below 1.5E4 µm2 · L · min−1. The other models seem to have a very similar performance,
whereas the (2 – Trap) model predictions show highest oscillation in the values.
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Figure 7.11: Deposition efficiency versus impaction parameter for the wall models tested in the
USP throat
Figure 7.12 depicts the Deposition Efficiency versus the Impaction Parameter in the case of
Compact Space Chamber, for each wall-particle interaction model tested. The results show the
Deposition Efficiency on the VHC walls. It can be observed a very distinct behaviour between the
wall models, which differ from the previous results. The underestimation effect of model (3) in the
deposition efficiency of particles with small Impaction Parameter is more noticeable. On the hand,
model (4) strongly underestimates the deposition of particles with high Impaction Parameter. This
behaviour renders these two models lesser adequate for modelling the particle-wall interaction on
the VHC surfaces, since it was expected that a VHC device would entrap more coarser particles
than smaller ones. The other models have a similar trend.
By evaluating the effect of wall models on the Deposition Efficiency, for pMDI solo or Compact
Space Chamber cases, it can be concluded that the best models are (2) and (5). Together with the
previous conclusions from the drug deposition in the surfaces versus the experimental data, the
model (5) was considered the best fit and used throughout the rest of the study herein reported.
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Figure 7.12: Deposition Efficiency versus Impaction Parameter for the wall models tested in the
Compact Space Chamber
Drug Deposition
Taking data from the experimental assessment at 60 L/min, Figure 7.13 provides a direct compari-
son against the numerical predictions, for the VHC device, USP Throat and Sizable Mass (SM).
The experimental data were presented together with theirs experimental uncertainty, shown as
error bars.
Starting by the VHC deposition, the numerical model appears to generally underestimate the
deposition inside the device. This might be linked to the wall model, which is the same applied
to all surfaces and which does not consider extra forces, such as, the electrostatic attraction
or adhesion forces caused by humidity. Spray parameters are other source of uncertainty like
injection velocity, which was modelled as constant over time (i.e. a solver limitation) contrarily
to what was experimentally observed [CJM09]. Also the spray angle and size distribution might
not be accurate. Other strongly influential fact is that all droplets were modelled with the same
mass fraction of API (i.e. a solver limitation), which is known not to be true [SSM12]. Analysing
the results, it is observed that the calculated drug entrapment inside the device is closely related
to experimental data for the Aerochamber (3.0 µg) and Space Chambers (5.1 µg and 6.9 µg),
while a large deviation is observed for the Volumatic (19.6 µg) and Nebuchamber (19.3 µg).
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The Volumatic is the device with highest volume, which will reduce greatly the spray impaction
deposition. However, the electrostatic attraction force which is not accounted for in the wall models,
may be the reason behind the great deviation of numerical prediction from the experimental results.
In the Volumatic (a polycarbonate device - non-dissipative polymer) case this is more noticeable
due to its high surface area. The Nebuchamber deviation from the experimental results might be
explained with the lack of consideration, in the numerical model, of the surface roughness in the
particle entrapment. Aluminium shaped devices have higher roughness than those produced by
mould injection [BK07].
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Figure 7.13: Experimental mass deposition versus CFD at three different zones, for all the assessed
devices
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The numerically predicted drug entrapment in USP Throat is globally overestimated when compared
with the experimental results. The highest deviations are found for Compact Space Chamber (17.6
µg), Aerochamber (13.9 µg) and Space Chamber (12.5 µg); while the lowest are found for the
Nebuchamber (4.8 µg) and A2A Spacer (6.2 µg). The deviations may arise from several factors:
• air flow downstream the valve is dependent on the valve opening dimensions that might be
not accurate (i.e. higher jet velocities lead to higher USP deposition);
• influence of the excess of mass emitted by the VHC;
• the wall model for the USP Throat surface is not correct and should be different from that
applied to the VHC surfaces.
The predicted SM mass emitted from the geometries are a balance between the overestimation of
the USP Throat deposition and the underestimation of the VHC devices deposition. The results are
obviously strongly influenced by the deposition on the previous stages. Nevertheless the lower
deviation is found for the Compact Space Chamber (4.2 µg) and Volumatic (6.5 µg). The highest
deviation is found for A2A Spacer (25.4 µg).
7.4 Drug Deposition Evaluation
The numerical results for the drug deposition were processed from collection files set at the VHC
Body and Valve surfaces, USP throat surfaces and at the exit of the domain that corresponds
to the drug mass passing to the MSLI, i.e. the SM. Upon the post processing of these files
using sub-routines in Python language, the results were assessed in terms of total mass, emitted
distribution, deposition location, and impaction parameter. All results correspond to a time of 4
seconds.
Figure 7.14 depicts the amount of mass collected in four zones of the domain, for each on of
the geometries. It can be seen that using pMDI solo results in half of the drug dosage loss by
throat entrapment through impaction. The majority of the particles are liquid and did not have
enough volume to evaporate and decelerate before colliding against the USP throat walls. Throat
deposition in the cases where the VHC device was present are completely distinct, ranging from
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11.1µg (i.e. A2A Spacer) to 23.0 µg (i.e. Compact Space Chamber). The use of the VHC reduced
the throat deposition between 57.9% and 79.7%.
Valve deposition is higher for the Volumatic (8.0 µg), followed by the A2A Spacer (3.2 µg),
Aerochamber (3.1 µg), Compact Space Chamber (3.0 µg), SpaceChamber (2.3 µg) and Neb-
uchamber (1.8 µg). This supports the previous conclusion, that valves with non-open centre design
or with centralised obstacles downstream create recirculation areas that entrap more particles
than other designs. Valves that create a major obstacle for the air flow are obviously zones of
increased deposition by impaction, such is the case of the Volumatic Coin valve design.
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Figure 7.14: Numerical prediction of the mass collected in each zone of the domain for the different
geometries (t = 4 s)
VHC Body deposition ranges as Aerochamber (31.9 µg) > Compact SpaceChamber (31.6 µg) >
SpaceChamber (30.4 µg) > Volumatic (22.6 µg) > A2A Spacer (22.6 µg) > Nebuchamber (14.5
µg). The results are strongly related with the impaction distance of each device, i.e. the body
length and diameter.
The SM is the amount of drug entering the MSLI (or another CI), which is the equivalent to the patient
lungs. The results show the highest value for the A2A Spacer (61.7 µg), and the lowest is found for
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the Volumatic (38.9 µg). Experimentally the results point to opposite conclusions, which indicates
that the wall model used is missing some key parameter (such as the electrostatic attraction) and in
addition some valve opening dimensions, may not be very accurate. Additionally, the wall model de-
pends on the assumed Young Modulus and Poisson’s Ratio values for the materials of each surface.
Figures 7.15 through 7.21 depict the particle drug deposition in the surfaces coloured by diameter,
corresponding to pMDI solo, A2A Spacer, Aerochamber Compact Space Chamber, Nebuchamber,
Space Chamber, and Volumatic respectively. Each figure is composed by an isometric view of the
domain deposition and two closer views of the deposition upstream and downstream the device’s
valve.
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Figure 7.15: Particle deposition locations coloured by diameter for the pMDI solo geometry
From the previous results, it is known that the drug deposition in the throat is higher for the case
where the pMDI is used without a VHC, this also can be observed in Figures 7.15 through 7.21. It
is noticeable that the larger particles deposit mainly by impaction in the upper portion of the throat.
In the case where a VHC is used, the VHC body deposition is mainly made by impaction of the
bigger particles (i.e. >17 µm), and by sedimentation of those above 3 µm. The throat deposition
when a VHC is used, is lower and is mainly composed by small particles (i.e. < 6 µm). Some
devices, more than others, show a radially uniform deposition in the upper portion of the throat,
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which indicates a more stable airflow downstream the of valve. A2A Spacer has the lowest throat
deposition results (see Figure 7.14) as it can be observed in Figure 7.16. Throat deposition pattern
is most uniform in the Aerochamber (see Figure 7.17).
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Figure 7.16: Particle deposition locations coloured by diameter for the A2A Spacer geometry
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Figure 7.17: Particle deposition locations coloured by diameter for the Aerochamber geometry
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Figure 7.18: Particle deposition locations coloured by diameter for the Compact Space Chamber
geometry
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Figure 7.19: Particle deposition locations coloured by diameter for the Nebuchamber geometry
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Figure 7.20: Particle deposition locations coloured by diameter for the Space Chamber geometry
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Figure 7.21: Particle deposition locations coloured by diameter for the Volumatic geometry
VHC valve deposition is more noticeable for particles with sizes around 7 µm, which may be due
to the fact that those with higher diameter are entrapped inside the VHC body before they reach
the valve, while the smallest can pass through the domain without colliding. In devices for which
the valve geometry causes great recirculation downstream, it is noticeable that the deposition of
smaller particles in the valve and mouthpiece is higher and more spatially scattered, as previously
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hypothesised from the velocity streamline results. The Aerochamber impaction cup (closely located
to the valve) illustrates the entrapment of high diameter particles (see Figure 7.17), reduce their
oral deposition, as opposed to the open centre valve designs (see Figures 7.16, 7.18, 7.20 and 7.19).
Figure 7.22 depicts the Deposition Efficiency in the VHC surfaces (i.e. body and valve) ver-
sus the particle diameter (dp). The Nebuchamber shows the lowest deposition efficiency for all
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Figure 7.22: Deposition Efficiency versus the Impaction Parameter for the mass retrained by each
VHC device (t = 4 s)
particle size range. The Aerochamber has the highest deposition for particles above 20 µm.
Volumatic presents an unexplainable peak of deposition for particles around 11 µm. The other
VHCs have similar deposition efficiency curves. Devices with open-centre valve design (i.e. Neb-
uchamber, A2A Spacer, Compact Space Chamber and Space Chamber) do not present 100% high
diameter particle entrapment. Some of the higher size particles pass in the centre of the valve
and impact in the USP IP.
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8 Optimisation of the VHC Geometry
Using CFD Models
8.1 DOE Study of VHC Body Shape
8.1.1 Geometry Definition
An idealised VHC geometry is given in Figure 8.1. This has smooth curves, AB for the expansion
region and BC for the contraction region, connected at point B. The latter is a corner point of an
expansion zone, and since one of the objectives of the VHC device is to reduce spray velocity, the
greater the internal volume of the device the better it can perform this function. The further the
point B is from the central axis, the greater this area shall be; however this increase comes with a
weight cost (i.e. latter resulting in production, material, packing and shipping costs). Additionally,
the radial distance of point B is directly connected to the increase of the recirculation area inside
of the VHC body, due to the early flow detachment from wall [OTMT12]. The research hypothesis
is that the increase of the recirculation area is strongly linked to the entrapment of small drug
particles resulting in a reduction of the FPM emitted by the device. A previous study made with a
dispersion of solid particles (without accounting for evaporation and complex wall models) did not
found a correlation between both events [OTMT14b].
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Figure 8.1: Geometry used in the design study
In the idealised geometry, several dimensions were kept constant, as well as some geometrical
constraints were added. The valve was based in the Volumatic shape and size. The entrance (
22.6 mm) and exit ( 24.5 mm) dimensions were based on those from a typical commercial VHC
device. In the study herein, the position of point B is moved in length (axially) and height (radially)
for different spatial geometrical combinations. Two quadratic curves were used as segments AB
and BC, with zero derivative in points A (for segment AB ) and B (for segment BC). Additionally,
all other dimensions were kept constant.
Geometric limits vary between a length of 30 mm to 150 mm, and a height of 30 mm to 70 mm.
The spatial combinations of point B were made accordingly to a full factorial design, yielding a
total of 30 combinations.
8.1.2 Mesh Generation
The mesh is created in Meshing software from ANSYS, with boundary layer refinements for the
valve and body walls, whereas the first layer height was made to be y+ close to 1 (as required
by the k − ω SST model). Local mesh refinement was applied in a radius of 30 mm from the
point B (size of 0.5 mm) and at 15 mm surrounding the valve walls (size of 0.1 mm). Additionally,
a global automatic refinement for proximity and curvature in the geometry, was applied. A good
mesh quality was assured by manually assessing the meshes created for the extreme cases within
the 30 combinations created. The meshes size ranged from 56.5k to 70.4k elements.
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8.1.3 Boundary Conditions
The boundary conditions are similar to those previously reported in chapter 3.5.However the
velocity was provided by a turbulent flow profile defined by the 1/7 power law (Equation 8.1). The
latter was used on the solver though a UDF, which calculated the average velocity based in the
flow rate of 30 L/min (this air flow rate is closer to the human PIF).
Ux (y) = 1.2244 · U ·
(
R− y
R
)1/7
(8.1)
with R as the maximum radius of the entrance, y is the radial coordinate and Ux and U is the
axial and average velocity, respectively.
8.1.4 Solver Configuration
The solver of choice was FLUENT from ANSYS, and the models employed here were the same
as described in chapter 3.6. The properties of the materials and spray definition were the same
as for all simulations. The major differences are that this study was carried in 2D axisymmetric
manner, improving the balance between the mesh resolution and the computational time required.
Additionally, the spray injection was modelled for a 2D geometry (using the same inputs as
chapter 3.7). Another limitation is that, due to the 2D axisymmetric study, no gravity acceleration
was accounted for. The simulations ran for 4 s, whereas the spray was only injected at 0.6 s for a
total duration of 0.1 s. The particle-wall collision was treated as a combination of the evaporation
entrapment for liquid particles and the solid particles entrapment/reflection was decided upon the
critical velocity model (considering all walls made of polycarbonate).
8.1.5 Post-Processing
The particles were collected at the exit, at the valve and on other walls. Afterwards, these data were
post-processed using custom made Python scripts. Whereas, the FPM emitted was evaluated, as
well as, the size distribution, temperature, evaporated fraction and spatial distribution. CFD-Post
from ANSYS was used for post-processing the HFA concentration and the value for the recirculation
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area in the body of the VHC design by a methodology based in the stream function, reported
elsewhere [OTMT12].
This method was previously employed in a computational simulation study for estimating the
amount of recirculation area created by stent struts in the blood stream [BSM+00]. It consists in
creating a field contour of the stream function that ranges from a maximum (corresponding at
the centre of the recirculation area) to a minimum(corresponding at the wall reattachment point).
Then, it is calculated the total area of this zone, which is divided by the total area of the field. This
percentage was used as an output variable for quantifying the amount of recirculation for a given
geometry.
The stream function is the relation between a streamline and the mass conservation equation,
through the Equation 8.2 and 8.3 [BSM+00, ANS13], only applicable to 2D flow fields.
u =
∂Ψ
∂y
(8.2)
v =
∂Ψ
∂x
(8.3)
A streamline can be defined as a line that is tangent to the velocity vector of the moving fluid and
connects points of constant stream function, ∂Ψ = 0. The procedure starts by identifying the
location of zero wall shear stress within the spacer’s body. Two points are usually found which
represent the locations of flow separation and reattachment. From the reattachment point, the
points with a constant stream function are located. Because of the properties of the stream
function, this boundary separates the location of the flow recirculation from the main flow.
8.1.6 Results
After post-processing the numerical results for the 30 design points, the percentage recirculation
area, FPM and VHC volume were used to construct correlative regression surfaces, see Figures 8.2,
8.3 and 8.4 respectively. These regression surfaces correlate the spatial position of the expansion
corner (i.e. length and height) with the predicted recirculation area, emitted FPM and VHC volume.
Such surfaces were produced in Surfer (from Golden software, USA) using cubic splines. From
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Figure 8.2, it is possible to observe that the recirculation area decreases with the length, however
it increases even more rapidly with the displacement in height. As expected, when the expansion
corner point is moved further from the centre of the flow stream, the boundary layer detachment
occurs over a greater extension of the geometry. On the other hand, the displacement of the corner
point along the axial direction will slightly decreases the recirculation area, due to the geometrical
constraints of curves AB and BC. The maximum value of recirculation is set in 62% (for length =
30 mm and height = 70 mm), whereas the minimum is 22% (for length = 150 mm and height =
30 mm).
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Figure 8.2: Correlative surface for the length and height with the percentage recirculation area
Results for FPM (see Figure 8.3) show a more complex pattern. Nevertheless there is an increase
of the FPM with the length and reduction with the height. Values range from 34 µg (at length =
30 mm and height = 70 mm) to 57 µg (at length = 150 mm and height = 30 mm). The extreme
values of FPM are opposite to those found for the recirculation area. This shows that the smaller
this recirculation area, the higher emitted FPM, supporting the hypothesis of this study.
VHC Volume results (see Figure 8.4) appear to be highly related with the values of recirculation
area previously reported. The increase in height leads to higher volumes than the increase of
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length. The lowest volume is 270 mL (at length = 150 mm and height = 30 mm) and the highest
is 1560 mL (at length = 30 mm and height = 70 mm).
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Figure 8.3: Correlative surface for the length and height with the FPM
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Figure 8.4: Correlative surface for the length and height with the VHC volume
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The flow field for the two extreme combinations are depicted in Figures 8.5 and 8.6. Additionally,
the greyscale coloured contours represent the VHC body area under recirculation, ranging from
high (lighter) to the low (darker) values of the stream function.
Figure 8.5: Computational results of the velocity vector field and the calculated recirculation zone
(length = 150 mm and height = 30 mm)
Figure 8.6: Computational results of the velocity vector field and the calculated recirculation zone
(length = 30 mm and height = 70 mm)
An analysis of the domain for the presence of HFA as a vapour at 4 s, is represented in Figures 8.7
and 8.8 for the two previously discussed extreme cases. Even although 3.3 seconds after the
injection of the spray is completed, some HFA can be found inside the VHC. The amount of
propellant gas is very small, however, its concentration is higher for the geometry with higher
recirculation area (see Figure 8.8). The recirculation zone traps the HFA in its centre, whereas the
air velocity is close to zero.
By tracking the various sizes of particles released by the spray, a 3D rendering of the particles
entrapped in the fluid can be represented. The particles are scaled by their diameter and the
two extreme geometries are depicted (see Figures 8.9 and 8.10). Also, in the same figures, a
longitudinal section of the VHC is used to show the propellant mass fraction. It can be seen
that the particles suspended in the fluid are indeed entrapped mostly located in the recirculation
areas. Whereas higher recirculation areas have greater amount of particles entrapped. This high
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concentration of particles in the recirculation areas can explain the reason behind the higher
concentration of HFA in these regions.
Figure 8.7: Coloured contours of the concentration of HFA propellant in the air (length = 150 mm
and height = 30 mm)
Figure 8.8: Coloured contours of the concentration of HFA propellant in the air (length = 30 mm
and height = 70 mm)
Figure 8.9: Coloured contours of the concentration of HFA propellant along with the representation
of the particles entrapped in the domain at 4 seconds (length = 150 mm and height = 30 mm)
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Figure 8.10: Coloured contours of the concentration of HFA propellant along with the representation
of the particles entrapped in the domain at 4 seconds (length = 30 mm and height = 70 mm)
By analysing the particle size distribution at the exit for both cases (see Figure 8.11), it can be
observed significant differences between both cases, and more so in comparison with the injected
profile.
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Figure 8.11: Particle size distribution of two emitted plumes in comparison with the injected
salbutamol distribution
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The low recirculation area configuration shows a great reduction of particles above 4 µm, leaving
particles below this value practically unchanged. On the other hand, the high recirculation configu-
ration presents a high reduction of the mass for all diameters alike.
Figure 8.12 presents the comparison between the recirculation area and the FPM for the 30 design
points. Those are identified by markers for the values of height and labels identifying the values of
length. From the comparison of both output variables, it is noticeable a certain degree of correlation
between them. The highest recirculation areas lead to lowest emitted FPM values, and the other
way around. The results for lower values of height appear to have less uncertainty and more likely
to be highly correlated by the power function (FPM = 101.805 · Area−0.244; R2 = 0.460). In
Figure 8.12 the grey shadowed area represents the 95% confidence interval for the correlation
curve.
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Figure 8.12: Comparison between the recirculation area and the emitted FPM (labelled with the
length values)
Figure 8.13 depicts the comparison of the recirculation area versus the volume of the device,
whereas is noticeable a strong correlation between both. As the volume increases by spatial
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displacement of the transition point, the recirculation area increases accordingly to a logarithmic
function (i.e. Area = 23.02 · ln (Volume) − 105.78; R2 = 0.992). The grey shadowed zone
indicates the 95% confidence interval. From Figures 8.2 and 8.4, is noticeable that higher values
of height produce designs with higher volume and higher recirculation areas.
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Figure 8.13: Comparison between the recirculation area and the design volume
8.2 New VHC Design
Based on the experimental and numerical conclusions obtained through this work, a new VHC
design concept is proposed in this section. The body shape is built upon an axisymmetric solid,
inspired in the shape of a pear. This will have smooth curvature surfaces composed by quadratic
curves that meet at a transition point, whereas the influence of its position on the efficiency has
been described in section 8.1. The position of the corner point is associated with a VHC volume,
which is important to be adequate to lung capacity of the target patient. For a target patient, i.e., a
6 years old child, the volume should be close to the tidal volume (i.e. 150 mL); accordingly to
Figure 8.4 the lowest volume corner point combination is of length equal to 150 mm and height
equal to 30 mm. However, the total length of the device makes it impractical for carrying it around.
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A more compact design configuration was chosen for the expansion corner: 80 mm length and 25
mm of height.
The experimental results identified the Volumatic valve as that with the lowest throat mass deposition
and the highest increase in the FPM output, but this might be connected to the Volumatic high
volume. However this idealised VHC design will have even a lower volume. Experimental results
showed that Leaflets valve type are more effective for small volume devices, therefore the valve
design should be similar to those of Compact Space Chamber or Space Chamber. This valve
design has also shown virtually no air leakage (see section A.5).
This new design will be of a modular concept, made by parts easily manufactured by injection
moulding. This shall keep the device production cost relatively low for a high production volume.
The concept will include two additional features that can be combined with the other parts allowing
the improvement of the device usability for a wide range of users characteristics and commercial
formulations. One will be an expansion ring that will increase the volume of the device for patients
with higher lung capacity (i.e. adults). Another improvement consists of an impaction ring that is
composed by a centred half spherical cup, that will greatly increase the removal of the central
spray coarse fraction. The size of the impaction rings can be tailored for different commercial
spray formulations.
All parts can be combined resulting in different devices, which will produce distinct outputs for the
patient:
• A - without extra parts
• B – with the impaction ring
• C – with expansion ring
• D – with the expansion and impactor rings
Figure 8.14 depicts the four possible variations of the basic design. The body of the device, as well
as the extra rings can be produced in polycarbonate or ABS with anti-static properties for reducing
the drug loss by electrostatic charge.
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A
B
C
D
Figure 8.14: New VHC design combinations
For an easy assembly by the patient, some fool-proof features were added, such as a one-way
interlock connection between the parts. That will prevent the patient to assemble the impaction
ring with the concavity towards the spray. The device mouthpiece is also of oval shape on the
outside so it will reduce the chances of air leakage by the patient mouth corners.
The pMDI adapter shall be universal fit design and made of silicone rubber, so it can fit all the
possible commercial pMDI actuators in the market. The inhalation one-way valve shall also be
produced in a silicon rubber material so it can properly function by deforming its structure by
interacting with air flow solicitation.
A missing feature in this design is the exhalation valve (or vents), and the addition of a whistle for
flow control during inhalation effort.
Children need to carry the VHC device around so portability is a very important feature to keep in
mind when designing a new VHC device. This design has a maximum weight of 51 g (i.e. with the
two extra rings) and a minimum of 42 g. The maximum dimensions for the configuration D are
176 mm x 54 mm of diameter. For configuration A is 150 mm x 54 mm of diameter.
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9 Conclusions and Future Work
9.1 Main Conclusions
Herein this chapter, the most relevant conclusions regarding both experimental and numerical
assessment of the VHCs performance are presented.
9.1.1 Experimental
The experimental performance assessment of eight VHC devices was done at constant and variable
flow rate. For this, a Full Dose and a MSLI Cascade Impactor setups were used for collecting the
salbutamol sulphate emitted by the pMDI Ventolin HFA, and evaluate its plume characteristics.
Four of the VHCs were assessed at variable flow, using a breath simulator, which was developed to
reproduce a typical child breath waveform. The main conclusions for the data are given bellow:
• It was noticed that the mass deposition in the pMDI actuator has a nearly constant value for
all devices at constant flow rate (≈10 µg), and twice for variable flow rate. This indicates
that the mass deposition is deeply related with the pMDI actuator design characteristic.
• The amount of drug deposited in the VHC reduces with increasing the air volume passing
through the device. Results suggest that the deposition in each device is related with a
considerable number of different variables.
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• Throat deposition is reduced (64% - 94%) when a VHC is used, in comparison to the pMDI
solo. The oropharyngeal deposition is highly related to the VHC valve type. Comparing the
valve types in terms of mass deposition reduction, they can be ranked as: Duck > Annulus
Flap > Leaflets > Coin. This is an effect observed through different flow rates.
• Using a VHC provides an increase of the FPM for most of the devices. The FPM emitted from
the VHC devices shows no statistically significant differences (p>0.05) when compared to
the pMDI solo, proving the bioequivalence of the add-on device. Also, there is not statistical
evidence that valve type is related to the emitted FPM at 30 L/min (p>0.05). Similar
observations were found for 60 L/min. However the FPM emited by the VHC under the
breath pattern is systematically lower than the pMDI solo. These results may be indicative
of a problem within the setup or that the breath pattern has a low tidal volume for these
commercial devices.
• All VHC (tested at constant flow rate) are able to reduce the coarse fraction by more than
60% in comparison with the solo pMDI, as advisable by the guidelines.
• The results indicate a reduction of the FPM with the reduction of the flow rate. Thus,
logarithmic correlations were found between the volume of air passing through the VHC
and the emitted FPF, for each valve type group.
• Similarly, logarithmic correlations were found between the Throat mass deposited (nor-
malised by the TEM) and the volume of air drawn, for each valve design.
• Some degree of linear correlation was found between the FPM and the oropharyngeal
deposition, for each valve type.
• Limitations were found in the evaluation of the different metrics, due to the CI apparatus
(i.e. MSLI) poor resolution.
9.1.2 Numerical
The numerical work consisted in the modelling of the pMDI spray using CFD tools (i.e. FLUENT).
The model predicted the drug deposition in the VHC device and in the USP Induction Port surfaces.
Several models for particle-wall interaction were tested and compared against literature and
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experimental data. The most important conclusions can be summarised:
• The highest air flow velocities are found in the VHC regions of greater geometric constraint
(i.e. valve opening). The Nebuchamber geometry induced the highest velocity (≈37 m/s),
while the lowest was found for the both Space Chamber devices (≈22 m/s).
• The air flow pattern inside the VHC shows the formation of large recirculation regions, near
the walls.
• The Nebuchamber mouthpiece design places the valve centre radially misaligned with the
USP IP. This leads to a non-symmetric airflow in the upper portion of the throat.
• Air flow pattern downstream of the valve is more uniform for open-centre valve designs,
rather than for the other valve types. The latter favour the appearance of recirculation
regions.
• Evaporation of the propellant rapidly increases during the spray injection; afterwards it exits
the VHC at a rate that is related to the device volume. Whereas, the Volumatic (with highest
volume VHC) retains the HFA for a longer time period.
• The drug deposition predictions showed that the A2A Spacer geometry emitted the highest
amount of drug, and that Nebuchamber had the lowest throat mass deposition. All simulated
VHC geometries highly reduced the throat drug deposition.
• Validation of the numerical results with literature and experimental data have shown that
the best wall-particle interaction model to be used in the USP throat surfaces is the one
that considers that entrapment is only applied to liquid droplets, or to solid particles if the
wall normal velocity is lower than the particle critical velocity. However, it is important to
mention that this model underestimates the deposition of small particles.
• The validation of drug deposition with the experimental data, showed large differences
in the drug deposition on some VHCs, namely the Volumatic, the A2A Spacer and the
Nebuchamber. This may indicate that the wall-particle collision model used for the USP
throat is not adequate for the VHC surfaces, as additional forces, such as the electrostatic
attraction, are not taken into consideration.
• The numerical results for the drug deposited in the throat and the emitted Sizable Mass differ
from the experimental data. This outcome may be the result of the inaccurate predictions
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of deposition on the VHC walls.
• A new design with ennhanced features was proposed considering its portability and its
efficiency. The feature that most contribute to the increase of efficiency is the addition of
two modular parts pieces to increase the volume. This higher volume allows the device to
be used by patients with higher tidal volumes, which means that it can be used by a wider
age range.
9.2 Future Work
There is an ample room for improving the work developed herein this thesis, both in experimental
assessment and numerical simulation.
9.2.1 Experimental
A more comprehensive set of experimental tests could be performed upon the VHCs and pMDI
spray. These additional analyses should include:
• Use of a NGI apparatus to improve the accuracy of the experimental data.
• Evaluate all VHC devices under variable flow different breathing patterns (covering a range
of different ages and pathologies).
• Test the effect of the delay between the actuation and the inhalation, and the actuation
during exhalation phase.
• Evaluate the spray plume inside the VHCs using PIV technique and/or LDA.
• Measure the spray plume size distribution near the nozzle.
9.2.2 Numerical
The numerical model could benefit from improved input parameters and mathematical models, as
well as, an extensive sensibility analysis to some parameters. Some examples of improvements to
the numerical simulations include:
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• The introduction of coalescence phenomena between the droplets.
• The introduction of an anisotropic correction near the wall in the turbulent dispersion for
the DPM.
• Performing a sensitivity analysis to study the influence of the particle-wall model rebound
coefficient in the drug deposition results.
• The addition of the effect of the electrostatic attraction to the particle body force balance.
• Modelling multi-component droplets, composed by two materials, solid API and liquid
propellant.
• Study the influence of water vapour concentration (i.e. relative humidity) and temperature
in the propellant evaporation and, subsequently, the plume size distribution.
• The simulation of transient air flow breathing patterns and spray injection in different
moments.
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A Axillary Experimental Measurements
A.1 Rotameter Validation
Two of the flowmeters used in this study are rotameters (D10A11 from ABB, Switzerland), whose
reading is on a percentage scale. This is converted to the desired flow units giving a known
value for the 100% mark, since flow increases linearly with the marks in the scale. This is due
to the fact that the pressure drop along the rotameter tube is constant, independent of the float
position. As the float rises (due to the flow rate increment), the tube cross-section area enlarges,
to accommodate a constant pressure drop. The rotameter needs to be vertically positioned to
properly work. In addition, the temperature, fluid viscosity, humidity and pressure, play a very
important part in the real flow rate measured. Therefore it is necessary to control/quantify these
variables during calibration process.
Hence it becomes necessary to know accurately the value of air flow rate that corresponds to the
readings on the percentage scale. Although there are several methods to accomplish this objective,
three methodologies where used:
Method 1 – Static pressure measurement at a bell mouth entrance;
Method 2 – Integration of the flow velocity profile measured by Laser Doppler Anemometry (LDA);
Method 3 – Direct comparison with a calibrated digital flowmeter.
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A.1.1 Method 1
This method comprises the attachment of a bell mouth of elliptical shape, upstream of the rotameter
that is going to be assessed. Between them it is advisable to include a straight section to develop
the flow. The rotameter was then coupled to a vacuum system constituted by two pumps (GS-6
from General Europe Vacuum, Italy). A ball valve allowed the pressure drop regulation, controlling
the flow rate through the rotameter. The static pressure was measured at the throat of the bell
mouth, by means of a digital manometer (Series HM28 from Love Controls, USA). A schematic
representation of the experimental setup can be found in Figure A.1.
ΔP
ON OFF
Ball Valve
Vacuum Pump
Digital Manometer
Acrylic tube
Eliptical Nozzle
Rotameter
Figure A.1: Schematic representation of the setup used for calibration of the rotameter using
method 1
The air entering the elliptical nozzle would smoothly accelerate from a velocity close to 0 m/s
to a maximum value. At the bell mouth throat ( = 15 mm) a pressure taping enables the
static pressure measurement that, when subtracted to the pressure at the nozzle entrance (i.e.
atmospheric pressure), can be related to the fluid theoretical average velocity by Bernoulli modified
Equation A.1. Finally, multiplying the velocity by the section area, the fluid flow rate is obtained.
U =
√
2×∆P
ρ
(A.1)
ρ was assumed to be 1.205 kg/m3
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The position of the float inside the rotameter, was controlled to provide readings every 10% of the
scale. The results are listed in Table A.1 along with the calculated theoretical flow rates.
Table A.1: Experimental pressure drop values obtained (uncertainty within three measurements),
along with the calculated flow rate values, using method 1
Rotameter Scale (%)
Rotameter 1 Rotameter 2
∆P3 - Pressure
Drop (Pa)
Flowrate
(L/min)
∆P3 - Pressure
Drop (Pa)
Flowrate
(L/min)
10 0.(7) ± 0.3 11.(0) ± 2.0 0.(8) ± 0.3 12.(3) ± 2.0
20 2.(2) ± 0.3 20.(1) ± 1.1 2.(0) ± 0.0 19.(3) ± 0.0
30 5.(3) ± 0.5 31.(5) ± 1.5 5.(0) ± 0.0 30.(5) ± 0.0
40 9.(2) ± 0.3 41.(4) ± 0.6 8.(8) ± 0.3 40.(6) ± 0.6
50 14.(3) ± 0.5 51.(7) ± 0.9 13.(7) ± 0.3 50.(5) ± 0.5
60 20.(2) ± 0.3 61.(3) ± 0.4 19.(7) ± 0.5 60.(6) ± 0.8
70 27.(5) ± 0.5 71.(6) ± 0.7 26.(7) ± 0.8 70.(5) ± 1.0
80 35.(5) ± 0.0 81.(4) ± 0.0 34.(5) ± 1.0 80.(2) ± 1.2
90 44.(8) ± 0.3 91.(5) ± 0.3 44.(5) ± 0.0 91.(1) ± 0.0
100 54.(5) ± 0.0 100.(8) ± 0.0 54.(8) ± 0.3 101.(2) ± 0.2
( ) - uncertain digit
∆P3 - averaged pressure drop of three measurements
A.1.2 Method 2
In the following methodology a LDA technique was applied to measure the velocity profile. This
technique allowed the measurement of the velocity of seeding particles velocity, which followed
the air flow inside of an acrylic tube ( = 22 mm). The probe was connected to a Burst Spectrum
Analyser (BSA) unit that controlled the laser beams characteristics and processed the signal
obtained through the detectors. A filter and drain were connected downstream of the acrylic
tube for collection of the seeding particles. The latter connected to the entrance of the rotameter,
and this one to the vacuum system along the ball valve. Figure A.2 depicts the layout of the
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experimental components in the experimental setup.
A nebulizer provided the system with a seeded flow. A compressed air source from the laboratory
grid atomises an aqueous solution of droplets and 2.2 µm polystyrene latex calibrated particles
(Coulter Electronics, UK).
Ball Valve
Vacuum Pump
Data Processing Unit
(BSA)
Acrylic tube
Compressed
Air Source
Rotameter
L
D
A
P
ro
b
e
Filter and
Manual Drain
Black Paint
CoatingNebulizer
Figure A.2: Schematic representation of the setup used for calibration of the rotameter using
method 2
The transparent acrylic tube had one side coated with a black extra matte paint (Cináqua from CIN,
Portugal) to reduce laser reflections that would interfere in the data acquisition. The rotameter float
was positioned at 100% of the scale and the several measurements were made along a diameter
of the acrylic tube.
Initially the measurement volume was placed at the outer wall of the tube, and then displaced a
pre-calculated distance through the wall. This value depends on the thickness of the tube, due to
the fact that light scatter differently in different mediums, the passage from air to acrylic, change
the laser beams angle resulting in a different point of intersection (see Figure A.3). The procedure
started by placing the laser beams intersection (control volume) in the tube outer wall, at the half
height of the tube diameter, and setting this position as zero axial displacement. At this position
the values of h2 and h3 are zero, no α2 neither α3 are present. The value of h0 is half of the
beam spacing (Sb = 38.4 mm), and the length, on the optical axis, between the intersection and
the lens is the focal length (FL = 161.1 mm).
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h2
h0
h1
h3
da xi
α1
α2
α3
AcrylicAir Air
Figure A.3: Schematic representation of the laser beam crossing the different media
The angle between the beams is calculated by Equation A.2. The value of α1 is half of the beams
angle (α0).
α0 = 2× arctan
(
Sb
2× FL
)
(A.2)
The second scenario is the intersection of the laser beams in the inner wall of the acrylic tube
(with thickness, da = 4 mm). As can be seen in Figure A.3 by the dotted lines, the beams were
supposed to intersect in a certain position, however due to the acrylic medium distinct refractive
index, the intersection occurs in a shorter distance. It is necessary to use Snell’s law to calculate
the angle of the intersecting beams inside the acrylic medium (αair) Equation A.3.
α2 = arcsin(
nair × sin(α1)
nacrylic
) (A.3)
Considering:
nair = 1.0 (refractive index of the air)
nacrylic = 1.491 (refractive index of the acrylic)
In this case the value of h2 can be assessed through simple trigonometric calculation Equation A.4.
h2 = da × tan(α2) (A.4)
Since h0 is the sum of h1 and h2, the value can be easily calculated. Hence, the distance from
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the lens to the outer wall (xi) of the tube is given by Equation A.5.
xi =
h1
tan(α1)
=
h0 − h2
tan(α1)
=
(Sb/2)− (da × tan(α2))
tan(α1)
(A.5)
Summarising, the distance from the lens to the probe volume when in air (FL) is known, however
given the fact that the beams crossed 4 mm of acrylic wall, xi gives the actual distance from the
tube to the lens. By subtracting one to the other (see Equation A.6), it results in the real distance
(dr = 2.672 mm) travelled for the beams to cross 4 mm of acrylic.
dr = FL − xi (A.6)
Once this displacement was applied to the probe, one was sure that the measurement volume
ii located at the inner wall of the acrylic tube and it is ready to acquire the velocity data. By
giving increments in the probe axial movement, the velocity profile along the tube section could be
measured. At each location 2,000 data points were collected to retrieve the local average velocity.
The results along with the error is shown in Figure A.4. By integrating the experimental data the
flow rate can easily be determined. In the Figure A.4 legend the values of the flow rate at 100%
rotameter scale, are shown.
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Figure A.4: Averaged velocity profiles inside of the  = 22 mm tube for both rotameters, error is
represented in the form of bars. The values for the calculated flow rate are shown in the legend
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A.1.3 Method 3
In this methodology the rotameters were evaluated by direct comparison with a pre-calibrated
mass flowmeter (Model 4043 from TSI, USA), placed just upstream of the rotameter inlet (see
Figure A.5). The float height was set, in 10% intervals, with the help of the ball valve.
60.0 L/min
Ball Valve
Vacuum Pump
Mass Flowmeter
Rotameter
Figure A.5: Schematic representation of the setup used for calibration of the rotameter using
method 3
The results are presented in the Table A.2. The values estimated for the calibration of the
rotameters, obtained through the three methodologies previously presented, are not the same
since each methodology rely upon some degree of experimental uncertainty added by: orthogonally
misalignments, reading uncertainties, addition of dead volume to the setup, flow friction within the
bell mouth. The most accurate comparison is obtained by method 3, and since the mass flowmeter
was recently calibrated and it accounts for temperature and pressure corrections. Furthermore it
would be used along with the rotameters in the pharmacological experimental setup.
In Figure A.6 the calibration results at 100% scale for both rotameters, is shown for the three
methods. If the method 3 is considered the most accurate, the methodology 1 overestimates the
flow rate while the method 2 underestimates it. The difference observed with method 2 (LDA) may
be due to difficulties in guaranteeing a correct positioning of the probe volume inside the pipe
section and beam reflections from the pipe walls. Method 1 might overestimate the flow rate due
to the fact that friction in the bell mouth wall was not accounted for.
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Table A.2: Mass flowmeter values measured according to method 3, along with the associated
error
Rotameter (%) Rotameter 1 Rotameter 2
10 7.1(7) ± 0.05 8.3(0) ± 0.15
20 18.9(0) ± 0.35 19.0(7) ± 0.35
30 28.9(3) ± 0.20 28.7(3) ± 0.20
40 38.4(8) ± 0.30 38.1(7) ± 0.05
50 48.6(0) ± 0.10 47.7(0) ± 0.10
60 58.5(7) ±0.30 57.6(0) ± 0.10
70 68.9(3) ± 0.30 67.4(3) ± 0.35
80 78.9(7) ± 0.10 77.9(0) ± 0.10
90 88.8(0) ± 0.30 88.1(7) ± 0.15
100 99.0(0) ± 0.65 98.9(0) ± 0.10
( ) - uncertain digit
averaged values from three measurements
values units in L/min
Method 1 Method 2 Method 3
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Figure A.6: Comparison the results for both rotameters calibration, at 100% scale, by three methods
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A.2 Paper Filter Evaluation
Upon the fact that no standard type neither specifications are given by the Pharmacopoeia for the
correct paper filter to be used in the MSLI, studies were carried out to evaluate the most adequate.
The three factors evaluated were:
• the amount of absorbance (considered contamination) produces;
• pressure drop versus flow rate curve (specifically at 30 and 60 L/min);
• the possible loss of drug caused by the filter porosity.
The first point was evaluated by putting a sample of each paper filter, with = 38 mm, in a 20 mL
solution of 0.01M NaOH and under 10 min of sonic shaking. The absorbance was then evaluated
by UV-Vis spectroscopy at 244 nm of wavelength (was described in section 5.2.1), results are
shown in Table A.3.
Table A.3: Evaluated characteristics of the possible paper filters for use in the MSLI
Filter Name
Particle
Retention [µm]
Absorbance Peak
at 244 nmb
Pressure drop at
60 L/min [Pa]
Total Collected
Mass (mg)e
MN 617c 7.0-12.0 0.08 3.1 1.23 ± 0.03a
MN 619c 2.0-4.0 0.02 37.7 1.23 ± 0.03a
MN 1674c 2.0-4.0 0.04 58.6f 1.25 ± 0.02a
MN GF-1c 0.7 0.20 6.1 -
GE GF-6d 1.0 0.06 11.8 -
GE 934-AHd 1.5 0.22 5.7 -
a ANOVA test shows that are not statistically significant difference between the means (p > 0.05)
b In a solution volume of 50 mL, the same used throughout the experiments
c MN stands for Macherey-Nagel, Germany
d GE stands for GE Healthcare, UK
e Tests were done at 30 L/min using a full dose setup (N=7)
f Data obtained at 54 L/min
The pressure drop produced by each paper filter for a certain flow rate is directly related to its
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porosity. This evaluation was carried out using the a setup (see Figure A.7) that was composed by
a mass flowmeter (which allowed the measurement of the flow rate and pressure) placed at the
inlet port of a filter casing and a negative pressure manometer (PN7009, IFM from UK) placed at
the opposite side. A vacuum system extracted the air flow that passed through the filter and was
regulated by a ball valve placed at a T-junction branch. This setup allowed the variation of the flow
rate and reading of pressure before and after the filter. Results are presented in Figure A.8 in the
form of curves relating the pressure drop with the flow rate.
- L/min
Manometer
Ball Valve
Vacuum Pump
Mass Flowmeter
Filter Casing
Figure A.7: Schematic of the setup for measuring the pressure drop caused by different paper
filters
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Figure A.8: Pressure drop versus flow rate characteristic curves for several paper filter types
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Upon the evaluation of the results, the MN 619 filter was selected for carrying out the experimental
tests within the MSLI, as it provided a lowest contamination, low drug loss and reasonable pressure
drop when compared to the other filters.
A.3 High-speed Camera Setup
The spray plume inside the VHC was analysed by means of a high-speed camera. The setup,
depicted in Figure A.9, was composed by a vacuum pump (GS-6 from General Europe Vacuum,
Italy) and a ball valve for flow regulation, connected to a digital mass flowmeter (Model 4043 from
TSI, USA). This was connected to a filter (for drug collection), and to the VHC device tested. The
high-speed camera (FASTCAM APX RS from Photron, USA) with a lens (50 mm 1:2.8 DG Macro
D from Sigma, Japan), was positioned at 90 degrees to the VHC centreline and parallel to the
ground plane, allowed the capture of events at a rate of 3000 frames per second. Two 1 kW lamps
were added to the setup, positioned perpendicular to both the VHC and high-speed camera axis,
to provide enough light for the acquisition of the photos at such high rates.
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Figure A.9: High-speed photographic data acquisition setup
Results are presented in Table A.4, whereas it is also included the pMDI solo into stagnant room
air. In order to enhance the visualisation, the gray-scale curve was manipulated for all pictures.
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Table A.4: Selected frames obtained, using high–speed camera photography, during the plume
release, for the pMDI solo and coupled to the A2A Spacer, Compact Space Chamber and Space
Chamber
A2A CSC SC pMDI
t=0.00s
t=0.02s
t=0.04s
t=0.06s
t=0.08s
t=0.10s
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A.4. Valve Openning Cross-section Setup
The assessment was made for three VHC (A2A Spacer, SpaceChamber and Compact SpaceCham-
ber) at 30 L/min as the experiment could only be conducted in transparent devices. The necessary
use of the lighting sources, lead to reflections in the devices curved surfaces, which tainted the
data. After the removal of the electrostatic coating of the devices (i.e. bath in anionic soapy water
followed by 24 h drying), around one third of the bottom interior surface of the VHC inner surface
was covered with black tape to avoid reflections.
A.4 Valve Openning Cross-section Setup
This experimental setup consisted in placing a photographic camera with its optical axis aligned
with the VHC valve centreline. This allowed the capture of photographs of the VHC valve opening
cross-section, with a minimum of optical distortion, for two flow rates (i.e. 30 L/min and 60
L/min). The VHC mouthpiece was connected to a mass flowmeter (Model 4043 from TSI, USA)
and subsequently to the vacuum system made up by one pump (GS-6 from General Europe
Vacuum, Italy). The flow rate was regulated by a ball valve placed at a junction between the
flowmeter and the vacuum system. The setup schematic can be found in Figure A.10. A total of
six devices were assessed in this apparatus, each one with a distinct type of valve.
- L/min
Camera
Vaccum
system
Ball valve
Mass
FlowmeterVHC
Valve
Figure A.10: Schematic representation of the experimental setup used for acquiring photographs
of the valve opening shape at different flow rates
The images allowed the estimation of the shape of the cross-section shape and its area (important
information for drawing the computational simulation models). Some of the VHC devices did not
allowed the cross-section estimation due to the type of valve aperture being perpendicular to the
optical axis, whereas the mouthpiece geometry did not allow for a clean shot (see Table A.5).
237
Appendix A. Axillary Experimental Measurements
The information for those that were possible to be estimated, using an image measurement
open-source software (ImageJ developed by Wayne Rasband), is given in Table A.6.
Table A.5: Photographic results of the VHC device’s valves opening at different flow rates
Device 0 L/min 30 L/min 60 L/min
A2A
CSC
OCD
NC
V
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Table A.6: Valve cross-section area and dimensions estimated from the photographs at 30 L/min
and 60 L/min, for some VHC devices
VHC Device Schematic 30 L/min 60 L/min
V L
L = 3.19 mm
Area = 28.48 mm2
L = 6.12 mm
Area = 54.75 mm2
NC L
L = 3.44 mm
Area = 24.81 mm2
L = 4.87 mm
Area = 33.62 mm2
OCD L
L = 1.38 mm
Area = 9.51 mm2
L = 3.33 mm
Area = 27.02 mm2
CSC L
L = 2.73 mm
Area = 42.44 mm2
L = 3.33 mm
Area = 53.92 mm2
A2A L
L = 3.66 mm
Area = 22.17 mm2
L = 4.91 mm
Area = 41.90 mm2
A.5 Leakage test Setup
The valve leakage in each VHC was evaluated through three different tests, as represented
schematically in Figure A.11. Setup (a) consisted in the insufflation of compressed air at a
constant flow rate directly onto the VHC valves. Whereas the inhalation valve should fully close
not allowing air to escape into the VHC body, devices with an exhalation valve provide a more
efficient exhaustion route for the air. The mass flowmeter (Model 4043 from TSI, USA), placed
at the device’s pMDI adapter, registered the amount of air passing through the inhalation valve
due to leakage. Configuration (b) enables the evaluation of the flow rate passing through the VHC
adapter, for a constant flow rate calibrated at the device’s mouthpiece. The difference results from
leakages between the device’s modules; the exhalation valve; or other secondary flow passing
through devices adapter / whistle. Finally, setup (c) provides a more realistic evaluation of the
valves operation when presented with a patient breath waveform. Differences between the original
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waveform and those registered at the device’s adapter are related with the leakages evaluated at
the previous setups (a) and (b).
- L/min
Flowmeter VHC
(c)
(b)
(a)
Flow
regulator
Pressure
Regulator
Compressed
air
Vaccum
System
Breath
Machine
Figure A.11: VHC leakage evaluation setup: (a) with positive pressure; (b) with negative pressure
and (c) with a breath profile
The results obtained from the three different tests are detailed in Table A.7 and Figures A.12
and A.13. The test using setup (a) was carried out at 30 L/min and 60 L/min and identifies the
occurrence of leakage during the closure of the inhalation valve. The results point out that upon
air insufflation, against the VHC valve, some have more leakage than others, with the Coin type
(Volumatic) showing the worst performance (with a leakage of ≈36% of the insufflated flow). As
expected, leakage increases with flow rate. Leaflets valves such as those present in the Space
Chamber series (i.e. CSC and SC), show the best performance with virtually no leakages. However,
the Leaflets valve type show good results, the same is not verified with the model present in
A2A Spacer, which has a considerable leakage at 30 L/min (worse results could be expected for
60 L/min). The Annulus Flap type valves show a very good performance with minimal leakage,
followed by the Duck valves.
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Table A.7: Experimental results for the leakage tests: (a) and (b), for all the VHC devices
(a) - insufflation (b) - suction
Valve type Device 30 L/min 60 L/min 30 L/min 60 L/min
Annulus Flap AC 0.0(4) 0.0(8) 23.6(0) 55.8(0)
Coin VOL 10.9(0) 22.9(0) 13.9(0) 28.8(0)
Duck NC 1.2(0) 1.8(0) 18.9(0) 45.6(0)
Duck OCD 0.5(8) 0.7(1) 20.7(5) 48.1(0)
Duck V 0.0(1) 0.0(2) 26.0(0) 49.0(0)
Leaflets A2A 3.2(0) n.p. 12.6(0) 31.2(0)
Leaflets CSC 0.0(0) 0.0(1) 27.0(0) 56.7(0)
Leaflets SC 0.0(0) 0.0(0) 27.5(0) 57.2(0)
( ) - uncertain digit
n.p. - not possible to execute, the valve anchor was not strong enough to handle the flow pressure and detached from the device’s body
Unit in L/min
The setup (b) tests were performed by extracting a constant 30 L/min and 60 L/min flow rate.
The results point out that some leakage can be found in all devices. As some of them do not
possess an exhalation valve, opening vents provide the exhaust during the exhalation phase.
This leads to a secondary flow of air entering the mouthpiece that reduces the flow rate passing
through the device’s body. The existence of such valveless vents can be found in A2A Spacer
and Volumatic. Hence, the worst leakage results are found for A2A Spacer (≈45% of the suction
flow) and Volumatic (≈47% of the suction flow). The best results are found for the SpaceChamber
(≈91% of the suction flow) series and Aerochamber (≈80%of the suction flow). The Vortex shows
a good performance, with low leakage, as approximately 90% of the flow passing through the
device’s body. However, the Nebuchamber and Optichamber (both with the same valve type as
Vortex) present a performance of ≈70% of the suction flow. Results of the setup (c), depicted in
Figures A.12 and A.13, point out a more realistic influence of the flow in the valves and potential
leakages in the devices.
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Figure A.12: Leakage results from the inhalation phase, using the setup (c), performed on the
VHC devices in comparison with the input breath waveform
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Figure A.13: Leakage results from the exhalation phase, using the setup (c), performed on the
VHC devices in comparison with the input breath waveform
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The tests were carried out with the mass flowmeter connected to the pMDI adapter of each
VHC device, and keeping the secondary vents open (i.e. whistle, vortex channels and exhalation
vents). The results show that the inhalation leakage ranked as: Aerochamber (has a whistle)
> Volumatic (has exhalation vents) > A2A Spacer (has exhalation vents) > Optichamber (has a
whistle) > Nebuchamber > Vortex (has helicoidal vents at the adapter)> Compact Space Chamber.
The exhalation results show that only Volumatic has a considerable high leakage. Nebuchamber,
Optichamber, Aerochamber and Vortex present a minor leakage during exhalation phase.
243
This page was intentionally left in blank
244
B Drug Assessment Raw Data
245
Appendix B. Drug Assessment Raw Data
Ta
bl
e
B.
1:
Ex
pe
rim
en
ta
ls
al
bu
ta
m
ol
su
lp
ha
te
m
as
s
co
lle
ct
ed
in
Fu
ll
Do
se
se
tu
p
at
a
co
ns
ta
nt
flo
w
ra
te
of
30
L/
m
in
D
ev
ic
es
Ac
tu
at
or
VH
C
Fi
lte
r
C
as
in
g
Fi
lte
r
M
D
Is
ol
o
(N
=2
)
12
.5
0±
1.
50
-
54
.2
5±
3.
05
57
.0
0±
2.
70
A2
A
Sp
ac
er
(N
=8
)
13
.2
0±
1.
79
76
.2
6±
6.
56
3.
12
±0
.8
7
30
.2
5±
7.
92
Ae
ro
C
ha
m
be
r
(N
=5
)
12
.0
2±
1.
19
61
.6
9±
6.
44
2.
95
±0
.6
0
41
.2
8±
8.
59
C
om
pa
ct
Sp
ac
eC
ha
m
be
r
(N
=8
)
14
.4
7±
3.
12
72
.4
1±
3.
71
3.
81
±0
.6
6
31
.4
5±
5.
10
N
eb
uc
ha
m
be
r
(N
=6
)
12
.8
2±
1.
93
65
.7
6±
8.
87
6.
22
±1
.4
8
35
.1
2±
12
.8
8
O
pt
ic
ha
m
be
r
(N
=4
)
12
.2
4±
0.
95
70
.2
1±
3.
45
6.
05
±1
.2
0
38
.3
4±
9.
35
Sp
ac
eC
ha
m
be
r
(N
=6
)
13
.4
8±
1.
96
67
.2
7±
6.
53
3.
52
±1
.1
4
35
.7
1±
9.
25
Vo
rt
ex
(N
=4
)
11
.8
4±
0.
88
52
.3
5±
4.
60
5.
09
±0
.7
8
49
.0
8±
5.
98
Vo
lu
m
at
ic
(N
=6
)
12
.2
0±
2.
60
68
.9
8±
15
.8
4
4.
47
±0
.6
8
38
.2
4±
14
.2
5
Ta
bl
e
B.
2:
Ex
pe
rim
en
ta
ls
al
bu
ta
m
ol
su
lp
ha
te
m
as
s
co
lle
ct
ed
in
Fu
ll
Do
se
se
tu
p
at
a
va
ria
bl
e
flo
w
ra
te
D
ev
ic
es
Ac
tu
at
or
VH
C
Fi
lte
r
C
as
in
g
Fi
lte
r
M
D
Is
ol
o
-
-
-
-
A2
A
Sp
ac
er
(N
=5
)
25
.8
9±
1.
46
77
.3
3±
7.
76
1.
75
±0
.8
5
8.
27
±3
.8
4
Ae
ro
C
ha
m
be
r
(N
=3
)
23
.0
8±
1.
80
73
.0
0±
6.
27
2.
53
±1
.2
0
17
.2
3±
0.
52
C
om
pa
ct
Sp
ac
eC
ha
m
be
r
(N
=5
)
20
.6
8±
1.
12
76
.2
4±
4.
46
2.
79
±1
.2
3
16
.6
3±
3.
17
N
eb
uc
ha
m
be
r
(N
=4
)
24
.0
1±
3.
70
68
.6
0±
7.
85
4.
72
±0
.3
0
15
.1
4±
1.
42
O
pt
ic
ha
m
be
r
(N
=6
)
19
.3
4±
2.
66
73
.9
2±
6.
05
3.
36
±0
.8
8
17
.3
7±
1.
89
Sp
ac
eC
ha
m
be
r
(N
=4
)
19
.7
1±
2.
45
75
.5
4±
4.
40
3.
09
±0
.7
2
19
.6
9±
2.
75
Vo
rt
ex
(N
=5
)
21
.6
6±
1.
31
79
.8
3±
10
.6
0
4.
36
±1
.7
0
15
.8
9±
4.
00
Vo
lu
m
at
ic
(N
=5
)
21
.0
3±
3.
21
77
.2
9±
8.
85
2.
01
±0
.4
3
9.
26
±2
.8
3
246
Ta
bl
e
B.
3:
Ex
pe
rim
en
ta
ls
al
bu
ta
m
ol
su
lp
ha
te
m
as
s
co
lle
ct
ed
in
M
SL
Is
et
up
at
a
co
ns
ta
nt
flo
w
ra
te
of
30
L/
m
in
D
ev
ic
es
Ac
tu
at
or
VH
C
Th
ro
at
M
ix
er
St
ag
e
1
St
ag
e
2
St
ag
e
3
St
ag
e
4
St
ag
e
5
(F
ilt
er
)
M
D
Is
ol
o
(N
=6
)
13
.2
2±
0.
72
-
55
.3
5±
4.
98
-
4.
96
±0
.7
4
2.
62
±0
.7
1
5.
78
±0
.4
9
7.
40
±1
.0
7
17
.3
4±
1.
99
A2
A
Sp
ac
er
(N
=5
)
10
.6
9±
0.
50
57
.8
4±
8.
49
4.
55
±0
.8
4
-
2.
34
±0
.9
0
2.
18
±0
.7
7
4.
67
±0
.7
8
6.
18
±1
.7
2
18
.5
0±
3.
79
Ae
ro
C
ha
m
be
r
(N
=6
)
12
.0
1±
1.
39
55
.2
3±
5.
32
5.
99
±0
.5
8
-
2.
63
±0
.8
9
2.
50
±0
.6
4
5.
53
±0
.8
1
8.
88
±1
.5
9
20
.2
1±
3.
65
C
om
pa
ct
Sp
ac
eC
ha
m
be
r
(N
=7
)
12
.2
6±
1.
46
56
.5
6±
5.
30
4.
41
±0
.8
5
-
2.
36
±0
.5
5
2.
45
±0
.5
6
5.
02
±0
.8
1
7.1
9±
1.
97
19
.4
9±
2.
79
N
eb
uc
ha
m
be
r
(N
=5
)
12
.3
4±
2.
32
53
.5
8±
4.
25
10
.0
4±
0.
83
-
1.
59
±0
.3
0
1.
71
±0
.6
3
4.
11
±0
.4
8
6.
85
±1
.0
5
18
.9
5±
1.
29
O
pt
ic
ha
m
be
r
(N
=5
)
11
.6
8±
0.
51
61
.9
4±
3.
54
9.
66
±0
.1
5
-
3.
45
±0
.5
8
2.
18
±0
.6
8
4.
24
±0
.5
4
4.
64
±2
.5
5
15
.5
5±
2.
18
Sp
ac
eC
ha
m
be
r
(N
=6
)
12
.1
3±
1.
46
50
.3
5±
7.
94
4.
58
±0
.9
4
-
2.
94
±0
.8
2
2.
16
±0
.5
1
5.
42
±1
.1
5
8.
58
±3
.2
1
20
.2
8±
5.
82
Vo
rt
ex
(N
=5
)
11
.4
3±
1.
45
49
.7
9±
3.
46
9.
16
±1
.2
7
-
2.
48
±0
.6
7
1.
86
±0
.4
7
5.
26
±0
.8
9
8.
04
±0
.9
8
19
.7
4±
2.
47
Vo
lu
m
at
ic
(N
=6
)
10
.0
9±
0.
80
50
.5
4±
9.
60
2.
95
±0
.4
6
-
2.
75
±0
.8
2
2.
90
±1
.2
0
5.
73
±0
.6
9
8.
62
±1
.8
2
23
.4
7±
6.
60
Ta
bl
e
B.
4:
Ex
pe
rim
en
ta
ls
al
bu
ta
m
ol
su
lp
ha
te
m
as
s
co
lle
ct
ed
in
M
SL
Is
et
up
at
a
co
ns
ta
nt
flo
w
ra
te
of
60
L/
m
in
D
ev
ic
es
Ac
tu
at
or
VH
C
Th
ro
at
M
ix
er
St
ag
e
1
St
ag
e
2
St
ag
e
3
St
ag
e
4
St
ag
e
5
(F
ilt
er
)
M
D
Is
ol
o
(N
=6
)
11
.5
2±
0.
71
-
45
.4
8±
2.
75
-
6.
10
±0
.8
9
5.
08
±0
.5
3
11
.7
9±
1.
19
8.
93
±1
.3
2
15
.2
6±
1.
79
A2
A
Sp
ac
er
(N
=8
)
10
.1
1±
1.
07
47
.7
6±
3.
78
4.
89
±0
.6
7
-
1.
93
±0
.5
6
2.
48
±0
.4
3
9.
39
±0
.8
9
9.
16
±1
.3
1
15
.2
5±
1.
85
Ae
ro
C
ha
m
be
r
(N
=7
)
10
.3
3±
0.
51
38
.0
5±
3.
20
7.
02
±0
.6
1
-
2.
22
±0
.2
2
3.
37
±0
.2
7
13
.2
9±
0.
82
13
.8
1±
1.
05
19
.2
2±
1.
12
C
om
pa
ct
Sp
ac
eC
ha
m
be
r
(N
=8
)
9.
51
±0
.6
9
41
.6
0±
3.
23
5.
37
±0
.5
4
-
2.
63
±0
.6
9
3.
18
±0
.1
6
12
.2
9±
1.
19
12
.0
4±
1.
60
17
.3
4±
2.
15
N
eb
uc
ha
m
be
r
(N
=6
)
9.
76
±1
.4
6
35
.4
9±
1.
67
15
.9
5±
1.
03
-
1.
44
±0
.2
2
2.
20
±0
.1
8
10
.1
7±
0.
58
11
.3
3±
0.
81
17
.2
5±
1.
08
O
pt
ic
ha
m
be
r
(N
=6
)
10
.1
4±
1.
05
41
.9
3±
2.
31
12
.7
3±
1.
16
-
2.
50
±0
.4
7
2.
71
±0
.1
7
10
.0
0±
0.
86
10
.2
3±
0.
98
15
.5
5±
1.
89
Sp
ac
eC
ha
m
be
r
(N
=6
)
11
.0
2±
0.
64
37
.7
9±
2.
53
5.
40
±0
.3
3
-
2.
43
±0
.4
4
3.
49
±0
.4
7
12
.7
0±
1.
25
12
.7
6±
1.
34
18
.2
6±
1.
28
Vo
rt
ex
(N
=8
)
10
.4
1±
0.
83
26
.3
8±
2.
70
12
.5
3±
0.
88
-
2.
40
±0
.4
0
3.
40
±0
.2
7
13
.6
0±
0.
91
13
.7
0±
0.
87
18
.9
7±
1.
87
Vo
lu
m
at
ic
(N
=6
)
9.
95
±0
.8
1
50
.2
1±
4.
53
2.
76
±0
.1
6
-
1.
47
±0
.2
2
2.
46
±0
.2
9
11
.3
1±
1.
02
12
.6
1±
1.
03
18
.9
6±
1.
48
247
Appendix B. Drug Assessment Raw Data
Ta
bl
e
B.
5:
Ex
pe
rim
en
ta
ls
al
bu
ta
m
ol
su
lp
ha
te
m
as
s
co
lle
ct
ed
in
M
SL
Is
et
up
at
a
va
ria
bl
e
flo
w
ra
te
D
ev
ic
es
Ac
tu
at
or
VH
C
Th
ro
at
M
ix
er
St
ag
e
1
St
ag
e
2
St
ag
e
3
St
ag
e
4
St
ag
e
5
(F
ilt
er
)
M
D
Is
ol
o
(N
=6
)
18
.2
5±
2.
39
-
54
.1
0±
3.
48
0.
13
±0
.0
0
2.
21
±0
.4
3
1.
94
±0
.0
9
7.
73
±0
.1
0
6.
37
±0
.2
1
12
.8
8±
0.
48
A2
A
Sp
ac
er
-
-
-
-
-
-
-
-
-
Ae
ro
C
ha
m
be
r
(N
=7
)
17
.0
1±
2.
48
69
.7
8±
6.
05
6.
09
±0
.7
2
0.
21
±0
.0
0
0.
46
±0
.1
6
0.
85
±0
.2
5
4.
49
±1
.3
9
3.
85
±1
.5
4
7.
39
±2
.0
8
C
om
pa
ct
Sp
ac
eC
ha
m
be
r
(N
=7
)
14
.3
4±
1.
52
74
.2
0±
4.
40
5.
59
±0
.7
5
0.
38
±0
.0
0
0.
80
±0
.1
0
1.
07
±0
.1
8
5.
12
±0
.7
5
4.
27
±0
.8
5
8.
34
±1
.1
0
N
eb
uc
ha
m
be
r
-
-
-
-
-
-
-
-
-
O
pt
ic
ha
m
be
r
-
-
-
-
-
-
-
-
-
Sp
ac
eC
ha
m
be
r
-
-
-
-
-
-
-
-
-
Vo
rt
ex
(N
=7
)
16
.0
4±
1.
47
73
.9
5±
6.
91
6.
45
±1
.6
0
0.
13
±0
.0
0
0.
65
±0
.1
5
0.
74
±0
.1
7
3.
33
±0
.9
5
2.
64
±0
.8
3
5.
88
±1
.4
1
Vo
lu
m
at
ic
(N
=7
)
17
.4
9±
1.
51
72
.5
5±
1.
37
2.
97
±0
.6
5
0.
39
±0
.0
0
0.
51
±0
.1
7
0.
93
±0
.2
2
4.
70
±0
.8
5
4.
04
±0
.7
6
7.
99
±1
.0
8
248
Bibliography
[Abr07] Sofia Abreu. Study of different spacers for pressurized inhalers. Master thesis,
University of Minho, Braga, 2007.
[ALCH04] Michael J Asmus, Judy Liang, Intira Coowanitwong, and Günther Hochhaus. In Vitro
Performance Characteristics of Valved Holding Chamber and Spacer Devices with a
Fluticasone Metered-Dose Inhaler. Pharmacotherapy, 24(2):159–166, feb 2004.
[ANS13] ANSYS. ANSYS FLUENT Theory Guide. ANSYS Inc, Canonsburg, PA, USA, release
15 edition, 2013.
[AR85] Michael D. Allen and Otto G. Raabe. Slip Correction Measurements of Spherical
Solid Aerosol Particles in an Improved Millikan Apparatus. Aerosol Science and
Technology, 4(3):269–286, jan 1985.
[ASAT08] Sofia Abreu, Luís F Silva, Henedina Antunes, and Senhorinha F. C. F. Teixeira.
Multiphase flow inside the Volumatic spacer: a CFD approach. In E C Ferreira and
M Mota, editors, Proceedings of the 10th International Chemical and Biological
Engineering Conference - CHEMPOR 2008, page 6, Braga, 2008.
[ASM98] ASME. PTC 19.1 - 1998 - Test Uncertainty, 1998.
[BCLM11] G. Brambilla, T. Church, D. Lewis, and B. Meakin. Plume temperature emitted from
metered dose inhalers. International Journal of Pharmaceutics, 405(1-2):9–15,
2011.
249
Bibliography
[BD92] Raymond M. Brach and Patrick F. Dunn. A Mathematical Model of the Impact and
Adhesion of Microsphers. Aerosol Science and Technology, 16(1):51–64, jan 1992.
[BD95] Raymond M. Brach and Patrick F. Dunn. Macrodynamics of Microparticles. Aerosol
Science and Technology, 23(1):51–71, jan 1995.
[Bis95] Hans Bisgaard. A metal aerosol holding chamber devised for young children with
asthma. European Respiratory Journal, 8(5):856–860, 1995.
[BK07] J T Black and Ron Kohser. DeGarmo’s Materials & Processes in Manufacturing.
John Wiley & Sons, USA, 10th edition, 2007.
[BO95] P.W. Barry and Chris O’Callaghan. The Optimum Size and Shape of Spacer Devices
for Inhalational Therapy. Journal of Aerosol Medicine, 8(3):303–305, jan 1995.
[BO99a] Peter W Barry and Chris O’Callaghan. A comparative analysis of the particle size
output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propi-
onate metered dose inhalers used with the Babyhaler, Volumatic and Aerochamber
spacer devices. British Journal of Clinical Pharmacology, 47(4):357–360, dec
1999.
[BO99b] Peter W Barry and Chris O’Callaghan. The output of budesonide from spacer devices
assessed under simulated breathing conditions. Journal of Allergy and Clinical
Immunology, 104(6):1205–1210, dec 1999.
[BOS01] Hans Bisgaard, Chris O’Callaghan, and Gerald C. Smaldone. Drug Delivery to the
Lung, 2001.
[BP09] Elna B Berg and Robert J Picard. In vitro delivery of budesonide from 30 jet nebuliz-
er/compressor combinations using infant and child breathing patterns. Respiratory
care, 54(12):1671–8, dec 2009.
[BRW+01] D Brocklebank, F Ram, J Wright, Peter W Barry, C Cates, L Davies, G Douglas,
M Muers, D Smith, and J White. Comparison of the effectiveness of inhaler devices
250
Bibliography
in asthma and chronic obstructive airways disease: a systematic review of the
literature. Health technology assessment, 5(26):1–149, jan 2001.
[BSM+00] Joel L Berry, Aland Santamarina, James E. Moore, Jr., Suranjan Roychowdhury,
and William D Routh. Experimental and Computational Flow Evaluation of Coronary
Stents. Annals of Biomedical Engineering, 28(4):386–398, apr 2000.
[CAM+01] A L Coates, P D Allen, C F MacNeish, S L Ho, and L C Lands. Effect of size and
disease on estimated deposition of drugs administered using jet nebulization in
children with cystic fibrosis. Chest, 119(4):1123–30, apr 2001.
[Can08] Arnaldo Cantani. Asthma. In Ute Heilmann, editor, Pediatric Allergy, Asthma and
Immunology, chapter Chapter 11, pages 725–873. Springer Berlin Heidelberg,
Berlin, Heidelberg, 2008.
[CAS99] R.P. Chhabra, L Agarwal, and N.K. Sinha. Drag on non-spherical particles: an
evaluation of available methods. Powder Technology, 101(3):288–295, mar 1999.
[CC00] N Y Chew and H K Chan. The effect of spacers on the delivery of metered dose
aerosols of nedocromil sodium and disodium cromoglycate. International journal of
pharmaceutics, 200(1):87–92, apr 2000.
[CFYZ01] Y.S. S Cheng, C.S. S Fu, D. Yazzie, and Y. Zhou. Respiratory Deposition Patterns of
Salbutamol pMDI with CFC and HFA-134a Formulations in a Human Airway Replica.
Journal of Aerosol Medicine, 14(2):255–266, jun 2001.
[CGR+08] Ismail B. Celik, Urmila Ghia, Patrick J. Roache, Christopher J. Freitas, Hugh Coleman,
and Peter E. Raad. Procedure for Estimation and Reporting of Uncertainty Due to
Discretization in CFD Applications. Journal of Fluids Engineering, 130(7):078001,
2008.
[CGW05] Roland Clift, John R. Grace, and Martin E. Weber. Bubbles, drops, and particles.
Dover Publications, 2005.
251
Bibliography
[Che14] Yung Sung Cheng. Mechanisms of Pharmaceutical Aerosol Deposition in the
Respiratory Tract. AAPS PharmSciTech, 15(3):630–640, 2014.
[CJM09] Brian Michael Crosland, Matthew Ronald Johnson, and Edgar Akio Matida. Charac-
terization of the spray velocities from a pressurized metered-dose inhaler. Journal
of aerosol medicine and pulmonary drug delivery, 22(2):85–97, jun 2009.
[Cla91] Andrew Reginald Clark. Metered Atomisation for Respiratory Drug Delivery. Phd
thesis, Loughborough University of Technology, 1991.
[Cla96] Andrew R Clark. MDIs: physics of aerosol formation. Journal of aerosol medicine,
9 Suppl 1(s1):S19–26, mar 1996.
[Cro06] Graham Crompton. A brief history of inhaled asthma therapy over the last fifty years.
Primary Care Respiratory Journal, 15(6):326–31, dec 2006.
[CRR04] José a Castro-Rodriguez and Gustavo J Rodrigo. Beta-Agonists through Metered-
Dose Inhaler with Valved Holding Chamber versus Nebulizer for Acute Exacerbation
of Wheezing or Asthma in Children under 5 Years of Age: A Systematic Review with
Meta-Analysis. The Journal of pediatrics, 145(2):172–7, 2004.
[Cun10] E. Cunningham. On the Velocity of Steady Fall of Spherical Particles through
Fluid Medium. Proceedings of the Royal Society A: Mathematical, Physical and
Engineering Sciences, 83(563):357–365, mar 1910.
[CYF+14a] Yang Chen, Paul M. Young, David F. Fletcher, Hak Kim Chan, Edward Long, David
Lewis, Tanya Church, and Daniela Traini. The Effect of Actuator Nozzle Designs on
the Electrostatic Charge Generated in Pressurised Metered Dose Inhaler Aerosols.
Pharmaceutical Research, 32(4):1237–1248, 2014.
[CYF+14b] Yang Chen, Paul M. Young, David F. Fletcher, Hak Kim Chan, Edward Long, David
Lewis, Tanya Church, and Daniela Traini. The Influence of Actuator Materials and
Nozzle Designs on Electrostatic Charge of Pressurised Metered Dose Inhaler (pMDI)
Formulations. Pharmaceutical Research, 31(5):1325–1337, may 2014.
252
Bibliography
[CZR08] CAN/CSA-Z264.1-02(R2008). Spacers and Holding Chambers for Use with Metered-
Dose Inhalers. Canadian Standards Association, Torento, Canada, 2008.
[CZS15] Yung Sung Cheng, Yue Zhou, and Wei-Chung Su. Deposition of Particles in Human
Mouth–Throat Replicas and a USP Induction Port. Journal of Aerosol Medicine and
Pulmonary Drug Delivery, 28(3):147–155, jun 2015.
[DD11] Myrna B. Dolovich and Rajiv Dhand. Aerosol drug delivery: developments in device
design and clinical use. Lancet, 377(9770):1032–1045, mar 2011.
[Deh08] A. Dehbi. Turbulent particle dispersion in arbitrary wall-bounded geometries: A
coupled CFD-Langevin-equation based approach. International Journal of Multiphase
Flow, 34(9):819–828, sep 2008.
[Deh11] A Dehbi. Prediction of Extrathoracic Aerosol Deposition using RANS-Random Walk
and LES Approaches. Aerosol Science and Technology, 45(5):555–569, 2011.
[DF01] Myrna B. Dolovich and James B. Fink. Aerosols and devices. Respiratory care
clinics of North America, 7(2):131–173, jun 2001.
[DGB03] J.C. Dubus, C Guillot, and M Badier. Electrostatic charge on spacer devices and
salbutamol response in young children. International Journal of Pharmaceutics,
261(1-2):159–164, aug 2003.
[DH00] Craig A. Dunbar and Anthony J. Hickey. Evaluation of probability density functions
to aporoximate particle size distributions of representative pharmaceutical aerosols.
Journal of Aerosol Science, 31(7):813–831, jul 2000.
[DM04] Myrna B. Dolovich and Jolyon P Mitchell. Canadian Standards Association standard
CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding
chambers used with pressurized metered-dose inhalers. Canadian respiratory
journal, 11(7):489–95, oct 2004.
253
Bibliography
[DMZ+14] William Ditcham, Jasminka Murdzoska, Guicheng Zhang, Christina Roller, Dirk
von Hollen, Kurt Nikander, and Sunalene G Devadason. Lung Deposition of 99m
Tc-Radiolabeled Albuterol Delivered through a Pressurized Metered Dose Inhaler and
Spacer with Facemask or Mouthpiece in Children with Asthma. Journal of Aerosol
Medicine and Pulmonary Drug Delivery, 27(S1):S–63–S–75, 2014.
[Dol04] Myrna B. Dolovich. In my opinion - Interview with the Expert. Pediatric Asthma
Allergy & Immunology, 17(4):292–300, 2004.
[DS03] Richard Dalby and Julie Suman. Inhalation therapy: technological milestones in
asthma treatment. Advanced drug delivery reviews, 55(7):779–91, jul 2003.
[Dun96] Craig A. Dunbar. An experimental and theoretical investigation of the spray issued
from a pressurised metered-dose inhaler. Phd thesis, University of Manchester,
1996.
[Dun97] Craig A. Dunbar. Atomization mechanisms of the pressurized metered dose inhaler.
Particulate Science and Technology, 15(3-4):253–271, jul 1997.
[DWM97] Craig A. Dunbar, A P Watkins, and J F Miller. An experimental investigation of the
spray issued from a pMDI using laser diagnostic techniques. Journal of Aerosol
Medicine, 10(4):351–68, jan 1997.
[EABB11] Najla El Gharbi, Rafik Absi, Ahmed Benzaoui, and Rachid Bennacer. An improved
near-wall treatment for turbulent channel flows. International Journal of Computa-
tional Fluid Dynamics, 25(1):41–46, jan 2011.
[EFAvV+04] J E Esposito-Festen, B Ates, F J M van Vliet, A F M Verbraak, J C de Jongste, and
H A W M Tiddens. Effect of a facemask leak on aerosol delivery from a pMDI-spacer
system. Journal of aerosol medicine : the official journal of the International Society
for Aerosols in Medicine, 17(1):1–6, jan 2004.
[FBGD00] M R Feddah, K F Brown, E M Gipps, and N M Davies. In-vitro characterisation of
metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of
254
Bibliography
inspiratory flow rates. Journal of pharmacy & pharmaceutical sciences : a publication
of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des
sciences pharmaceutiques, 3(3):318–24, 2000.
[Fin98] Warren H. Finlay. Inertial sizing of aerosol inhaled during pediatric tidal breathing
from an MDI with attached holding chamber. International Journal of Pharmaceutics,
168(2):147–152, jun 1998.
[Fin01] Warren H. Finlay. The mechanics of inhaled pharmaceutical aerosols: an introduc-
tion. Academic Press, 2001.
[FK99] Scott A Foss and Jean W Keppel. In Vitro Testing of MDI Spacers: A Technique for
Measuring Respirable Dose Output with Actuation In-Phase or Out-of-Phase with
Inhalation. Respiratory Care, 44(12):1474–1485, 1999.
[FK13] Y. Feng and C. Kleinstreuer. Analysis of non-spherical particle transport in complex
internal shear flows. Physics of Fluids, 25(9):091904, 2013.
[Flo09] Paulo Flores. Projecto de mecanismos Came-Seguidor. Publindústria, Porto,
Portugal, 2009.
[Fol02] A Foland. Improvement of metered-dose inhaler administration technique: the effect
of training sessions at a specialized pediatric asthma compliance and technique
clinic. Current Therapeutic Research, 63(2):142–147, feb 2002.
[FP03] Joel H Ferziger and Milovan Peric. Computational methods for fluid dynamics.
Springer, 3 edition, jul 2003.
[FWZS07] Ahmed Fadl, Jinbo Wang, Zongqin Zhang, and Yung Sung Cheng. Effects of MDI
spray angle on aerosol penetration efficiency through an oral airway cast. Journal
of Aerosol Science, 38(8):853–864, aug 2007.
[FZ98] Warren H. Finlay and P. Zuberbuhler. In Vitro Comparison of Beclomethasone and
Salbutamol Metered-Dose Inhaler Aerosols Inhaled During Pediatric Tidal Breathing
From Four Valved Holding Chambers. Chest, 114(6):1676–1680, dec 1998.
255
Bibliography
[FZM97] Warren H. Finlay, P. Zuberbuhler, and M. Mandl. Particle Size Measurements for the
Space-Chamber Metered Dose Inhaler Holding Chamber Compared with Aerocham-
ber and Metered Dose Inhaler Alone. Journal of Aerosol Medicine, 10(3):213–219,
jan 1997.
[GA04] Athanasia M. Goula and Konstantinos G. Adamopoulos. Influence of Spray Drying
Conditions on Residue Accumulation—Simulation Using CFD. Drying Technology,
22(5):1107–1128, 2004.
[GAN+13] Talita Mota Goncalves, Kamel Alhanout, Alain Nicolay, Jean-Christophe Dubus,
Davi Pereira de Santana, and Veronique Andrieu. Comparative In Vitro Performance
of Three Small-Volume Valved Holding Chambers with Beclomethasone/Formoterol
Pressurized Metered Dose Inhaler. Journal of Aerosol Medicine and Pulmonary
Drug Delivery, 26(4):223–227, aug 2013.
[GL83] A. D. Gosman and E. Loannides. Aspects of Computer Simulation of Liquid-Fueled
Combustors. Journal of Energy, 7(6):482–490, nov 1983.
[Glo14] Global Initiative for Asthma. Global strategy for asthma management and prevention.
Technical report, GINA, 2014.
[GSV99] B J Gabrio, S W Stein, and D J Velasquez. A new method to evaluate plume
characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers.
International journal of pharmaceutics, 186(1):3–12, sep 1999.
[Hic03] Anthony J. Hickey. Pharmaceutical inhalation aerosol technology. Marcel Dekker,
Inc., New York, USA, 2nd editio edition, 2003.
[Hin99] William C. Hinds. Aerosol Technology: Properties, Behavior, and Measurement of
Airborne Particles. John Wiley & Sons, New York, USA, 2nd edition, 1999.
[HvHSS14] Ross H M Hatley, Dirk von Hollen, Dennis Sandell, and Lois Slator. In vitro charac-
terization of the OptiChamber Diamond valved holding chamber. Journal of aerosol
medicine and pulmonary drug delivery, 27 Suppl 1:S24–36, aug 2014.
256
Bibliography
[IDQ08] A.H. Ibrahim, P.F. Dunn, and M.F. Qazi. Experiments and validation of a model for
microparticle detachment from a surface by turbulent air flow. Journal of Aerosol
Science, 39(8):645–656, aug 2008.
[JAC+05] L. L. Janssen, N. J. Anderson, P. E. Cassidy, R. A. Weber, and T. J. Nelson. Interpre-
tation of Inhalation Airflow Measurements for Respirator Design and Testing. Journal
of the International Society for Respiratory Protection, 22(3):122–141, 2005.
[JBGJ00] G Jepson, T Butler, D Gregory, and K Jones. Prescribing patterns for asthma by gen-
eral practitioners in six European countries. Respiratory medicine, 94(6):578–583,
jun 2000.
[JKR71] K. L. Johnson, K. Kendall, and A. D. Roberts. Surface Energy and the Contact of
Elastic Solids. In Proceedings of the Royal Society of London. Series A, Mathematical
and Physical Sciences, volume 324, pages 301–313. The Royal Society, 1971.
[JWE+02] R Janssen, M Weda, M B Ekkelenkamp, J-W J Lammers, and P Zanen. Metal
versus plastic spacers: an in vitro and in vivo comparison. International journal of
pharmaceutics, 245(1-2):93–8, oct 2002.
[KCC06] Philip Chi Lip Kwok, Richard Collins, and Hak-Kim Chan. Effect of spacers on the
electrostatic charge properties of metered dose inhaler aerosols. Journal of Aerosol
Science, 37(12):1671–1682, dec 2006.
[KCD+05] D Keochkerian, M Chlif, S Delanaud, R Gauthier, Y Maingourd, and S Ahmaidi.
Timing and driving components of the breathing strategy in children with cystic
fibrosis during exercise. Pediatric pulmonology, 40(5):449–56, nov 2005.
[KHDL15] Navvab Khajeh-Hosseini-Dalasm and P. Worth Longest. Deposition of particles in the
alveolar airways: Inhalation and breath-hold with pharmaceutical aerosols. Journal
of Aerosol Science, 79:15–30, jan 2015.
257
Bibliography
[Kir72] W.F. Kirk. In Vitro Method of Comparing Clouds Produced from Inhalation Aerosols
for Efficiency in Penetration of Airways. Journal of Pharmaceutical Sciences,
61(2):262–265, feb 1972.
[KSZ07] Clement Kleinstreuer, Huawei Shi, and Zhe Zhang. Computational analyses of a
pressurized metered dose inhaler and a new drug-aerosol targeting methodology.
Journal of aerosol medicine, 20(3):294–309, jan 2007.
[KTH+06] Yasmeen Khan, Yufei Tang, Guenther Hochhaus, Jonathan J. Shuster, Terry Spencer,
Sarah Chesrown, and Leslie Hendeles. Lung bioavailability of hydrofluoroalkane
fluticasone in young children when delivered by an antistatic chamber/mask. Journal
of Pediatrics, 149(6):793–797, 2006.
[LA85] David Leighton and Andreas Acrivos. The lift on a small sphere touching a plane in
the presence of a simple shear flow. ZAMP Zeitschrift fur angewandte Mathematik
und Physik, 36(1):174–178, jan 1985.
[LDG12] Xiaofei Liu, William H Doub, and Changning Guo. Evaluation of metered dose inhaler
spray velocities using Phase Doppler Anemometry (PDA). International journal of
pharmaceutics, 423(2):235–239, feb 2012.
[LHCB07] P. Worth Longest, Michael Hindle, Suparna Das Choudhuri, and Peter R. By-
ron. Numerical Simulations of Capillary Aerosol Generation: CFD Model Develop-
ment and Comparisons with Experimental Data. Aerosol Science and Technology,
41(10):952–973, aug 2007.
[LHDX08] P. Worth Longest, Michael Hindle, Suparna Das Choudhuri, and Jinxiang Xi. Com-
parison of ambient and spray aerosol deposition in a standard induction port and
more realistic mouth–throat geometry. Journal of Aerosol Science, 39(7):572–591,
jul 2008.
[LMF16] E.W. Lemmon, M.O. McLinden, and D.G. Friend. Thermophysical Properties of Fluid
Systems. In P.J. Linstrom and W.G. Mallard, editors, NIST Chemistry WebBook,
258
Bibliography
NIST Standard Reference Database Number 69. National Institute of Standards and
Technology, Gaithersburg MD, 2016.
[LV07] P. Worth Longest and Samir Vinchurkar. Effects of mesh style and grid convergence
on particle deposition in bifurcating airway models with comparisons to experimental
data. Medical Engineering and Physics, 29:350–366, 2007.
[LX07] P. Worth Longest and Jinxiang Xi. Effectiveness of Direct Lagrangian Tracking Models
for Simulating Nanoparticle Deposition in the Upper Airways. Aerosol Science and
Technology, 41(4):380–397, mar 2007.
[MA72] S. A. Morsi and A. J. Alexander. An investigation of particle trajectories in two-phase
flow systems. Journal of Fluid Mechanics, 55(02):193, sep 1972.
[MAK13] J. Milenkovic, A.H. Alexopoulos, and C. Kiparissides. Flow and particle deposition
in the Turbuhaler: A CFD simulation. International Journal of Pharmaceutics,
448(1):205–213, may 2013.
[Mar04] Virgil a. Marple. History of Impactors—The First 110 Years. Aerosol Science and
Technology, 38(3):247–292, mar 2004.
[Mar07] J A Marques. Asma. In M A Ferreira and E Loureiro, editors, O Essencial da Saúde,
volume 15. QuidNovi, Lisboa, 2007.
[McD14] John H. McDonald. Handbook of Biological Statistics. Sparky House Publishing,
Baltimore, Maryland, USA, 3rd edition, 2014.
[MD12] Jolyon P Mitchell and Myrna B Dolovich. Clinically relevant test methods to establish
in vitro equivalence for spacers and valved holding chambers used with pressurized
metered dose inhalers (pMDIs). Journal of aerosol medicine and pulmonary drug
delivery, 25(4):217–42, aug 2012.
[Men93] Florian R. Menter. Zonal Two Equation k-omega Turbulence Models for Aerodynamic
Flows. In 24th AIAA Fluid Dynamics Conference, page 21, Orlando, FL; United
States, 1993.
259
Bibliography
[MFHB04] Matthew Masoli, Denise Fabian, Shaun Holt, and Richard Beasley. The global
burden of asthma: executive summary of the GINA Dissemination Committee report.
Allergy, 59(5):469–78, may 2004.
[MFLG04] E. A. Matida, Warren H. Finlay, C. F. Lange, and B. Grgic. Improved numerical
simulation of aerosol deposition in an idealized mouth–throat. Journal of Aerosol
Science, 35(1):1–19, jan 2004.
[MGH+99] T Manczur, A Greenough, R Hooper, K Allen, S Latham, J F Price, and G F Rafferty.
Tidal breathing parameters in young children: comparison of measurement by
respiratory inductance plethysmography to a facemask pneumotachograph system.
Pediatric pulmonology, 28(6):436–41, dec 1999.
[Mil02] Nicholas C. Miller. US 6435004 - Apparatus and process for aerosol size measure-
ment at varying gas flow rates, 2002.
[Mil05] M. R. Miller. Standardisation of spirometry. European Respiratory Journal,
26(2):319–338, aug 2005.
[MKBZ12] Jacquelyn Cruz McCabe, Franciscus Koppenhagen, Julian Blair, and Xian-Ming Zeng.
ProAir HFA Delivers Warmer, Lower-Impact, Longer-Duration Plumes Containing
Higher Fine Particle Dose Than Ventolin HFA. Journal of Aerosol Medicine and
Pulmonary Drug Delivery, 25(2):104–109, 2012.
[MN97] Jolyon P Mitchell and Mark W Nagel. In vitro performance testing of three small
volume-holding chambers under conditions that correspond with use by infants and
small children. Journal of Aerosol Medicine, 10(4):341–349, 1997.
[MN03] Jolyon P Mitchell and Mark W Nagel. Cascade impactors for the size characterization
of aerosols from medical inhalers: their uses and limitations. Journal of Aerosol
Medicine, 16(4):341–77, jan 2003.
260
Bibliography
[MN07] Jolyon P. Mitchell and Mark W. Nagel. Valved holding chambers (VHCs) for use
with pressurised metered-dose inhalers (pMDIs): A review of causes of inconsistent
medication delivery. Primary Care Respiratory Journal, 16(4):207–214, 2007.
[MNT00] Edgar Akio Matida, Koichi Nishino, and Kahoru Torii. Statistical simulation of particle
deposition on the wall from turbulent dispersed pipe flow. International Journal of
Heat and Fluid Flow, 21(4):389–402, aug 2000.
[Mon11] Matteo Monticelli. Generalized Wall Functions for RANS Computation of Turbulent
Flows. Master thesis, Politecnic of Milan, 2011.
[Mor78] Folke Morén. Drug deposition of pressurized inhalation aerosols I. Influence of
actuator tube design. International Journal of Pharmaceutics, 1(4):205–212, jul
1978.
[MSDK+16] Nicholas Mason-Smith, Daniel J. Duke, Alan L. Kastengren, Peter J. Stewart, Daniela
Traini, Paul M. Young, Yang Chen, David A. Lewis, Julio Soria, Daniel Edgington-
Mitchell, and Damon Honnery. Insights into Spray Development from Metered-Dose
Inhalers Through Quantitative X-ray Radiography. Pharmaceutical Research, feb
2016.
[MvHvK+14] Kirby Tong Minh, Dirk von Hollen, Annemieke J. von Königslöw, Kurt Nikander, and
Hettie M. Janssens. An Instrumented Valved Holding Chamber with Facemask
to Measure Application Forces and Flow in Young Asthmatic Children. Journal of
Aerosol Medicine and Pulmonary Drug Delivery, 27(S1):S–55–S–62, aug 2014.
[MW79] Nils F E Moren and Kjell I L Wetterlin. Device for use with medicinal inhalation
devices, 1979.
[Nat07] National Heart Lung and Blood Institute. Expert Panel Report 3: Guidelines for the
Diagnosis and Management of Asthma. Technical report, National Heart Lung and
Blood Institute (NHLBI), Bethesda, 2007.
261
Bibliography
[NDSW01] Kurt Nikander, John Denyer, Nick Smith, and Per Wollmer. Breathing Patterns
and Aerosol Delivery: Impact of Regular Human Patterns, and Sine and Square
Waveforms on Rate of Delivery. Journal of Aerosol Medicine, 14(3):327–333, sep
2001.
[New04] Stephen P Newman. Spacer devices for metered dose inhalers. Clinical pharma-
cokinetics, 43(6):349–360, jan 2004.
[New05] Stephen P Newman. Principles of metered-dose inhaler design. Respiratory care,
50(9):1177–1190, sep 2005.
[New06] Stephen P Newman. Aerosols. In Geoffrey J. Laurent and Steven D. Shapiro, editors,
Encyclopedia of Respiratory Medicine, pages 58–64. Elsevier, 2006.
[NMLJ+84] S P Newman, A B Millar, T R Lennard-Jones, F Morén, and S W Clarke. Improve-
ment of pressurised aerosol deposition with Nebuhaler spacer device. Thorax,
39(12):935–941, 1984.
[NNDP14] Kurt Nikander, Clare Nicholls, John Denyer, and John Pritchard. The Evolution of
Spacers and Valved Holding Chambers. Journal of aerosol medicine and pulmonary
drug delivery, 27(S1):S4–S24, 2014.
[Nor02] Robert L. Norton. Cam design and manufacturing handbook. Industrial Press, New
York, USA, 2002.
[NWBM02] Mark W Nagel, Kimberly J Wiersema, Sara-Lou Bates, and Jolyon P Mitchell. Perfor-
mance of large- and small-volume valved holding chambers with a new combination
long-term bronchodilator/anti-inflammatory formulation delivered by pressurized
metered dose inhaler. Journal of aerosol medicine : the official journal of the
International Society for Aerosols in Medicine, 15(4):427–433, 2002.
[OFT+14] Ricardo F Oliveira, Ana C M Ferreira, Senhorinha F. C. F. Teixeira, José Carlos
Teixeira, and Helena Maria Cabral Marques. A CFD Study of a pMDI Plume Spray.
262
Bibliography
In Gi-Chul Yang, Sio-Iong Ao, and Len Gelman, editors, Transactions on Engineering
Technologies, pages 163–176. Springer Netherlands, 2014.
[O’N68] M.E. O’Neill. A sphere in contact with a plane wall in a slow linear shear flow.
Chemical Engineering Science, 23(11):1293–1298, nov 1968.
[OTMT12] Ricardo F Oliveira, José Carlos Teixeira, Helena Maria Cabral Marques, and Senhor-
inha Teixeira. Modeling Flow Recirculation Inside a Holding Chamber. In Volume 2:
Biomedical and Biotechnology, page 325, Houston, Texas, USA, nov 2012. ASME.
[OTMT14a] Ricardo F Oliveira, Senhorinha F C F Teixeira, Helena Maria Cabral Marques, and
José Carlos Teixeira. Efficiency evaluation of VHC: a CFD comparison study at
constant flow. In Proceedings of the 2014 International Conference on Mechanics,
Fluid Mechanics, Heat and Mass Transfer, Interlaken, Swiss, 2014. EUROPMENT.
[OTMT14b] Ricardo F Oliveira, Senhorinha F C F Teixeira, Helena Maria Cabral Marques, and
José Carlos Teixeira. Flow Recirculation in VHC Designs. In Eugenio Oñate, Xavier
Oliver, and Antonio Huerta, editors, 6th European Conference on Computational
Fluid Dynamics (ECFD VI), volume VI, pages 7342–7350, Barcelona, Spain, 2014.
International Center for Numerical Methods in Engineering (CIMNE).
[OTS+12] Ricardo F Oliveira, Senhorinha F C F Teixeira, Luís F Silva, José C F Teixeira, and
Henedina Antunes. Development of new spacer device geometry: a CFD study (part
I). Computer methods in biomechanics and biomedical engineering, 15(8):825–833,
jan 2012.
[OTT+12] Ricardo F Oliveira, Senhorinha F. C. F. Teixeira, José Carlos Teixeira, Luís F Silva, and
Henedina Antunes. pMDI Sprays: Theory , Experiment and Numerical Simulation.
In Chaoqun Liu, editor, Advances in Modeling of Fluid Dynamics, chapter 11, page
300. Intech, Rijeka, Croatia, 2012.
263
Bibliography
[PCS01] Lexley Pinto Pereira, Yuri Clement, and Donald Simeon. Educational intervention
for correct pressurised metered dose inhaler technique in Trinidadian patients with
asthma. Patient Education and Counseling, 42(1):91–97, jan 2001.
[PLK01] Donald L Pavia, Gary M Lampman, and George S Kriz. Introduction to Spectroscopy:
A guide for students of organic chemistry. Thomson Learning Inc., USA, 3rd edition,
2001.
[PM61] Irving Porush and George Louis Maison. Aerosol dispensing apparatus, 1961.
[RCN+06] Joseph L Rau, Dominic P Coppolo, Mark W Nagel, Valentina I Avvakoumova, Cathy C
Doyle, Kimberly J Wiersema, and Jolyon P Mitchell. The importance of nonelec-
trostatic materials in holding chambers for delivery of hydrofluoroalkane albuterol.
Respiratory care, 51(5):503–510, 2006.
[RG99] D L Ross and B J Gabrio. Advances in metered dose inhaler technology with the
development of a chlorofluorocarbon-free drug delivery system. Journal of aerosol
medicine : the official journal of the International Society for Aerosols in Medicine,
12(3):151–60, jan 1999.
[RJF13] Conor A Ruzycki, Emadeddin Javaheri, and Warren H. Finlay. The use of com-
putational fluid dynamics in inhaler design. Expert opinion on drug delivery,
10(3):307–23, mar 2013.
[RMSBCR12] Carlos E. Rodriguez-Martinez, Mónica P. Sossa-Briceño, and Jose A. Castro-
Rodriguez. Comparison of the bronchodilating effects of albuterol delivered by
valved vs. non-valved spacers in pediatric asthma. Pediatric Allergy and Immunol-
ogy, 23(7):629–635, 2012.
[RR13] Bart L. Rottier and Bruce K. Rubin. Asthma medication delivery: Mists and myths.
Paediatric Respiratory Reviews, 14(2):112–118, jun 2013.
[RZLF02] Muhib F Rahmatalla, Peter C Zuberbuhler, Carlos F Lange, and Warren H. Fin-
lay. In vitro effect of a holding chamber on the mouth-throat deposition of QVAR
264
Bibliography
(hydrofluoroalkane-beclomethasone dipropionate). Journal of aerosol medicine,
15(4):379–385, jan 2002.
[San07] Mark Sanders. Inhalation therapy: an historical review. Primary care respiratory
journal, 16(2):71–81, apr 2007.
[SB07] Liming Shi and David J. Bayless. Comparison of boundary conditions for predicting
the collection efficiency of cyclones. Powder Technology, 173(1):29–37, apr 2007.
[SB11] Scottish Intercollegiate Guidelines Network and British Thoracic Society. British
guideline on the management of asthma: A national clinical guideline. Technical
report, BTS and SIGN, UK, 2011.
[SB13] Mark J Sanders and Ronald Bruin. Are we misleading users of respiratory spacer
devices? Primary Care Respiratory Journal, 22(4):466–467, nov 2013.
[SBB+06] Hugh Smyth, Geoff Brace, Tony Barbour, Jim Gallion, Joe Grove, and Anthony J.
Hickey. Spray pattern analysis for metered dose inhalers: effect of actuator design.
Pharmaceutical research, 23(7):1591–6, jul 2006.
[SBKM14] Poonam Sheth, Matthew D. Bertsch, Carrie L. Knapp, and Paul B. Myrdal. In
vitro evaluation of nonconventional accessory devices for pressurized metered-dose
inhalers. Annals of Allergy, Asthma & Immunology, 113(1):55–62, jul 2014.
[SH91] Olof Selroos and Maija Halme. Effect of a volumatic spacer and mouth rinsing on
systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry
powder inhaler. Thorax, 46(12):891–894, dec 1991.
[SHB+06] H Smyth, Anthony J. Hickey, G Brace, Tony Barbour, Jim Gallion, and J Grove. Spray
pattern analysis for metered dose inhalers I: Orifice size, particle size, and droplet
motion correlations. Drug development and industrial pharmacy, 32(9):1033–1041,
oct 2006.
[Shi97] Shimadzu Corporation. Intruction Manual User’s System Guide Spectrophotometer
UV-2401PC. Technical report, Shimadzu Corporation, Kyoto, Japan, 1997.
265
Bibliography
[SLT09] Mark Saunders, Philip Lewis, and Adrian Thornhill. Research Methods for Business
Students. FinancialTimesPrentice-Hall, Harlow, England, 5th. editi edition, 2009.
[SM09] Pavel E. Smirnov and Florian R. Menter. Sensitization of the SST Turbulence Model
to Rotation and Curvature by Applying the Spalart–Shur Correction Term. Journal
of Turbomachinery, 131(4):041010, 2009.
[SM14] Dennis Sandell and Jolyon P Mitchell. Considerations for Designing In Vitro Bioequiv-
alence (IVBE) Studies for Pressurized Metered Dose Inhalers (pMDIs) with Spacer
or Valved Holding Chamber (S/VHC) Add-on Devices. Journal of aerosol medicine
and pulmonary drug delivery, 27(0):1–26, aug 2014.
[SMB00] Thomas Stifter, Othmar Marti, and Bharat Bhushan. Theoretical investigation of
the distance dependence of capillary and van der Waals forces in scanning force
microscopy. Physical Review B, 62(20):13667–13673, nov 2000.
[Smy03] H Smyth. The influence of formulation variables and the performance of alter-
native propellant-driven metered dose inhalers. Advanced Drug Delivery Reviews,
55:807–828, 2003.
[Spr14] Elizabeth Sprigge. Non uniform deposition of pMDI aerosol in a large volume spacer.
Master thesis, Carleton University, 2014.
[SSHM13] Stephen W. Stein, Poonam Sheth, P. David Hodson, and Paul B. Myrdal. Advances
in Metered Dose Inhaler Technology: Hardware Development. AAPS PharmSciTech,
15(2):326–338, 2013.
[SSM12] Stephen W Stein, Poonam Sheth, and Paul B Myrdal. A model for predicting size
distributions delivered from pMDIs with suspended drug. International journal of
pharmaceutics, 422(1-2):101–15, jan 2012.
[Sul00] Sulzer Innotec. Best Practices Guidelines: ERCOFTAC Special Interest Group on
”Quality and Trust in Industrial CFD”. ERCOFTAC, 2000.
266
Bibliography
[Tan15] Akihiko Tanaka. Past, Present and Future Therapeutics of Asthma: A Review. Journal
of General and Family Medicine, 16(3):158–169, 2015.
[Tas98] Donald P. Tashkin. New devices for asthma. Journal of Allergy and Clinical Im-
munology, 101(2):S409–S416, feb 1998.
[Tay97] John Robert Taylor. An introduction to error analysis: the study of uncertainties
in physical measurements. University Science Books, Sausalito, California, 2nd
edition, 1997.
[TIA13] Jiyuan Tu, Kiao Inthavong, and Goodarz Ahmadi. The Human Respiratory System.
In Elias Greenbaum, editor, Computational Fluid and Particle Dynamics in the
Human Respiratory System, Biological and Medical Physics, Biomedical Engineering,
chapter 2, pages 19–44. Springer Netherlands, Dordrecht, 2013.
[Tom06] J. Tomas. Mechanics of Particle Adhesion. Technical report, Otto-von-Guericke-
University, Magdeburg, Germany, 2006.
[US 14] US Pharmacopeial Convention. <1602> Spacers and valved holding chambers
used with inhalation aerosols (USP38-NF33): In-Process Revision, 2014.
[VCD+08] J C Virchow, G K Crompton, R Dal Negro, S Pedersen, A Magnan, J Seidenberg,
and Peter J. Barnes. Importance of inhaler devices in the management of airway
disease. Respiratory medicine, 102(1):10–19, jan 2008.
[VLP09] Samir Vinchurkar, P. Worth Longest, and Joanne Peart. CFD simulations of the
Andersen cascade impactor: Model development and effects of aerosol charge.
Journal of Aerosol Science, 40(9):807–822, sep 2009.
[VM95] Henk K. Versteeg and W. Malalasekera. An introduction to computational fluid
dynamics: the finite volume method. Longman, Harlow, England, 1995.
[vS59] Wilton E van Sickle. Enclosed medicament container and atomizer, 1959.
267
Bibliography
[VVSV04] Sylvia Verbanck, Chris Vervaet, Daniel Schuermans, and Walter Vincken. Aerosol
Profile Extracted from Spacers as a Determinant of Actual Dose. Pharmaceutical
Research, 21(12):2213–2218, dec 2004.
[WDH+96] J H Wildhaber, S G Devadason, M J Hayden, R. James, A P Dufty, R A Fox, Q A Sum-
mers, and P N LeSouëf. Electrostatic charge on a plastic spacer device influences
the delivery of salbutamol. The European respiratory journal, 9(9):1943–1946, sep
1996.
[WFT+12] William Wong, David F. Fletcher, Daniela Traini, Hak Kim Chan, and Paul M. Young.
The use of computational approaches in inhaler development. Advanced Drug
Delivery Reviews, 64(4):312–322, 2012.
[Whi98] Frank M White. Fluid Mechanics. McGraw-Hill, New York, 4th edition, 1998.
[WJ99] Yi Wang and P. W. James. On the effect of anisotropy on the turbulent disper-
sion and deposition of small particles. International Journal of Multiphase Flow,
25(3):551–558, 1999.
[WVH02] G. Wigley, H. K. Versteeg, and D. Hodson. Near-orifice PDA measurements and
atomisation mechanism of a pharmaceutical pressurised metered dose inhaler. In
ILASS-Europe, Zaragoza, 2002.
[XHvH+14] Zhen Xu, Wenchi Hsu, Dirk von Hollen, Ashwin Viswanath, Kurt Nikander, and
Richard Dalby. Methodology for the In Vitro Evaluation of the Delivery Efficiency
from Valved Holding Chambers with Facemasks. Journal of Aerosol Medicine and
Pulmonary Drug Delivery, 27(S1):S–44–S–54, aug 2014.
[YIT15] Morteza Yousefi, Kiao Inthavong, and Jiyuan Tu. Microparticle Transport and
Deposition in the Human Oral Airway: Toward the Smart Spacer. Aerosol Science
and Technology, 49(11):1109–1120, nov 2015.
268
Bibliography
[YNY+14] A. Yazdani, M. Normandie, M. Yousefi, M.S. Saidi, and G. Ahmadi. Transport and de-
position of pharmaceutical particles in three commercial spacer–MDI combinations.
Computers in Biology and Medicine, 54:145–155, nov 2014.
[ZFM04] Y. Zhang, Warren H. Finlay, and E. A. Matida. Particle deposition measurements
and numerical simulation in a highly idealized mouth–throat. Journal of Aerosol
Science, 35(7):789–803, jul 2004.
[ZKKC04] Zhe Zhang, Clement Kleinstreuer, Chong S. Kim, and Yung S. Cheng. Vaporizing
Microdroplet Inhalation, Transport, and Deposition in a Human Upper Airway Model.
Aerosol Science and Technology, 38(1):36–49, jan 2004.
[ZSB+08] Mira G Zuidgeest, Henriëtte A Smit, Madelon Bracke, Alet H Wijga, Bert Brunekreef,
Maarten O Hoekstra, Jorrit Gerritsen, Marjan Kerkhof, Johan C. de Jongste, and
Hubert G Leufkens. Persistence of asthma medication use in preschool children.
Respiratory Medicine, 102(10):1446–1451, oct 2008.
269
